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ABSTRACT

Structural and Functional Characterization of the LDP3 (VHZ)
Protein Tyrosine Phosphatase

by

Vyacheslav I. Kuznetsov, Doctor of Philosophy
Utah State University, 2013

Major Professor: Alvan C. Hengge
Department: Chemistry and Biochemistry

PTPs represent a large family of enzymes responsible for the intracellular
dephosphorylation. Together with protein tyrosine kinases (PTKs), PTPs control the level
of protein phosphorylation which modulates numerous aspects of cell life. VHZ, a
recently discovered PTP, expresses in most fetal tissues and is associated with several
types of cancer. It was originally classified as a dual specificity phosphatase (DUSP23)
and named after the prototypical member as VH1 related protein member Z.

Our

preliminary screening assays of VHZ performed with 360 phosphopeptides have revealed
a number of phosphotyrosine containing substrates, but no activity toward
phosphothreonine or phosphoserine substrates, thus strongly suggesting that this enzyme
is not related to DUSPs. We solved a crystal structure to 1.1 Å resolution, which,
together with sequence analysis showed that VHZ is more related to classical PTPs rather
than DUSPs. The crystal structure revealed an unusual metavanadate (VO3) ion in the
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active site of VHZ which has never been observed in the aqueous environment. Its
appearance in our crystal structure, together with computational studies, allowed us to
propose a mechanism by which PTPs can enzymatically interconvert different noninhibiting vanadate species dominating at physiological pH to generate the inhibiting
metavanadate ion observed in our structure. We also evaluated VHZ catalytic properties
by several techniques including steady-state and pre-steady-state kinetics, kinetic isotope
effects, kinetic inhibition studies combined with site-directed VHZ modification, and
computer modeling. We found that the catalytic activity of VHZ was significantly
underestimated by previous researchers. Unlike any other PTP, VHZ has evolved with
two general acids in the active site – a phenomenon that was expedited by two substrate
binding orientations. Finally, we show that VHZ is capable of performing hydrolysis as
well as alcoholysis of its phosphate monoester substrates. We were able to identify a
single mutation in the area of the active site responsible for this unusual
phosphotransferase behavior. Considering that the level of intracellular phosphorylation
affects a number of normal and pathological physiological processes, our finding may
explain the relation of VHZ to several types of cancer and justify this enzyme as a
promising drugable target.

(219 pages)

v

PUBLIC ABSTRACT
Structural and Functional Characterization of the LDP3 (VHZ)
Protein Tyrosine Phosphatase
by Vyacheslav I. Kuznetsov
Utah State University, 2013
Protein phosphorylation is as an important regulatory mechanism that controls a large
number of physiologically important cellular processes. Proteins are phosphorylated on
aliphatic (serine and threonine) as well aromatic (histidine and tyrosine) residues
predominantly located on sterically accessible loops. Phosphorylation affects threedimensional structures of proteins resulting in conformational changes which activate or
deactivate enzymatic functions. Because of the ability of protein phosphorylation to
modulate a multitude of diverse cellular processes, it became an appealing and promising
target for drug therapy.
Attachment of phosphate is accomplished by kinases, whereas the removal of the
phosphoryl group is performed by protein phosphatases. Traditionally, protein kinases
have been studied more intensely than protein phosphatases due to the earlier belief that
they confer fine regulation to protein phosphorylation, whereas protein phosphatases act
to nonspecifically remove phosphate groups. In recent years the protein phosphatases
were subjected to thorough analysis to reveal a number of diverse properties which
formed the basis for phosphatase classification. The family of protein tyrosine
phosphatses (PTPs) represents the largest group of protein phosphatases known today.
We focused our study on the 150 amino acids VHZ phosphatase, which was originally
classified as a dual-specificity enzyme which can dephosphorylate aliphatic (phospho
serine, phospho threonine) and aromatic (phospho tyrosine) residues. We solved a crystal
structure of VHZ refined to 1.1 Å resolution and performed an extensive structural,
biological and kinetic analysis which revealed that this enzyme is not a dual specificity
phosphatase. Activity screening with 360 biologically relevant peptides indicated strict
phospho-tyrosine specificity and provided important information about its physiological
substrates. Mechanistic studies using steady-state and pre-steady state kinetics, as well as
inhibition studies and kinetic isotope effects (KIE) explain the significantly reduced
catalytic parameters of VHZ, and contribute to our understanding of the PTP catalytic
mechanism in general.
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CHAPTER 1
INTRODUCTION
1-1. Introduction to protein phosphorylation
Within cellular signaling, protein phosphorylation is one of the most abundant
posttranslational modifications. Protein phosphorylation/dephosphorylation (Figure 1-1)
is recognized as an important regulatory mechanism affecting cell physiology, health and
pathology (1, 2). It controls inter- and intracellular communication, gene transcription,
tissue homeostasis, organ development and immune response.

Proteins are

phosphorylated on aliphatic (1, 3) as well aromatic (histidine and tyrosine) residues
located primary on sterically accessible loop regions. Phosphorylation affects three
dimensional structures of proteins resulting in conformational changes which activate or
deactivate enzymatic function or/and triggers protein-protein interaction. Protein kinases
and protein phosphatases regulate the level of intracellular phosphorylation and hereby
considered to be the main players in this dynamic process. Because of their importance
protein kinases and phosphatases are often called Yin and Yang of the phosphatome (2).
1-2. Classification of protein phosphatases
The crucially important step in understanding newly discovered enzymes is their
proper characterization and classification. Protein phosphatases are classified based upon
catalytic mechanism, presence of cofactors, structural arrangement, sequence similarities
(signature motifs, often related to the mechanism), subcellular localization, and substrate
specificity. Figure 1-2 shows the classification of protein phosphatases.
Phosphoserine/phosphothreonine specific enzymes are grouped into the PPP and
PPM families (4). Proteins in this family require metal cofactors to support activity and
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are also known as metallophosphatases (5). They utilize a multi-subunit architecture
which contains a small catalytic subunit that binds regulatory and/or targeting subunits in
vivo. Enzymes in this family have evolved to selectively target protein sites containing
serine and threonine-phosphorylated residues. The further discussion of this family lies
outside of the scope of the present work.
Another family of protein tyrosine phosphatase (PTPs) requires no cofactor to
support activity. It is subdivided into Class I, Class II, Class III, and Class IV
phosphatases based on evolutionary relation revealed by the amino acid and structural
similarities, which, in turn, are often associated with the scope of potential substrates and
biological functions. Class I, Class II, and Class III enzymes utilize the same catalytic
mechanism, which is shown in Figure 1-2.
The largest class, Class I, consists of the tyrosine specific (classical PTPs) and
dual

specificity

phosphatases,

the

latter

which

target

both

phosphoserine,

phosphothreonine as well as phosphotyrosine residues. It comprises 99 members that are
divided into 38 classical tyrosine-specific PTPs and 61 DSPs.

They could have

potentially evolved from a common ancestor due to the high structural similarity of
catalytic domains, which are easily superimposable, despite the fact they share very little
(<30%) primary sequence similarity (4). Classical PTPs can be further subdivided into
two groups of 21 and 17 genes encoding receptor PTPs (PTP-Rs) and non-receptor PTPs
(PTP-NRs), respectively. The DSP subfamily is divided into seven different groups
including

PTEN phosphatases, slingshot

myotubularins (MTMRs).

phosphatases (SSHs), MKPs, and

3

Figure 1-1. Catalytic mechanism utilized by Class I, Class II, and Class III PTPs.
The Mitogen Activated Protein Kinase phosphatases (MKPs) are specific (11
proteins) which target ERK, JNK and p38 kinases (6). These MAPKs are simultaneously
phosphorylated on threonine and tyrosine residues within a TXY activation loop region
required for full activity (7). The complete inactivation by MKPs requires
dephosphorylation at both sites as well. Although MKPs have very little sequence
similarity to classical PTPs, they share a very similar structural fold and are highly
superimposable with catalytic domains of classical PTP enzymes.
There are 16 atypical VH1-related DSPs, which are highly similar to MKPs,
except for lacking CH2 homology domain and represented by a sole catalytic subunit (8).
They are named after the first enzyme cloned – the VH1 protein from Vaccinia Virus.
They target MAPK and STAT1, but an increasing amount of evidence indicates the
substrate scope is not restricted to these enzymes. Because atypical DSPs contain no
additional regulatory or targeting domains these enzymes likely interact with additional
subunits in vivo, and, similar to serine/threonine specific phosphatases, utilize a
multisubunit arrangement. Similar to MKPs, atypical DSPs have dual specificity and can
dephosphorylate both pY and pT residues (8). It was shown, however, that VHR has a
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2000-fold preference for phosphotyrosine over phosphoserine/ phosphothreonine residues
(9).
PTEN

phosphatases

target

phosphatidylinositol

(3,4,5)-trisphosphate

phospholipids to generate phosphatidylinositol 4,5-bisphosphate (PIP2) which directly
opposes PI3 - kinase activity. It is a crucial part of many signaling pathways (10). Its
structure containing a CH2 targeting domain has been described (11).
There are 16 myotubularins, which, similar to the PTEN phosphatases, can
dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate and are highly conserved
from yeast to human (12-15). The physiological role of these enzyme remains unclear,
however, it was shown that more than a half of the known enzymes in this group lack
catalytically important cysteine, arginine and aspartic acid residues and are thus
catalytically inactive.
The PRL family of phosphatases contains the PRL-1, PRL-2, and PRL-3
enzymes. These enzymes contain a conserved PTP catalytic domain as well as C-terminal
CAAX region which is required for post-translational farnesylation of these enzymes
(16). These enzymes are believed to localize close to the cell membrane but the actual
role and biological functions remains largely unknown.
The only Class II enzyme found in humans is a Low Molecular Weight (LMW)
protein tyrosine phosphatase. Despite sharing the same mechanism as classical PTPs and
DSPs, LMW-PTPs have a strikingly different catalytic domain topology and cannot be
superimposed with classical PTP or DSPs. With the exception of the C(X5)R(S/T)
catalytic signature motif highly conserved in all PTPs, and the catalytic aspartic acid
required for catalysis (17), LMWs share no sequence homology with other PTPs. They
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are related to evolutionary conserved bacterial type II phosphatases. LMW PTPs target a
number of tyrosine kinases, and similar to classical PTPs can only dephosphorylate pY
residues (18).
Class III is exemplified by three p80 CDC25 phosphatases – CDC25A, CDC25B
and CDC25C. These enzymes are known cell cycle regulators which specifically target
Cdc2 kinase by dephosphorylating tyrosine and threonine residues located on the (pT)-P(pY) phosphorylation lip. This dual dephosphorylation activates Cdks promoting cell
division cycle progression. Similar to Class II enzymes, Class III is structurally distinct
from other PTP family members (19) and with the exception of the PTP signature motif
share no sequence homology (3). Despite sharing the catalytic PTPase motif the enzymes
are not inhibited by oxyanions suggesting their mechanism is more related to the bacterial
rhodanese (20) which catalyzes transfer of sulfane sulfur from thiosulfate to cyanide
generating thiocyanate and sulfite. What is remarkable about Class III enzymes is that,
working as phosphatases, they are themselves dependent on phosphorylation of
conserved tyrosine residues near the active site.
All PTPs except for class IV utilize the same two step double displacement
mechanism and contain a consensus catalytic signature (H/V)CX5R(S/T) motif in which
cysteine and arginine residues are invariant and essential for enzymatic activity of all
members. By contrast, the class IV members contain a conserved (DXDXT/V) domain
and use an aspartic acid as a key element for catalysis (21). The class IV enzymes have
been demonstrated to display pS or pY phosphatase activity as well (22). EyA (eye
absent) tyrosine specific phosphatases and HAD (haloacid dehydrogenase) are pY or pS
specific and target various substrates including proteins, phospholipids and sugars.
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Most of the PTPs, unlike S/T-phosphatases have a modular structural architecture.
In other words, 79 out of 107 known PTPs contain at least one additional non-catalytic
(extracatalytic) domain which is important for enzyme-substrate interaction, or
intracellular localization and represents a part of the same polypeptide chain which is
permanently attached to the catalytic subunit (23). For example, receptor type PTPs
contain a SH2 domain that consists of 100 residues and contains a pY binding site. MAP
kinase phosphatases contain a N-terminal CH2 (CDC25 homology) domain which targets
them to their natural substrates – ERK and JNK kinases (24-26). Myotubularins contain
an N-terminal PH (pleckstrin homology) domain and C-terminal coil domain which
targets these enzyme to specific subcellular location. Only a group of small atypical
VH1-related DSPs and Class II Low Molecular PTPs contains no additional
extracatalytic domains. As was exemplified by the SHP-1 PTP, the extracatalytic domain
may modulate the activity of the catalytic domain (27).
1-3. Association of PTPs with pathological processes
Protein phosphorylation plays an important role in multiple biological processes
such as proliferation, differentiation, adhesion and metabolic homeostasis. Because of the
crucial importance of the phosphorylation/dephosphorylation several PTPs were found to
be associated with cancer, diabetes, and immune deficiencies.

Type II diabetes or

diabetes mellitus is characterized by reduced insulin sensitivity (insulin resistance, IR) in
insulin target organs. Human PTP1B is responsible for the dephosphorylation of insulin
receptor kinase which generates a potent insulin mimetic effect and has been viewed as a
very potential target for anti-diabetes drugs (28). Somatic mutations in human cancer
specifically target PTEN at a high frequency, resulting in increased activity of the PI3K
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pathways that are associated with cell survival and tumor development and metastasis
(29, 30). Yersinia PTP (YopH, Yop51) is the known virulence factor in the bacterium
responsible for bubonic plague and is one of the most active phosphatases known to date

Figure 1-2. Classification of protein phosphatases. Metal containing phosphatases are
represented by PPM and PPP families. Protein tyrosine phosphatases (PTPs) require no
cofactor for catalysis and represented by aspartate-based PTPs, utilizing aspartic acid as a
nucleophilic residue, and more abundant cysteine based PTPs, containing nucleophilic
cysteine in the active site.
(25, 31). All three PRL members were found to overexpress in a variety of cancer cells
leading to cell proliferation and migration (32). While the presence of LMW PTP has
been correlated with a number of diseases such as rheumatoid arthritis, asthma, diabetes,
cardiomyopathy and Alzheimer’s disease, the physiological role of these enzymes is yet
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to be discovered (33, 34). Mutations in myotubularins were associated with
neuromuscular disease (35-37). Several MKPs were found to play an important role in
negative regulation of the inflammatory response (38, 39) as well as responsible for
several types of cancer (40). Atypical DSPs were found to overexpress in multiple cancer
cell lines including prostate cancer, breast cancer and colon cancer (41).
Unfortunately, the physiological functions of the individual PTPs are poorly
understood, owing to the lack of information about the genuine substrates of the
respective PTPs. Genetic and epigenetic alterations in genes encoding PTPs result in
changes to the equilibrium of kinase–phosphatase activity that might have deleterious
effects, including abnormal cell proliferation, which could ultimately lead to cancer. It
was noted that the mutations affecting the catalytic domain are known to be associated
with highly conserved regions. They were found to have an oncogenic effect and
simultaneously decrease the authentic phosphatase activity. In order to better understand
the effect of genetic alteration and mutations, the catalytic principles of individual PTPs
must be better understood. For example, it is not clear why different PTPs which share
the same catalytic protein fold and utilize the same mechanism differ by as much as four
orders of magnitude in their catalytic activity.
1-4. VHZ as a newly member of PTP superfamily
Human VHZ (also known as DUSP23 or LDP3) was cloned and characterized by
several research groups in recent years (23, 42, 43). Because of its small size stipulated
by the absence of any extracatalytic domains it was immediately tagged as an atypical
DSP and named VH1 related member Z. Its mRNA overexpresses in all fetal tissues, but
it is only present in adults’ testis and colon.

The VHZ sequence is evolutionarily
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conserved and did not alter significantly as revealed by its orthologues from frog, fish,
fly, and the Archaea, indicating an important physiological role which is yet to be
discovered. It was found to overexpress in several cancer cell lines, indicating it may
play some role in the tumor development process (44). The kinetic characterization of
this newly discovered phosphatase revealed it was one of the least active protein
phosphatases known to date. The research however stumbled over an unexpected
problem when VHZ was tested to identify its natural substrates from the list of MAPK
known to be atypical DSP targets (45). The results yielded conflicting reports and failed
to provide consistent evidence. The only crystal structure of VHZ in complex with
malate ion in the active site trapped from the crystallization cocktail was used to present
additional evidence for VHZ being a VH1 related DSP (46). The fact that the malate ion
was neither substrate nor product analogue for this class of enzymes (but was
nevertheless treated as such), and was involved in several unspecific interactions was
completely ignored. It was obvious that there was no consistent and reliable information
about VHZ that could be used to guide further research or make affirmative conclusions
about its biological role. At the same time its evolutionary conservation, expression in
several human tissues, and association with cancer development and progression made it
a particularly promising target for the future research.
In the following chapters we address important aspects of VHZ in more detail. In
Chapter 2 we show that from the very beginning its classification as a VH1 related DSP
was incorrect and was detrimental for essentially all subsequent research conducted with
this enzyme. We present a crystal structure of VHZ (PDBID 4ERC) with a
physiologically relevant metavanadate transition state analogue which allowed us to draw
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several important conclusions and revise the original classification of VHZ. Our
conclusions were consistent with the kinetic evidence obtained with a multi-peptide
library which indicated that VHZ reveals an exclusive phospho tyrosine specificity and
hereby cannot be treated as DSP. In Chapter 3 we show that VHZ has very unique,
unprecedented kinetic properties and significantly more active than it was previously
believed. We use SsoPTP from the thermophilic organism Sulfolobus solfataricus which
is structurally related to VHZ to show that the observed kinetic behavior was not
accidental but stipulated by the uniqueness of the structure. In Chapter 4 a potential
mechanism by which PTPs are inhibited by vanadate oxyanions is proposed and
discussed. It addresses the long lasting and controversial topic of how PTPs are inhibited
by complex mixtures of vanadate oxyanion, how closely vanadate mimics transition state
of PTP catalyzed reaction, and the nature of vanadate interaction with this family of
enzymes.
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CHAPTER 2
NEW ASPECTS OF THE PHOSPHATASE VHZ REVEALED BY A HIGH
RESOLUTION STRUCTURE WITH VANADATE
AND SUBSTRATE SCREENING1
Abstract
The recently discovered 150-residue human VHZ (VH1 related protein, Z
member) is one of the smallest protein tyrosine phosphatases (PTPs) known, and contains
only the minimal structural elements common to all PTPs.

We report a substrate

screening analysis and a crystal structure of the VHZ complex with vanadate at 1.1 Å
resolution, with a detailed structural comparison with other members of the protein
tyrosine phosphatase family, including classical tyrosine-specific protein tyrosine
phosphatases (PTPs) and dual specific phosphatases (DSPs).

A screen with 360

phosphorylated peptides shows VHZ efficiently catalyzes the hydrolysis of phosphotyrosine(pY)-containing peptides, but exhibits no activity toward phospho-serine (1) or
phospho-threonine (pT) peptides. The new structure reveals a deep and narrow active
site more typical of the classical tyrosine specific PTPs. Despite the high structural and
sequence similarities between VHZ and classical PTPs, its general acid IPD-loop is most
likely conformationally rigid, in contrast to the flexible WPD counterpart of classical
PTPs. VHZ also lacks substrate recognition domains and other domains typically found
on classical PTPs. It is therefore proposed that VHZ is more properly classified as an
atypical PTP rather than an atypical DSP, as has been suggested.
1
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Introduction
Protein tyrosine phosphatases (PTPs) are involved in multiple physiological
processes including cell growth and proliferation, control of the cell cycle, cytokine
activation and cytoskeletal integrity (2, 3). PTPs share the conserved signature motif
HCXXGXXR(S/T) that binds the substrate and provides transition state stabilization, and
a two-step catalytic mechanism with a cysteinyl-phosphate intermediate (4-6). PTP
family members are further subdivided into several subfamilies based on substrate
specificity and sequence similarity. In-vivo protein phosphorylation most commonly
occurs on hydroxyl containing aliphatic (serine/threonine) or aromatic (tyrosine) side
chains, and the classical PTPs (often referred to as tyrosine specific PTPs) hydrolyze only
phosphotyrosine containing polypeptides. The dual-specificity phosphatases (DSPs)
constitute a subset of (PTPs) that are characterized by the ability to dephosphorylate
phosphoserine and phosphothreonine residues in addition to phosphotyrosine (7, 8).
The active sites of all PTP family members are structurally similar and utilize an
invariant triad of amino acids to catalyze phosphate monoester hydrolysis, which includes
a nucleophilic cysteine; an arginine that, along with backbone amides, binds substrate and
provides transition state stabilization; and an aspartic acid that protonates the leaving
group. In the classical, tyrosine-specific PTPs the latter catalytic residue resides on a
flexible loop referred to as the WPD loop (9). In the DSPs, the general acid is believed to
reside on a structurally rigid element.
Despite the high structural similarities of catalytic domains, superimposable
active sites, and common mechanism, PTPs are selective for particular biological targets.
The accurate identification of substrate preference and the correct assignment of these
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enzymes into the various PTP subfamilies associated with different biological pathways
and pathological states is one of the most important goals of human phosphatome
research. The recently discovered 150-residue human VHZ (also designated as atypical
DSP 23) is one of the smallest PTP family members known to date, which contains only
the minimal set of secondary structural elements common to all PTPs (10-12). Because of
its small size and the absence of substrate targeting domains, it has been classified as an
atypical VH-1 related DSP (12) - a subfamily of cysteine based PTPs that regulates
mitogenic signaling pathways and cell cycle process (7, 13). Atypical DSPs have been
linked to cancer, but despite numerous studies knowledge about these enzymes still
remains contradictory and incomplete (1, 14). The attempts to identify the physiological
substrates of VHZ have provided conflicting and inconsistent evidence (10, 15, 16). It is
known, however, that VHZ is highly expressed in fetal tissues, and recent reports
associated VHZ with breast cancer (17).
The only crystal structure of VHZ published to date is a complex with malate
trapped in the active site (18). Malate ion is an important part of VHZ crystallization
conditions, but represents neither a substrate nor a product analogue. Potential resulting
distortions on the local geometry of the active site motivated us to seek a structure with a
physiologically relevant reaction analogue. We report a high-resolution X-ray structure
of VHZ complexed with the physiologically relevant transition state analogue
metavanadate which allows us to compare VHZ structurally with a number of classical
PTP and atypical DSP protein-ligand complexes. This analysis suggests that VHZ bears
more resemblance to the classical PTPs rather than DSPs, but probably lacks a movable
loop. These conclusions from the crystal structure support the results of a phosphopeptide
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substrate screen, which revealed that phosphotyrosine, but not phosphoserine or
phosphothreonine-containing peptides, are substrates for VHZ. The collected results
strongly suggest that VHZ is more related to the classical PTPs rather than the atypical
DSP subfamily, and in order to more properly guide future research in the biological
roles of VHZ, its current classification should be re-considered.
Experimental Procedures (Materials and Methods)
All buffer solids, EDTA, malic acid, ammonium sulfate and sodium
orthovanadate were obtained from Fisher. Chromatography columns were purchased
from GE Healthcare. Protease K was from Sigma. Polyethyleneimine (Mw 50000) was
from Acros Organics. A set of standard FastDigest restriction enzymes, DNA Pfu Turbo
Polymerase, dNTP master mix were obtained from Fermentas. Custom primer
oligonucleotides were synthesized by IDT. The phosphatase substrate screen was from
GPT Innovative Peptide Solution. DTT, antibiotics and protease inhibitors were from
GoldBio.
Protein cloning
The human VHZ WT gene was amplified using a two-step PCR strategy from a
GST-tagged version on a plasmid that was a generous gift of Dr. Subramanyam
Swaminathan (18). In the first step the gene was amplified using the following primers:
Fwd1:

GAAAACCTGTATTTTCAGGGCGTGCAGCCCCCC,

Rev1:

GGAGAGCTCTTATTTCGTTCGCTGGTAGA to incorporate TEV cleavage site (in
bold) immediately upstream of the first N-terminal GGC codon (methionine excluded).
At the same time SacI restriction site (GAGCTC) was added at the end of the sequence.
In the second PCR step, the product of the first step was used as a template and a KpnI
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restriction site was added upstream of the TEV protease cleavage sequence using the
following set of primers: Fwd2:CGGGGTACCGAAAACCTGTAT, Rev1:

GGAGA

GCTCTTATTTCGTTCGCTGGTAGA. The PCR product was digested with KpnI and
SacI restriction enzymes (Fermentas) and inserted into the pet-45(B+) vector (Novagen).
The obtained pet 45B+TEV-VHZ construct was successfully expressed in BL21-codon+
(DE3)-RIL cells and purified with Ni-Fast Flow High affinity resin (GE Healthcare).
Unfortunately, the resulting fusion protein was resistant to TEV cleavage of the polyhistidine tag and the tagged protein was unstable at low pH. Insertion of a short spacer
arm following the histidine tag did not improve TEV cleavage (19). A tagless enzyme
construct was prepared by removal of the histidine tag and TEV-cleavage site from the
pET 45b-TEV-VHZ construct using one-step overlap-extension PCR (20) using the
following

primers:

Fwd:

TATACCATGGGCGTGCAGCCC;

Rev:CGTGCACGCCCATGGTATATCT. The resulting construct was used to express
tagless VHZ WT in BL-21 DE-3 (codon+) cells.
Protein preparation
Tagless VHZ WT was expressed in BL21-codon+(DE3)-RIL cells. The cells were
grown at 37oC to an OD600 = 1.2-1.5. Protein expression was induced with IPTG
(100mg/L) and cell culture flasks were transferred to room temperature shaker for 20
hours before harvesting. The cells were harvested by centrifugation for fifteen minutes
and re-suspended in the lysis buffer containing 50 mM HEPES, 150 mm NaCl, 1mM
EDTA, 10 mM DTT, 5% glycerol pH 7.4 (4oC). Cells were disrupted by sonication on
ice and the pellet was separated by centrifugation. The supernatant was transferred into a
separate beaker and a 10 % w/v solution of polyethyleneimine (PEI, Mw50000, pH 8.0)
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was added dropwise to the supernatant at 4oC to reach a final PEI concentration of 0.5%
(w/v). A white precipitate formed immediately and was separated by centrifugation.
Ammonium sulfate was added to the supernatant (to 65% saturation), precipitated protein
was collected and re-suspended in 150 mL of SP-loading buffer containing 100 mM
sodium acetate, 1mM DTT, 1mM EDTA, 10 % glycerol, pH 5.6. The solution was
filtered and 15 mL of Hi-Trap SP-HP cation exchange resin (GE-Healthcare) preequilibrated with SP-loading buffer were added to the protein (4oC). The resin was
transferred into a column and washed with SP-loading buffer (2ml/min) to reach a stable
baseline. Protein was eluted using 120 mL linear gradient with elution buffer containing
100 mM sodium acetate, 1mm DTT, 1mM EDTA, 600 mM sodium chloride, 10 %
glycerol,

pH

5.6.

Fractions

containing

phosphatase

activity

toward

para-

nitrophenylphosphate (pNPP) were collected, concentrated to a volume of 3-5 mL and
loaded on a Superdex 75 26/60 gel filtration column (GE-Healthcare) pre-equilibrated
with buffer containing 10 mM HEPES, 150 mM NaCl, 1 mM methionine, 3 mm DTT, 10
% glycerol pH 7.5 (4 oC, 0.3 ml/min). The single peak correspondent to VHZ WT was
collected and estimated to be >98% pure based on the SDS PAGE analysis. Protein was
concentrated to 20 mg/mL as determined by UV using an A2801 mg/ml= 0.68.
Determination of substrate specificity
The

commercial

phosphopeptide

screen

from

JPT

Innovative

Peptide

Technologies (product code PhSS-360-250) was used. The full list of the
phosphopeptides comprising this screen is available at the manufacturer web site
(http://jpt.com) and is included in Supporting Information as Table A-1. 25 μL of buffer
containing 100 mM sodium acetate 0.5 mM DTT, 150 mM NaCl (pH5.5) and 0.25 units
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of VHZ WT (0.55mg/ml) were added in each well of 384-well microtiter plate containing
360 phosphopeptides (250 pmol per well) derived from human phosphorylation sites
together with 10 calibration standards. After incubation for two hours at 25 oC, 5 μL of
protease K (Sigma, 200 μg/ml) was added to digest the enzyme and prevent enzyme
precipitation after addition of the malachite green reagent. After 15 minutes, 30 μL of the
malachite green solution (Promega) were added and color developed for 10 minutes. The
absorbance at 600 nm was measured to quantify the amount of free inorganic phosphate
released by the enzyme using a standard curve. This was converted to a % of total
hydrolysis using the supplier-provided information for amounts of substrate in each well.
Subsequently, kcat and KM were measured for two peptide substrates, one that exhibited
among the highest percent of hydrolysis (QREAEpYEPETV) and one from the group
exhibiting the least (DADEpYLIPQQG). In a control experiment, incubation of pYcontaining peptides under the assay conditions without enzyme exhibited no measurable
hydrolysis after 48 hours.
Co-crystallization with sodium vanadate
All crystallization experiments were carried out at room temperature using the
sitting drop vapor diffusion method. VHZ WT concentrated to 20 mg/mL in the
crystallization buffer was mixed with 50 mM solution of sodium vanadate (final vanadate
concentration 10 mM, Ki=2.7 μM) prepared as previously described (21). One μL of
protein-vanadate complex was mixed with an equal volume of well solution containing
150 mM L-Malate, pH 7.0 and PEG3350 (15-20 %). 1M stock solution of sodium malate
was prepared by titration of malic acid with sodium hydroxide. Crystals grew within one
week.

24
Data collection and processing
The crystal in the droplet was transferred to a cryosolution containing the well
solution supplemented with 10% v/v glycerol and 10mM sodium vanadate for 10 min and
flash-frozen in liquid nitrogen. Diffraction data were collected at the Stanford
Synchrotron Radiation Lightsource (SSRL) on the beam line 9-2. The collection and
refinement statistics are shown in Table 2-1. Molecular replacement was performed with
Phenix (22) using the previously published VHZ structure (PDBID 2img) as a search
model with malate ion in the active site removed. Coot (23) and MolProbity (24) were
used for model building and validation. Phenix was used for model refinement. PyMol
(25) was used to prepare figures and superimpose structures. Structure factors and
coordinates have been deposited in the Protein Data Bank under accession code 4ERC.
Results
Substrate specificity of VHZ
The substrate specificity of VHZ was assessed using a phosphatase substrate set
containing 360 peptides, correspondent to natural in vivo phosphorylation sites
monophosphorylated on serine, threonine, or tyrosine.

Amino acids adjacent to the

phosphorylation site play an important role in the substrate recognition by different PTPs
(26). The structural diversity of JPT screen eliminates the bias resulting from adverse
binding effects caused by unfavorable amino acids proximal to the phosphorylated site,
which allows a reliable assessment of the comparative effectiveness of VHZ in catalyzing
the hydrolysis of pS, pT and pY containing peptides. Because the goal of this experiment
was to determine whether VHZ was a DSP or a PTP, reactions were given a sufficiently
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Table 2-1. Data collection and refinement statistics

Data collection
Beamline
Wavelength (Å)
Resolution range (outer shell) (Å)
No. of reflections
Unique
Total
Average redundancy
Mean I/σ(I)
Completeness (%)
Rsym (%)
Space group
Unit cell dimensions (a, b, c (Å); α = β =γ
90° )

Refinement
Rwork/Rfree (%)
Atoms in the structure
Protein
Waters
Ligands/ions
Average B-factors (Å2)
Protein
Water
R.M.S.D. bond (Å)/angle (degrees)
Protein geometry
Ramachandran favored (%)
Ramachandran outliers (%)
Rotamer outliers (%)
Protein Data Bank entry

VHZ-VO3
SSRL
9-2
0.97946
50.00-1.15 (1.19 -1.15)
94,449
1,237,514
13.1 (12.2)
31.3 (3.8)
99.6 (99.4)
6.8 (66.6)
P 21 21 21
33.0, 79.9, 99.7

12.8/14.5
5312
4838
466
8
13.6
26.6
0.008 /1.245
96.07%
0.66
1.57%
4ERC

long time to incubate before assay to insure that even substrates yielding very low
activity would be detected. After two hours, enzymatic activity was observed in every
well containing a pY-phosphorylated peptide, with an average hydrolysis completion of
50-60%. No activity was observed in wells containing either pS or pT-phosphorylated
peptides. In particular, no activity was observed in the wells containing serine/ threonine
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monophosphorylated peptides corresponding to the previously tested MBP (myelin
binding protein) and common DSP substrates containing TXY activation loop of MAPK
8—MAPK11. The peptide sequences that resulted in hydrolysis yielding greater than the
average are presented in Table A-2 of Supporting Information.

In subsequent

experiments, kcat and KM were determined for the substrate QREAEpYEPETV, one of the
substrates exhibiting the highest percent of hydrolysis, and for DADEpYLIPQQG, which
was among those that exhibited the lowest activity. These kinetic results are shown in
Table 2-2.
General structure description
The crystal structure of VHZ complexed with metavanadate was solved to 1.1 Å
resolution (Figure 2-1). The structure was refined to an Rwork/Rfree of 12.8/14.5% (Table
2-1). Two molecules of VHZ are contained in the asymmetric unit. The final model
includes the protein residues 1-150 and a metavanadate (VO3) ligand present in each
active site. VHZ is a single domain protein consisting of a central, twisted, five-stranded
β sheet surrounded by six α helices, two on one side and four on the other side (Figure 21). The conserved phosphate-binding loop (P-loop) connects the β5 strand and the α4
helix, and general acid loop (referred as IPD-loop (12) by analogy to the conserved WPD
loop of the classical PTPs) connects α3 and β4 elements. The D residue of the IPD motif
(D65) acts as the general acid during catalysis. The Q-loop (connecting α6 and α5)
further defines the active site cleft. The overall VHZ structure represents a typical for the
PTP family α/β domain. Both molecules in the asymmetric unit adopt a similar protein
conformation. The guanidinium side chains of R60 and R62 from the symmetry related
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VHZ molecule is observed in the area of the active sites of molecule A and molecule B,
respectively (Figure 2-2 A,C).
\

Comparison with VHZ-Malate structure
The structure of the VHZ-VO3 transition state complex differs in several important
details from the previously published VHZ-malate complex. In the VHZ-Mal structure
(not shown), the malate ion makes four hydrogen bonds to the backbone of the P-loop,
two hydrogen bonds to the side chain of R101, and one hydrogen bond to the backbone
of the IPD-loop. The catalytic acid D65 (in the IPD loop) and E134 (in the Q-loop) are
turned away from the active site (presumably repelled by the negative charge of the
malate carboxylate groups). As a result, the IPD-loop adopts a catalytically unfavorable
conformation in which D65 hydrogen bonds to the side chain of the conserved
phosphate-binding residue R101. Additionally, this catalytically unviable conformation
imparted by malate distorts the VHZ active site into a shallow and broad crevice
reminiscent of DSPs.

In the VHZ-Mal complex the side chain of Y136 from the

symmetry related molecule is trapped in the active site, which, together with the rest of
Table 2-2. Kinetic constants for peptide hydrolysis. Two substrates selected from the
substrate screen of differing percentages of hydrolysis. The last column shows the
percent of hydrolysis observed in the long time course general substrate screen.

Peptide Sequence

kcat (s-1)

KM (mM) 10-3 kcat/KM (M-1s-1) % hydrolysis

QREAEpYEPETV 0.56 ± 0.02 1.9 ± 0.2

0.3

100%

DADEpYLIPQQG 0.53 ± 0.06 4.2 ± 0.4

0.12

50%
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Figure 2-1. Structure of the VHZ-VO3 complex. Cartoon representation of the VHZ-VO3
structure reveals a classical PTP α/β fold with central region composed of β sheet (green)
surrounded by α helices (brown). The important active site residues and hydrogen bond
network (dashed lines) surrounding the VO3 oxyanion are shown.
the molecule, makes five additional crystal contacts in the area of the active site, further
complicating the interpretation of this structure.
In the VHZ- VO3 structure, the active site contains a region of distinct electon
density corresponding to a low B-factor water molecule. The water is located whithin
hydrogen bond distance from the equatorial oxygens of VO3, the side chains of E134 (Qloop), Q138 (Q-loop), and D65 (IPD-loop), and the backbone amide nitrogen of F66
(Figure 2-1). It is absent in the VHZ-Mal structure due to interactions of the malate ion,
but a water in this position is consistently observed in X-ray structures of classical PTPs
such as Yersinia PTP and PTP1B. It represents an important node coordinating the
primary active site elements in classical PTPs but not in VH1 related DSPs.
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Figure 2-2. Comparison of the VHZ-VO3 complex with analogous PTP1B structures. (A)
The VO3 molecule at the VHZ active site in Chain A coordinated by P-loop hydrogen
bonds. The structural water Ws shown in Figure 2-1 has been omitted for the sake of
clarity. Hydrogen bond distances (in red) are in Å. The vanadium-sulfur distance is
similar to that observed in PTP1B structure PDBID 3I7Z (shown in B) with a bound
vanadyl peptide. The R60 side chain belongs to the symmetry related VHZ molecule
trapped near the active site. (B) A transition state analog structure for the first catalytic
step of PTP1B (PDBID 3I7Z), consisting of the enzyme bound to the tyrosyl vanadyl
ester of the peptide DADEYL; (C) The VO3 moiety at the VHZ active site in Chain B.
(D) A crystal structure of YopH with bound nitrate, taken as a transition state analogue
for the second catalytic step of the PTP mechanism (PDBID 1YPT). The R62 side chain
nitrogen atom from a symmetry related VHZ molecule near the active site in Chain B in
(C) assumes a position that is analogous to the nucleophilic water molecule (WATNU).
The VHZ-VO3 complex (Figure 2-2) reveals the active site arrangement observed
in many classical PTP structures where all of the catalytic elements are properly
positioned for catalysis. The electron density in the active site region clearly reveals the
[VO3]- ion is coordinated in each active site to the P-loop amide backbone as well as to
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the side chain of R101. The sulfur of C95 is 2.4 Å from the central vanadium atom. The
electron density indicates 100% occupancy of the [VO3]- ion bound to one of the VHZ
molecules (chain A) but only 86% occupancy in the second molecule (chain B). The
guanidinium moiety of R101 makes bidentate hydrogen bonds with the bound
metavanadate, which is a transition state analog of the transferring phosphoryl group.
The general acid D65 is located in a position suitable for protonation of the scissile
oxygen atom, as is commonly observed in similar ligand-containing PTP structures. The
nucleophilic cysteine sulfur atom is in an apical position relative to the central VO3
moiety.
Interestingly, a gap in electron density exists between the C95 and the vanadate
in both the 2Fo-Fc difference map and in an unbiased composite omit map (Figure 2-3 A,
C). Modeling and refinement of a covalently bound cysteinyl-vanadate adduct resulted in
a large negative electron density peak in the region between the sulfur and vanadium
(Figure 2-3 B), whereas relaxation of the geometry constraints during refinement yielded
the original model with a non-covalent sulfur-vanadium interaction. This suggests a
primarily electrostatic interaction rather than a covalent bond between cysteine 95 and the
vanadium atom, which has been confirmed by a computational analysis (27).
Functional analysis of VHZ active site
The active site of classical PTPs is formed by the phosphate binding loop (Ploop), a glutamine-bearing loop (Q-loop), general acid loop (WPD-loop), and substrate
binding (recognition) loop. VHZ lacks a substrate recognition loop, which is normally
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Figure 2-3. The electron density at the VHZ active site. It reveals a non-covalently bound
vanadate molecule. (A) 2Fo-Fc (blue) contoured at 1.5 σ around catalytic C95,
metavanadate, and neighboring residues in the refined model. The arginine from the
symmetry related molecule was omitted for the sake of clarity. (B) 2Fo-Fc (1.5 σ) (blue)
and Fo-Fc (±3.0 σ) maps (green is positive; red is negative) produced after refining with a
covalently bound cysteinyl-vanadate model. (C) An unbiased composite omit map
contoured at 1.5 σ in the same orientation as (A).
located at the N- terminus of classical PTPs. These loop regions in VHZ, compared with
PTPs and DSPs, are discussed separately.
P-loop interactions (VHZ residues 95-102)
The P-loop interactions with bound VO3 in VHZ are presented in Figure 2-1. The
backbone amides of five P-loop residues make hydrogen bonds to the [VO3]- ion. The
amide of conserved G98 makes a catalytically important hydrogen bond to the side chain
of the nucleophilic C95 (28). The side chain of T102 also donates a hydrogen bond to the
C95 sulfur, assisting the breakdown of the phosphoenzyme intermediate in the second
step of the overall reaction, another conserved feature of the PTP family (29). The
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carbonyl oxygen of G98 makes a hydrogen bond to the side chain of R129, which,
together with the side chain of N7, provides conformational stability to the P-loop. This
arginine is highly conserved in all PTPs, and mutation leads to the loss of enzymatic
activity (30). In atypical DSPs, in addition to the structural role, this residue is important
for recognition of bisphosphorylated peptide substrates, providing a positive charge in the
second docking site on the protein surface (30). In classical PTPs this arginine is shielded
from the surface by protein structural elements and plays no role in the substrate
recognition. In VHZ, as in classical PTPs, R129 is shielded from the surface by the side
chain of N7 (Figure 2-1). The guanidinium R101 side chain, which binds the phosphate
moiety of the substrate, makes two hydrogen bonds to the metavanadate equatorial
oxygens, the carbonyl oxygen of I63 (in the IPD-loop) and to the carboxyl oxygen of
E44.
Q-loop interactions (residues 127-138)
In classical PTPs this region is characterized by two conserved Q residues and
participates in catalysis by activation and orientation of the nucleophilic water in the
second step (31, 32). Important Q-loop interactions are presented in Figure 2-1. The Qloop motif in VHZ is identical to that in classical PTPs with exception of the substitution
of the first Q by E, which, however, resulted in no functional changes in YopH (32). The
side chains of E134 and Q138 are directed toward the active site, and together with D65
(from the IPD-loop) serve to position the incoming nucleophilic water. The analogous Nloop region in atypical DSPs (Figure 2-4) is positioned such that it provides a broad and
shallow active site opening required for dual specificity that has no conserved
glutamines.
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IPD-loop interactions (residues 61-71)
The general acid loop in VHZ has been termed the IPD loop, by analogy with the
conserved WPD loop in the classical PTPs (18). This loop carries the D65 general acid
that protonates the leaving group in the first step, and acts as a general base in the second
step activating the nucleophilic water (16, 33, 34). The interactions involving IPD loop
residues are shown in Figure 2-1 and Figure 2-2. The IPD loop position corresponds with
the closed, catalytically active position of the WPD loops in classical PTPs. The side
chain of I63 docks in a hydrophobic pocket created by the aliphatic part of R101 and side
chains of M105, V93 and P69, providing hydrophobic interactions similar to those
involving the conserved W in classical PTP (35). Similar to clasical PTPs, the carbonyl
oxygen of I63 makes a hydrogen bond to R101 retaining its side chain in the catalyticaly
favourable substrate binding conformation. Additional hydrogen bonds occur between the
carboxyl oxygen of D65 and structural water WS as well as between carbonyl oxygen of
C67 and side chain nitrogen of Q138. Such interactions are characteristic in the WPDloop stabilization in classical PTPs (Figure2-4, A) but not of atypical DSPs (Figure 2-4,
B) (36). The structural water molecule is absent in all atypical DSP structures reported to
date. Instead, general acid positioning is provided by the side chain of a conserved
asparagine from the N-loop motif and the conserved serine from the P-loop. As the result,
the general acid position in relation to the leaving group differs in PTPs compared to
DSPs and protonation occurs from different angles (Figure 2-4, A and B).
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Figure 2-4. Important distinctions between atypical DSPs and classical PTPs. The
catalytic general acids are D356, D92 and D65 in YopH, VHR and VHZ respectively; all
structures are viewed at the same angle in relation to the structurally superimposable Ploop. Topology and hydrogen bond network of the general acid loop and Q-loop in
YopH-1YTW (A), VHR-1J4X (B) and VHZ-VO3 (C) reveal important distinctions
between classical PTPs (represented by YopH ) and atypical DSPs (represented by
VHR): 1) Stabilization of general acid WPD-loop in classical PTPs (Panel A) and
atypical DSPs (Panel B) is obviously different. In particular, the structural water (Ws)
provides stabilization to the general acid loop in YopH and VHZ, but is never observed in
atypical DSPs. In VHR (and other atypical DSPs) the general acid loop is stabilized by
the cluster of highly conserved serine/asparagine residues (S129/N163 in VHR, Panel B).
As a result, the position of the general aspartic acid in PTPs and DSPs is different and the
leaving group protonation occurs at different angles; 2) Classical PTPs use invariant Qloop residues (Q446 and Q450, Panel A) to orient the incoming nucleophilic water (not
shown in the figures). The analogous E134 and Q138 residues are present in VHZ (Panel
C). The analogous region in VHR, named N-loop, has no analogous residues and bears
the invariant structural asparagine (N163, Panel B); 3) Glycine residue in YopH (G408,
Panel A) and VHZ (G100, Panel C) provides the important access of Q446 and E134 into
the active site, whereas the invariant structural serine is present in VHR (S129, Panel B)
and other atypical DSPs.
Sequence analysis of VHZ
With the goal of ascertaining where VHZ fits in the PTP-DSP continuum, we
carried out sequence and structural comparisons between VHZ and several classical PTPs
and VH1-related DSPs. Because of significant size differences and little conservation
outside of the following regions, alignments were confined to the general acid-loop, Ploop, and Q-loop as the three most important catalytic regions. The results, shown in
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Appendix A, Figure A-1, A and B, reveal both significant resemblance of VHZ to the
classical PTPs, and important distinctions from atypical DSPs.
Sequence analysis of the P-loop
The general PTP family signature motif (P-loop motif) contains the
HCXXGXXR(S/T) sequence (2, 37). As can be seen from the sequence alignments in
Figure A-1, (A and B), the conserved motif in classical PTPs is HCXXGXGRT whereas
in atypical DSPs this sequence is HCXXGXSRS.

The H+6 position (in bold) is

exclusively occupied by glycine in classical PTPs and by serine in atypical DSPs. The
serine at this position in atypical DSPs donates a hydrogen bond to the general acid
(Figure2-4 B) contributing to its correct positioning for catalysis. Mutation of S129 to G
in VHR abolishes general acid catalysis by D92 (data not shown). In classical PTPs,
glycine occupies the analogous position (Figure 2-4, A), which permits conserved Q-loop
glutamine residues (Q446 and Q450 in YopH) to access the active site and participate in
the second step of the reaction by positioning the nucleophilic water (32, 38). VHZ
(Figure 2-4, C) resembles classical PTPs in having glycine (G100) rather than serine in
this position, which allows the E134 side chain to access the active site.
The sequence analysis of the Q-loop
In classical PTPs (Figure A-1, A) this region contains the motif
(V/I)Q(R/T)XXQ. The region is named after two catalytically important Q residues that
serve to orient and activate the nucleophilic water molecule in the second step (32, 38).
The corresponding N-loop in atypical DSPs characterized by the highly conserved
PNXXFXXQL sequence contains a conserved asparagine residue (N163 in VHR), which
together with the conserved S residue in the P-loop (S129 in VHR), forms a hydrogen
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bond with the general acid and stabilizes its catalytically favorable conformation (Figure
2-4, B).
The sequence analysis of the IPD-loop
In the atypical DSPs the general acid-bearing loop has no sequence conservation
(Figure A-1,B) with exception of the catalytic aspartic acid, and unlike the WPD-loop,
does not undergo conformational changes (36). The sequence alignment of VHZ with
classical PTPs (Figure A-1,A) shows its IPD-loop is highly analogous to the WPD-loop
in classical PTPs with the exception of I63 in place of the conserved W. The MOTIF
server was used to search the RSCB database for structures that simultaneously contain
the PTP family HCXXXXR[S/T] motif and a variable general acid XXDXXP loop region
(Figure A-1, C) but not the highly conserved PNXXXF N-loop sequence, thus allowing
us to eliminate atypical DSPs. The goal was to identify proteins that, like VHZ, are
related to classical PTPs but with variability of the general acid loop region. Alignment
of the retrieved structures (e.g. VSP (3AWF), PTEN (1D5R), KAP1 (1FPZ), PhyA
(3F41), SsoPTP (2I6I), CDC14B(1OHC) revealed the common PTP α/β-fold with
general acid XXD-loops superimposable with the IPD-loop in VHZ and WPD-loop in
classical PTPs (Figure A-1,C). These proteins share the active site architecture of
classical PTPs with substitutions for W in the general acid loop. Based on the sequence
alignment analysis and structural and functional information of the retrieved proteins,
VHZ is most closely related to S.solfataricus PTP rather than VSP, PTEN, KAP1, PhyA
or CDC14B.
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Discussion
Identification of VHZ Substrate specificity.
The substrate specificity of VHZ has been the subject of several conflicting
studies. In one study VHZ was found to effectively dephosphorylate ERK, but not JNK
or p38 (11). In another study, VHZ was found to effect JNK and p38 with no apparent
effect on ERK (10). These substrates are common ones among DSPs. The substrate
screen used in the present study contained several sequences corresponding to activation
loops of MAPK 8, MAPK 9, MAPK 10 and ERK1 monophosphorylated on pT or pS. No
activity was detected in these wells, indicating that if VHZ targets the reported proteins, it
may dephosphorylate only the phosphotyrosine of the pTXpY activation loops, unlike the
DSP VHR, which targets both sites (30). The observed dephosphorylation pattern is
characteristic of classical tyrosine-specific PTPs, which result in monophosphorylated
MAPK forms and retain reduced but significant activity compared to the biphosphorylated proteins (39). DSPs have a preference, but not specificity for,
bisphosphorylated substrates, and have the ability to act on singly phosphorylated pS and
pT-peptides. As described above, because R129 is shielded by the side chain of N7, it is
unlikely that VHZ has a preference for bisphosphorylated substrates (30, 40). These
results suggest that VHZ is phosphotyrosine specific PTP rather than a DSP.
Two substrates, one from among those showing the highest hydrolysis percentage
and one from the lowest, were chosen for more detailed kinetic analysis. Table 2-2
shows the kcat, KM, and kcat/KM for the substrates QREAEpYEPETV and
DADEpYLIPQQG. The substrates differ in KM but have similar kcat values. The kcat
values are higher than a reported value of kcat of 0.009 with pNPP (12). Related enzymes
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(VH1, VHX, and VHY) show kcat values in the range 0.2 to 0.9 s-1 with pNPP (12). The
substrate DADEpYLIPQQG has also been tested with YopH and PTP1B. At pH 6.6 and
30 C with YopH, kcat = 1314 ± 18 s-1 and KM = 59 ± 4 µM; with PTP1B, kcat = 75.7 ± 1.0
s-1 and KM = 2.63 ± 0.37 µM (41). Both YopH and PTP1B exhibit very similar kcat
values for a range of phosphopeptide substrates regardless of sequence. The same trend
is apparent in these two VHZ substrates, where the difference in hydrolysis arises from
KM rather than kcat. Such consistency in turnover number is a common feature of PTPs,
although kcat varies over several orders of magnitude among enzymes within the PTP
family. The lower kcat observed for the peptide substrates in this study for VHZ relative
to YopH and PTP1B parallels the lower rate reported for VHZ catalysis of pNPP (12). A
thorough search for substrate sequences with particularly strong affinity for VHZ is
beyond the scope of this study.
The apparent disagreement between our assay results and those of previous
reports of VHZ as a DSP led us to consider potential explanations. In one of the previous
reports, a commercial kit was used to estimate the phosphatase activity (11). Our
previous experiments with commercial kits based on malachite green assays have shown
a tendency to give false positives with some proteins, depending on the quantity of
protein used. In these cases addition of the acidic malachite green solution causes protein
precipitation, forming turbidity that is not always visible to the naked eye in the darkly
colored solution. The resulting light scattering can register as absorbance over the blank
where no protein is added. We avoided this problem by digesting the enzyme with a
phosphate-free protease prior to adding the malachite green solution.
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In another study, MBP (myelin basic protein) phosphorylated by protein kinase A
(PKA) was used in a dephosphorylation assay that followed radioactively labeled
phosphate release (10). The reported pS/pT dephosphorylation rate (0.0073 pmol/min)
was 1500 times lower than pY hydrolysis (1.1 pmol/min). Despite the fact that serine and
threonine are the predominant phosphorylation sites, the PKA phosphorylation of MBP is
not 100% specific, and produces detectable quantities of pY in addition to pS and pT
(42). A small incorporation of phosphotyrosine into MBP may explain the low activity of
VHZ detected with this substrate.
Finally, the VHZ used in these previous reports contained an N-terminal GST tag.
The N-terminal region in classical PTPs contains an important substrate recognition loop.
The GST tag alone showed no phosphatase activity, but its proximity to the active site
may affect substrate specificity.

In order to avoid potential complications with N-

terminal tags, all experiments in the present study used untagged VHZ.
Is the IPD loop of VHZ mobile?
The mobility of the WPD loop in classical PTPs has been extensively documented
(9, 43-47). In solution the loop is dynamic, and substrate/oxyanion binding shifts the
equilibrium to favor the closed conformation that brings the general acid into position
favorable for catalysis (9, 48). The crystal structure of the VHZ-VO3 complex shows the
IPD-loop is properly positioned for catalysis, and superimposes with the closed WPDloop conformation observed in classical PTPs. Because the highly conserved W residue is
important for WPD-loop dynamics (49), we searched for related proteins containing
substitutions for W in this position. Like VHZ, most of the sequences resulting from this
search (Figure A-1 C) contain isoleucine. Two of these proteins, the S. solfataricus PTP
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and the CDC14 B PTP (containing an IPD-loop and FAD-loop, respectively) have been
crystallized in both apo (PDBID 2I6I and 1OHC) and tungstate bound forms (PDB ID
2I6M and 1OHD). These structures reveal no difference in the loop position in ligandfree and ligand-bound forms, which contrasts with classical PTPs. Additionally, the
crystal structures of phytase (PDB IDs 2PS2 and 3D1H) obtained with no ligand bound
has the identical closed loop position. These findings suggest the general acid loop is not
a mobile element in these enzymes. To seek a further rationale for the apparent single
conformation of the IPD-loop in VHZ, we aligned the VHZ-VO3 complex with the YopH
WT ligand-free structure (PDB ID1YPT) where the loop occupies its open conformation.
The alignment revealed that, were the IPD loop of VHZ to adopt an open conformation,
D65 would clash with the anionic side chain of E44, which corresponds to the smaller
and neutral S287 in YopH (Figure A-2). The S. solfataricus PTP and phytase contain
analogous E37 and E132 residues in this location.

In all, there is no evidence or

likelihood that these enzymes undergo conformational changes in their general acid loop.
We conclude that, although VHZ is likely related to the classical PTPs in other structural
aspects and in substrate preference, its IPD loop probably does not undergo
conformational changes in the process of catalysis.
The shape of the active site
The active site width and depth are primary factors defining substrate specificity
in the PTP family. In Figure 2-5 the active sites of two DSPs (CDC14B (A) and VHR
(B)), the classical PTP YopH (C), and VHZ(D) are rendered as surface models. Two
peptide substrates containing pY and pS are modeled in the catalytically favorable
orientation. In this position the equatorial oxygens are stabilized by hydrogen bonds
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from the P-loop, and the scissile phosphate monoester oxygen is located within hydrogen
bond distance of the general acid. These common determinants allow one to model
substrates into the active sites of PTPs and DSPs with little ambiguity. Atypical DSPs are
characterized by shallow and/or broad active sites that allow them to accommodate the
aliphatic side chains of pS (2.63Å distance between phosphorus and the alpha-carbon)
and pT (3.76 Å), in addition to longer pY (7.44Å) residues (Figure 2-5 A and B). In
contrast, classical PTPs have a deep and narrow active site pocket that accommodates
pY-containing peptides (Figure 2-5 C and D). Modeling shows that the pT and pS side
chains of a polypeptide substrate are too short to reach the nucleophilic cysteine at the
bottom of the active site, consistent with their lack of activity by classical PTPs, although
low activity with monomeric alkyl phosphate esters has been reported (50). With its
shallower active site depth of 6 Å, the DSP VHR already displays a 2000-fold preference
for pY over pS/pT-containing substrates. The active site of VHZ is deeper than that of
VHR and is close to those of classical tyrosine specific PTPs (Figure 2-5 B, C, D). The
depth of the active site is a required but not exclusive factor that provides PTPs with the
ability to discriminate between aliphatic and aromatic substrates. For example, CDC14B
reveals a deep 8Å active site crevice but specifically targets cyclin-dependent kinases
phosphorylated on serine (51). This ability is provided by the greater width of its active
site, which renders dual specificity to some enzymes in the family. The active site of
VHZ is both narrow and deep, similar to classical PTPs. This provides a structural
rationale for the absence of activity toward pS and pT-containing peptides observed in
the substrate screen.
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In conclusion, a new structure of VHZ complexed with the physiologically
relevant inhibitor vanadate has been solved. This structure reveals important structural
evidence that, together with the results of broad phosphopeptide screening, allows the
following conclusions to be made:

Figure 2-5. The effect of active site geometry on PTP substrate specificity. The width and
depth, which explains the substrate selectivity observed in different PTP subfamilies
exemplified by: A) CDC14B (DSP), B) VHR(DSP), C) YopH (PTP) and D) VHZ (blue).
The active site dimensions are presented in angstroms. Phosphoserine (orange) and
phosphotyrosine (green) containing peptides are modeled in the active sites such as the
P-loop stabilized phosphate moiety is in the catalytic proximity to the nucleophilic
cysteine, and the scissile bridging oxygen on the leaving group is within hydrogen bond
distance from the catalytic general acid. The importance of the active site depth on the
substrate selectivity is illustrated in the top row, whereas the bottom row reveals the
effect of the width. The backbone of phospho serine - containing peptide in C and D is
buried below the protein surface indicating it clashes with several residues on the edge of
the active site. At the same time the binding of the phospho tyrosine containing peptide
reveals no such problem due to the longer side chain. The importance of this clash for the
substrate selectivity is consistent with the reported ability of classical enzymes to catalyze
monomeric alkyl phosphate esters but not when a part of a peptide (50).
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(a) VHZ is a viable catalyst for the hydrolysis of pY-containing peptides. In
contrast, no activity toward pS or pT residues was observed. This tendency is that of a
classical PTP rather than a DSP.
(b) Classical PTPs have a deep and narrow active site cavity consistent with the
observed specificity for pY-containing substrates. Atypical DSPs have a broader and
shallower active site in order to accommodate phosphoserine/threonine side chains. The
active site of VHZ more closely resembles those of classical PTPs.
(c) VHZ lacks the secondary positively charged binding site characteristic of
atypical DSPs that confers a preference for bis-phosphorylated substrates (30). A
conserved arginine residue characterizes this binding site. A correspondent R129 residue
in VHZ is in an analogous position as in the secondary binding pockets of atypical DSPs
(30), but it is blocked from the surface by the N7 side chain.
(d) In classical PTPs, a structural water molecule is seen in crystal structures that
stabilizes the position of the general acid loop. No such water molecule is observed in
DSP structures, where this structural role is fulfilled by the asparagine residue from the
N-loop and a serine residue from the P-loop. As a result of differences in the positioning
of the general acid loop, protonation of the leaving group occurs from different angles.
In both respects VHZ resembles PTPs rather than DSPs.
(e) The Q-loop motif containing two catalytically important glutamines
(QXXXQ) is present in all classical PTPs. Atypical DSPs contain the N-loop in the
analogous position. Its conserved PNXXF motif stabilizes the general acid and defines
the wide and shallow active site of atypical DSPs. Analogous to the classical PTPs , the
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Q-loop in VHZ contains E134 and Q138 residues superimposable with Q446 and Q450
in YopH. It is concluded that the Q-loop in VHZ operates as in classical PTPs.
While sharing a number of similarities, VHZ also bears several important
distinctions from the classical PTPs:
(a) In addition to the catalytic domain, classical PTPs contain multiple domains
defining substrate specificity and subcellular localization. The VHZ protein is comprised
of only a catalytic domain, and lacks the N-terminal extension containing a substrate
recognition loop found in all classical PTPs (26, 52).
(b) The general acid IPD-loop in VHZ, unlike the WPD-loop in classical PTPs, is
not mobile.
On total, the data suggest that VHZ does not fit the profile of an atypical DSP, but
rather is structurally and functionally more closely related to tyrosine-specific PTPs.
However, the absence of a substrate recognition loop and additional domains is not
consistent with its placement as either a receptor or non-receptor type classical PTP. It is
similar in size to the Class II low-molecular weight (LMW) phosphatases which display
the same phosphotyrosine specificity; however, significant sequence, functional, and
structural distinctions exist between the LMW family and VHZ (53, 54). We propose
that a separate category designated “atypical PTPs,” shown in the shaded box in Figure 26, is more appropriate for VHZ. Other analogous phosphatases, including that from S.
solfataricus, and others identified in section C of Figure A-1, may also prove to belong in
this category. The shaded box, is more appropriate for VHZ and probably for similar
enzymes in Figure A-1. PTPs are classified based on the basis of sequence similarity and
substrate specificity, as well as protein size and subcellular localization. Structural and
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Figure 2-6. A classification of PTP family members (2). On the basis of early reports
VHZ has been suggested to belong to the atypical DSP group. The evidence reported here
suggests VHZ is structurally and functionally more closely related to classical tyrosinespecific PTPs. However, the absence of a substrate recognition loop and additional
domains is not consistent with its placement as either a receptor or non-receptor type
classical PTP. We propose that a separate category designated “atypical PTPs”.
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functional distinction between classical PTPs and atypical PTPs can be used to
discriminate between the two subfamilies. The identification and proper classification of
VHZ will assist subsequent research into its biological role and its physiological
substrates.
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CHAPTER 3

NEW FUNCTIONAL ASPECTS OF THE ATYPICAL PROTEIN TYROSINE
PHOSPHATASE VHZ2

Abstract
LDP3 (VHZ) is the smallest classical protein tyrosine phosphatase (PTP)
known to date, and was originally misclassified as an atypical dual specificity
phosphatase (DSP). Kinetic isotope effects, steady state and pre-steady-state
kinetics of native VHZ and its mutants with para-nitrophenol phosphate (pNPP)
have revealed several unusual properties. VHZ is significantly more active than
earlier reported, but remains one of the least active PTPs. Highly unusual for a
PTP, VHZ possesses two acidic residues (E134 and D65) near the active site.
D65 occupies the position corresponding to the typical general acid in the PTP
family. However, VHZ primarily utilizes E134 as the general acid, with D65
taking over this role when E134 is mutated. This unusual behavior is facilitated
by two coexisting, but unequally populated, substrate binding modes. Unlike
most of the classical PTPs VHZ exhibits phosphotransferase activity. Despite the
presence of the Q-loop that normally prevents alcoholysis of the phosphoenzyme
intermediate in other classical PTP family members, VHZ readily phosphorylates
ethylene glycol.

Although mutations to Q-loop residues affect this

phosphotransferase activity, mutations on the IPD-loop that contains the general
2
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acid exert more control over this process. A single P68V substitution on this loop
completely abolishes phosphotransferase activity. The ability of native VHZ to
catalyze transphosphorylation may lead to an imbalance of intracellular
phosphorylation, which could explain why its overexpression has been correlated
with several types of cancer.

Introduction
The protein tyrosine phosphatases (PTPs) are a large family of enzymes
responsible for intracellular dephosphorylation. Together with protein tyrosine kinases
(PTKs), PTPs control the level of protein phosphorylation which modulates numerous
aspects of cell life, such as growth, proliferation, metabolism, intercellular interaction,
immune responses, and gene transcription (1).

PTPs contain a highly conserved

HCXXGXXRS/T signature sequence motif but share very little sequence similarities
outside of the conserved regions, which are comprised of the phosphate binding loop (Ploop); the general acid loop, often referred to as the WPD-loop; and the Q-loop that bears
conserved glutamine residues that orient the water nucleophile in classical PTPs and
prevent phosphotransferase activity to other potential nucleophiles.
All PTPs utilize a two-step double-displacement mechanism of phosphate
monoester hydrolysis (Scheme 3-1) mediated by an invariant cysteine-arginine-aspartic
acid triad of catalytic residues (2). The mechanism proceeds through a phosphoenzyme
intermediate with the second chemical step often being rate limiting (3). In the first step,
the P-loop orients the substrate as the nucleophilic cysteine attacks phosphorus with
simultaneous expulsion of the leaving group protonated by the catalytic general acid. In
the second step, the phosphoenzyme intermediate is attacked by a water molecule
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Scheme 3-1. Top, the chemical steps in the reaction catalyzed by PTPs. In the first
chemical step a nucleophilic cysteine attacks the phosphate ester with simultaneous
protonation of the leaving group by the conserved aspartic acid. In the second chemical
step water attacks the phosphoenzyme intermediate liberating inorganic phosphate and
free enzyme. Forward rate constants are numbered with odd subscripts, and reverse rate
constants are shown with even subscripts. The Q-loop which is only present in classical
PTPs serves to orient the incoming nucleophilic water and most commonly contains a
catalytic glutamine residue marked with a star. This residue is represented by isosteric
glutamic acid E134 in VHZ.
directed by the aspartic acid residue that served as the general acid in the first step and Qloop glutamine residues.
The PTP family is subdivided into several groups based on the substrate
specificity, subcellular localization, and size (4).

The classical PTPs selectively

hydrolyze phosphotyrosine containing peptides and includes the well-studied bacterial
effector protein YopH responsible for the virulence of notorious Y.pestis, and human
PTP1B, which plays an important role in the insulin signaling pathway (5). Classical
PTPs have a modular organization, and in addition to the catalytic phosphatase domain,
contain non-catalytic domains which control subcellular localization and protein-
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Figure 3-1. Side-by-side comparison of (A) VHZ/PTP (PDB ID 4ERC), and (B), SsoPTP
(PDB ID 2I6J). The proteins are very similar in size and structure, and both contain a
rigid IPD-loop (highlighted in red) in contrast to the conserved WPD-loop in classical
PTPs. Both proteins lack an N-terminal substrate recognition loop and contain no
additional extracatalytic domains.
substrate interactions. All classical PTPs are tyrosine specific enzymes. The members of
the dual-specificity phosphatases (DSPs) subfamily hydrolyze phosphoserine and
phosphothreonine in addition to phosphotyrosine containing target sites. Within the DSP
subfamily, the atypical DSPs are smaller and contain only a catalytic domain (6). The
classical PTPs and DSPs also differ in their phosphotransferase ability. In classical PTPs
the phosphoenzyme intermediate is attacked only by water due to the shielding effect of
conserved Q-loop residues, named for the presence of conserved glutamines (2). In
contrast, DSPs such as VHR, and the low-molecular weight LMW-Ltp1, both of which
lack the Q-loop, display significant phosphotransferase ability (3). On this basis, it has
been concluded that the presence of the Q-loop prevents phosphotransferase activity.
VHZ, and the closely related phosphatase S.solfataricus PTP (SsoPTP), are among
the smallest classical PTPs known to date. The SsoPTP (161 amino acids) is similar to
VHZ (150 amino acids) in size and catalytic activity (Figure 3-1). Both VHZ and
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SsoPTP consist of a single, catalytic domain that is more similar to classical PTPs than
DSPs (1, 7) and contain identical secondary structural elements, but, unlike most classical
PTPs, lack an N-terminal extension that forms a substrate recognition/binding loop. Like
VHZ, the general acid in SsoPTP resides on a rigid IPD-loop, which, unlike the flexible
WPD-loop in classical PTPs, permanently occupies a closed conformation. Unlike VHZ,
and like classical PTPs, SsoPTP/WT contains no additional general acid in its Q-loop
region.

VHZ was originally classified as an atypical DSP and named after its

prototypical member as VH1-related protein member Z. In previous work, we presented
results indicating that VHZ should be classified as a PTP rather than a DSP, on the basis
of a structural analysis and results of a phosphopeptide substrate screen in which VHZ
showed activity against pY–containing peptides but not toward pS- or pT-peptides (1).

Scheme 3-2. Partitioning of the enzyme-phosphate intermediate [E-P] between hydrolysis
and alcoholysis pathways. Alcohols, or a water nucleophile, in two competing pathways
attack the phosphoenzyme intermediate formed in the first step.

In the present work, we show that the catalytic activity of VHZ was significantly
underestimated in previous reports, as a result of pronounced product inhibition, and the
inhibitory effect of certain buffers. Despite much in common with classical PTPs, VHZ
is highly unusual in possessing two acidic residues in the active site, D65 and E134. Our
results indicate that under certain circumstances either of these residues can serve as the
general acid in the first step of the reaction. We also present results demonstrating that
VHZ, despite the presence of a Q-loop, catalyzes phosphoryl transfer to alcohols
(alcoholysis) in addition to water (hydrolysis) (Scheme 3-2).
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The mutagenesis of several residues in VHZ in parallel with SsoPTP has revealed
that, in addition to the Q-loop, particular residues in the general acid IPD-loop play a
crucial role in nucleophilic selectivity.

A combination of kinetics and mutagenesis

experiments have revealed unusual aspects of the kinetic behavior of VHZ and given
insights into factors that control the phosphotransferase activity of VHZ, and possibly in
other PTPs.
Experimental Procedures (Materials and Methods)
Protein cloning, expression and purification:
VHZ mutants were made using the Qiagen QuikChange Lightning Site-Directed
Mutagenesis Kit. VHZ and mutants were purified as previously described (1). A Histagged version of VHR was prepared as follows. In the first step the gene of VHR was
amplified from pT7-7 plasmid using the following primers: Fwd1: GAA AAC CTG
TAT TTT CAG GGC ATGTCGGGCT CGTTCGAGCT, Rev1: GGA GAG CTC CTA
GGG TTT CAA CTT CCC CTC CTT GGC TAG to incorporate TEV protease cleavage
site (Fwd1,in bold) immediately upstream of the protein gene, and Sac-I restriction site
(Rev1, in bold) was added at the end of the gene sequence. In the second step, the product
of the first PCR step was used as a template and a KpnI restriction site was added
upstream of the TEV protease cleavage sequence using the following set of primers:
Fwd2: CGGGGTACCGAAAACCTGTAT, Rev1: GGA GAG CTC CTA GGG TTT
CAA CTT CCC CTC CTT GGC. The resulting PCR product was digested with Kpn-I
and Sac-I (Fermentas) and ligated into the pet-45(B+) vector (Novagen) pre-digested
with the same set of restriction enzymes.

The E.coli DH5α competent cells were

transformed with 5 μL of the ligation mixture and plated on an ampicillin-containing agar
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plate. DNA sequencing confirmed the presence of the desired gene. BL-21 DE-3
(codon+) E.coli competent cells were transformed with the peT-45(B+) -VHR vector. 10
mL of LB media were inoculated with a single colony and incubated at 37 oC on a shaker
overnight.

1L of 2xYT media containing ampicillin and chloramphenicol were

inoculated with 10 mL of overnight cell growth. The cells were grown at 37oC until
OD600nm reached 1.2-1.5 a.u. 100 mg of IPTG were added (final concentration 100
mg/L), the flask was transferred to a room temperature shaker and incubated for 18-20
hours. The cells were harvested by centrifugation and re-suspended in Ni loading buffer
containing 50 mM Tris, 500 mM NaCl, 20 mM imidazole, 5 mM 2-mercaptoethanol, 5 %
glycerol, pH 8.0. Cells were sonicated on ice, and after centrifugation the supernatant
was decanted and filtered through 0.45 micron Millipore syringe filter. Ni-fast flow High
Affinity Resin (GE Healthcare) was washed 3 times with Ni loading buffer and incubated
with supernatant for 30 min at 4o C with gentle shaking. The resin slurry was transferred
to a 15 mL glass chromatography column. The column was extensively washed with Ni
loading buffer to reach baseline aabsorbance and protein was eluted with a 120 mL linear
gradient with buffer containing 50 mM Tris, 500 mM NaCl, 20 mM imidazole, 2mercaptoethanol, 5 % glycerol, pH 8.0 at 2 mL/min. The fusion VHR protein obtained
was dialyzed stepwise in TEV-cleavage buffers containing 50 mM Tris-Base, 0.5 mM
EDTA, 3 mM DTT, 5% glycerol and reducing concentration of NaCl (300 mM, 150 mM,
0 mM), at 1.5 hour per step followed by addition of 2 mg of TEV protease. The cleavage
of VHR was rapid and complete in two hours at 4 o C. VHR was dialyzed in the original
Ni-loading buffer to remove DTT and EDTA for two hours, and the solution was passed
through Ni-Fast flow High Affinity Resin for one hour to remove cleaved polyhistidine
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tag and TEV-protease. Collected supernatant was concentrated to 3-5 mL using Millipore
Centrifuge Concentrator tube and loaded on Superdex 75 26/60 gel filtration column
(GE-Healthcare) pre-equilibrated with buffer containing 50 mM HEPES, 150 mM NaCl,
50 mM Imidazole, 5 mM DTT, 10 % glycerol. A single peak corresponding to the VHR
was collected, concentrated to 6 mg/mL, flash-frozen in the liquid nitrogen and stored at 80 oC.
Cloning and purification of SsoPTP. The S.solfataricus.
PTP gene sequence from Uniprot was optimized for the E.coli expression system
and synthesized by GenScript delivered in a shuttle vector. The gene was ordered with a
KpnI restriction site followed by TEV cleavage site directly upstream of the SsoPTP
sequence (Uniprot ID Q97VZ7) and a SacI restriction site directly downstream of the
stop codon. The shuttle vector containing the described gene was amplified in E.coli
DH5α, isolated , and digested with KpnI –SacI restriction enzymes in the Green Buffer
(Fermentas).

The digestion products were separated by electrophoresis using

1%

agarose gel. The band correspondent to the desired gene was extracted using Qiagene Gel
Extraction Kit and ligated into pet45 (B+) plasmid pre-digested with the same set of
restriction enzymes. Unfortunately, unlike VHR (and similar to VHZ), the resulting
fusion protein was resistant to TEV cleavage, so the poly-His tag and TEV-cleavage site
was removed from the pet45B(+)-SsoPTP vector by one-step overlapping PCR using the
following

primers:

Fwd:

TATACCATGTACTGGGTCCGTCGCAAAACG;

Rev:

GACCCAGTACATGGTATATCTCCTTCTTAAAGTAAACAAAATTATTCTAG.
Tagless SsoPTP was expressed in E.coli BL-21 DE-3 (codon+) cells. The growth and
expression conditions were analogous to VHZ and VHR. The cells were harvested by
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centrifugation and re-suspended in the buffer containing 50mM Tris, 1mM EDTA, 10
mM DTT, 5% glycerol pH 7.4 (4oC). Cells were disrupted by sonication on ice, and the
pellet was separated by centrifugation. The supernatant was treated with a 10 % w/v
solution of polyethyleneimine (PEI, Mw 50000, pH 8.0 at 4 oC) added dropwise at 4oC to
reach a final PEI concentration of 0.5% (w/v). After centrifugation the supernatant was
loaded at 1mL/min on a Q-HiTrap (GE Healthcare) column pre-equilibrated with buffer
containing 50 mM sodium acetate, 1 mM EDTA, 3 mM DTT, pH 5.5. After washing the
protein was eluted with a 120 mL linear gradient (2 mL/min) buffer containing 50 mM
sodium acetate, 1 mM EDTA, 600 mM NaCl, 3 mM DTT , pH 5.5. A single isolated
peak eluted at 200-250 mM NaCl corresponding to SsoPTP, concentrated to 3-5 mL and
loaded on a Superdex 75 26/60 gel filtration column (GE-Healthcare) pre-equilibrated
with buffer containing 25 mM Tris, 50 mM imidazole, 150 mM NaCl, 1 mM EDTA, 5
mM DTT, pH 7.5 (at 4oC). A single peak was collected, concentrated to 10 mg/mL
(EC280 = 2.36 mL/mg) and flash frozen in liquid nitrogen in the same buffer with 25%
of glycerol added.
YopH, PTP1B and their mutants were expressed and purified as previously
described (8, 9).
All enzymes were purified to 99% + homogeneity based upon SDS PAGE
analysis (data not shown). Concentration of each enzyme was determined by measuring
absorbance at 280 nm using calculated extinction coefficients.
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Preparation of p-nitrophenyl phosphate (pNPP).
The dicyclohexylammonium salt of pNPP was synthesized as previously
described (10). A phosphate free solution of pNPP was prepared in two separate steps.
The crude product was dissolved in a minimal amount of 0.8 M NaOH.

Neutral

cyclohexylamine was extracted with five equal portions of chloroform, accompanied by
reduction of pH to 8.0-8.5. Inorganic phosphate was precipitated by addition of a 10x
solution containing 1M MgCl and 5 M NH4Cl (1:5 ratio of Mg2+/NH4+) to reach 0.1 M
final magnesium concentration.

The pH was adjusted to 9.0-9.3 with ammonium

hydroxide and stirred for 10 minutes until the solution turned cloudy due to the
precipitation of MgNH4PO4. The concentration of pNPP in solution remains essentially
unchanged, in contrast to calcium or magnesium chloride precipitation alone, which
mostly precipitates pNPP. The precipitate was removed by filtration using a fritted glass
funnel, and 10 g of pre-activated Chelex100 resin suspension in water (pH 9.0) was
added to scavenge the remaining magnesium. The resin was removed by filtration, and
cyclohexylammonium hydrochloride (Fisher) solution (pH 8-9) was added.

The

dicyclohexylammonium salt of pNPP precipitated, collected by filtration, washed with
cold absolute ethanol, and dried overnight under vacuum to yield phosphate-free
dicyclohexylammonium salt of pNPP as a white solid, which was stored at -20 oC under
nitrogen.
The sodium salt of pNPP allows preparation of stock solutions of higher
concentrations, and was produced by dissolving the dicyclohexylammonium salt,
obtained above, in 0.8 M NaOH solution followed by removal of cyclohexylamine by
chloroform extractions. The pH of the aqueous layer was adjusted to pH 12 with 0.1M
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NaOH, as necessary in order to completely remove any traces of cyclohexylamine. A
small amount (0.5-1 g) of Amberlite IR120 H resin, extensively pre-washed with
deionized water, was added to the solution and stirred for 1 minute. When pH reached
6.0-6.5 the resin beads were removed by filtration. The solution was adjusted to pH 8.5
with dilute sodium hydroxide, and stirred on ice under reduced pressure overnight to
remove any traces of organic solvent. The concentration of the stock solution was
assayed by adding 10 uL of the pNPP solution to 1 mL of 100mM Tris buffer (pH 10)
followed by complete hydrolysis with alkaline phosphatase. The final concentration of
liberated p-nitrophenol was found using the value of λ400= 18300 M-1cm-1.
Quantification of inorganic phosphate.
A malachite green assay was used to determine the concentration of inorganic
phosphate in the pNPP substrate, and the concentration of inorganic phosphate in
inhibition studies. Briefly, 1.5 g of ammonium hexamolibdate were dissolved in 85 mL of
deionized water. The volume was adjusted to 100 mL with 15 mL of concentrated
(60.5%) perchloric acid yielding Solution A. The use of perchloric acid was found to
improve sensitivity and rate of the color development. Malachite green hydrochloride
(0.2 g) were added to 50 mL of solution A with stirring. After 30 min the dark orange
solution was centrifuged to separate any undissolved particles yielding Solution B.
Solution A was used to adjust Solution B to a final A450 = 15 a.u. (measured by assaying
diluted aliquots and calculating back to the original concentrate). In a separate 250 ml
Erlenmeyer flask 2.5 g of hydrolyzed PVA (Acros) were stirred in 100 mL of deionized
water under gentle heating avoiding boiling for several hours to yield clear colorless
Solution C (2.5% w/v). Prior to use 2 ml of solution C were added to 10 mL of adjusted
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Solution B and mixed to yield a dark brown working solution. In a 96 well plate 280 µL
of working solution were mixed with 30 µL of diluted phosphate standards in the 0-200
μM range. The color was fully developed in 3-5 minutes and absorbance measured at 625
nM was plotted versus inorganic phosphate concentration to obtain a calibration curve.
Determination of inhibition constants.
The effect of buffers and other inhibitors on the activity of VHZ was tested with
pNPP (sodium salt) in 50 mM sodium acetate buffer (pH 5.5), which showed no
inhibitory effect, with inhibitor concentrations in the range 25-200 mM.

The data was

fitted to several inhibition models using non-linear least squares fit (Origin 8.5.1) with
the competitive model yielding the best results in all cases.
Steady-state kinetic analysis.
All reactions were performed in non-inhibitory buffers in the presence of 1mM
DTT and constant ionic strength adjusted to 150 mM with NaCl at 25 oC. The following
buffers, which showed no inhibition against VHZ, were used: pH 4.75-5.5, sodium
acetate; 5.75-6.5, sodium succinate; 6.75-7.25, 3,3-dimethylglutarate. All buffers were
50 mM. At least eight substrate concentrations ranging from 0.5-4 x KM were used for
each enzyme to obtain Michaelis-Menten curves.

Reaction progress was followed

continuously by the change in absorbance at 400 nm at each pH using a VersaMax plate
reader (Molecular Devices). Partial extinction coefficients obtained as described in the SI
were used to convert the measured absorbance values into amount of p-nitrophenol
released. The reaction was found to be susceptible to product inhibition, so linear initial
velocities were used at each substrate concentration. Control reactions in the absence of
enzyme verified that non-enzymatic hydrolysis could not be detected. The initial rates
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were plotted vs. substrate concentrations and fitted to the Michaelis-Menten equation
using Origin 8.5.1 to obtain kinetic parameters kcat and KM. The values of kcat and kcat/KM
were plotted versus pH and fitted to the equations shown in the SI to obtain the pKa
values of catalytically important ionizable residues, presented in the Table S1.
Isotope effect measurements.
Kinetic isotope effects (KIEs) on the VHZ-catalyzed reaction with pNPP were
measured using the competitive method, and thus are isotope effects on V/K. Figure 3-2
shows the positions where KIEs were measured in the substrate and the designations
used.

Figure 3-2. Positions of KIE measurement in the substrate pNPP. Oxygen-18 KIEs were
measured at the nonbridging oxygen atoms of the phosphoryl group (a) and the bridging
ester oxygen atom (b). The Nitrogen-15 KIE was measured in the nitro group (c).
Natural abundance pNPP was used for measurements of
18

(V/K)bridge and

18

15

(V/K). The

18

O KIEs

(V/K)nonbridge were measured by the remote label method, using the

nitrogen atom in p-nitrophenol as a reporter for isotopic fractionation in the labeled
oxygen positions (5). The isotopic isomers used are shown in the Appendix B, and their
synthesis was as previously described (11). KIEs were measured at pH 5.5 using the
buffer 100 mM acetate, 1 mM DTT, 0.5 mM EDTA. The reactions were conducted at
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25oC and [pNPP] = 25 mM.

All reactions for bridged, non-bridged and natural

abundance isotope effects were performed in triplicate and the progress was monitored
continuously by measuring absorbance at 400 nM. Reactions were stopped at 40, 50 and
60 % completion by acidification to pH 3.0 with HCl, which caused some precipitation of
protein, which was separated by centrifugation. To remove remaining enzyme, the
reaction solution was centrifuged in a Millipore Amicon-Ultra 3kDa protein concentrator.
The resulting solution was extracted with three 50 mL portions of diethyl ether. Ether
fractions were collected, dried with anhydrous magnesium sulfate, filtered, and ether was
removed by rotary evaporation. The unhydrolyzed pNPP remaining in the aqueous layer
was hydrolyzed using alkaline phosphatase after the pH was adjusted to 10 by addition of
1 M Tris to pH 11. After 8 hours the pNP product was extracted and collected as
previously described. After sublimation the p-nitrophenol samples were analyzed by
isotope ratio mass spectrometry. The isotope effect was calculated from the nitrogen
isotopic ratios in the p-nitrophenol product at partial reaction, in the residual substrate,
and the starting material, as described in Appendix B. The

18

(V/K)nonbridge values were

corrected for the dianionic fraction of pNPP at pH 5.5.
Detection of phosphotransferase activity in the presence of ethylene glycol.
The hydrolysis of pNPP by VHZ and VHZ/P68V was monitored using a JEOL
300 MHz NMR spectrometer at the 121.5 MHz 31P resonance frequency. Reaction was
started by addition of VHZ to a solution containing 20 mM pNPP in 50 mM sodium
acetate (pH5.5), 0.5 mM EDTA, 3mM DTT and 1M ethylene glycol. The instrument was
locked using D2O in a coaxial tube. The instrument was set to collect 64 scans, relaxation
delay 4 sec, sweep 50 ppm.
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The dependence of kcat was measured as a function of ethylene glycol
concentration for VHR, VHZ, VHZ/E134Q, VHZ/E134A, VHZ/D65A, VHZ/P68V,
SsoPTP, and SsoPTP/V72P by monitoring release of p-nitrophenol. Reactions were
performed in 50 mM sodium acetate buffer (pH 5.5) and concentration of ethylene glycol
varied in the range of 0-3 M.
Pre-steady-state kinetics.
Measurement of pNPP hydrolysis catalyzed by VHZ, VHR, as and VHZ/D65A
mutant were performed at 25 oC using a stopped-flow spectrophotometer (KinTek).
Release of p-nitrophenol was monitored by increase in absorbance at 400 nM in 100mM
succinate buffer (pH 5.85), using an extinction coefficient corrected for this pH (see SI).
Enzyme concentration varied in the range 20-65 μM. The pNPP concentration was 20
mM for VHZ/D65A, and varied from 0.5 KM to 100 mM for VHR/WT and VHZ.
Absorbance traces of at least five separate experiments at each substrate and enzyme
concentration were averaged. The data was fitted to the equation [p-nitrophenol] = At + B
(1-e-kt). At saturating concentrations of substrate, k = k3 + k5. The linear steady-state
phase A = k3k5 / (k3 + k5). The magnitude of the burst B = Eo [k3 / (k3 + k5)]2 / (1 + KM /
So)2.
Computational analysis of pNPP binding to VHZ:
The computational packages AutoDock (12) and FlexX (13) were used to model
the docking of pNPP in the active site of VHZ. The 1.15 Å resolution crystal structure of
the VHZ-metavanadate complex (PDBID: 4ERC) was used as the starting model. The
VO3 ligand at the active site was removed, and the following charges/protonation states
were assigned to the residues: C95 (-1) ; H94 and R101,(+1) ; D65 and E134, neutral.
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The side chains of D65, F66, L97, and E134 residues were treated as flexible, the rest of
the protein was rigid. The pNPP ligand coordinates were extracted from the crystal
structure of SsoPTP (PDBID: 2I6P) and the di-anionic form of the phosphate ester was
used for docking. Free rotation was allowed around the phosphate monoester bond,
while the p-nitrophenol ring was treated as planar. The Lamarckian Genetic algorithm
was selected for its reliability and ability to calculate “deeper minima” (14) and the
search was conducted within a 15 Å grid region centered at the active site.
Results
Buffer and oxyanion inhibition.
The effects of buffers and oxyanions on the catalytic activity of VHZ are summarized in
Table 3-1.

No inhibitory effects were observed for acetate, succinate, 3,3-

dimethylglutarate, or diglycine.

VHZ is weakly inhibited by triethanolamine

hydrochloride and cyclohexylamonium hydrochloride, while N-ethyl morpholine (NEM)
hydrochloride displayed no inhibitory effect.

As expected, the sulfonate containing

buffer HEPES showed relatively strong inhibition. Cyclohexylammonium is a common
counterion for the commercially available substrate pNPP, and although its effect was
relatively weak, the sodium salt was used in all experiments.
Kinetic isotope effects.
The KIEs in the positions shown in Figure 3-2 for the VHZ-catalyzed hydrolysis
of pNPP are presented in Table 3-2, together with previously reported KIEs for PTP1B
and VHR. The

18

(V/K)nonbridge KIEs for VHZ are very similar to these precedents,

suggesting that, like these related enzymes, the VHZ-catalyzed reaction proceeds via a
loose transition state. The 18(V/K)bridge KIE is higher in VHZ and a significant magnitude
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Table 3-1. Inhibition by buffers and oxyanions. Experiments were carried out at pH 5.5
in the 100 mM sodium acetate buffer where ionized form of tested buffering agents
dominates in solution.

Compound
Cyclohexylamine
EDTA
Inorganic phosphate
VHZ/WT
VHZ/D65A
VHZ/D65N
Sso/WT
VHR/WT
YopH/WT
PTP1B/WT
Other oxyanions
Sulfate
Arsenate
Vanadate
Buffers
Tris
N-ethyl morpholine NEM
Bis-Tris
Triethanolamine
HEPES
Glycylglycine
Sodium acetate
Sodium succinate
3,3-demethylglutarate

Inhibition Type Ki , mM
Competitive
140 ± 10
Competitive
22 ± 2
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive
Competitive

0.67 ± 0.05
0.43 ± 0.12
0.68 ± 0.11
0.54 ± 0.42
0.7 ± 0.3
4.4 ± 0.2
3.7 ± 0.1

Competitive
Competitive
Competitive

4.6 ± 0.3
0.13 ± 0.04
0.0027 ± 0.0003

Competitive
No
Competitive
Competitive
Competitive
Competitive
No
No
No

88 ± 9
No
122±12
52 ± 5
26 ± 3
118 ± 12
No
No
No

Table 3-2. Kinetic isotope effects of native VHZ, PTP1B and VHR.

PTP name

15

VHZ
PTP1B (8)
VHR (4)

1.0013±0.0004
1.0001±0.0002
0.9999±0.0004

(V/K)

18

(V/K)bridge

18

(V/K)non-bridge

1.0164±0.0017 0.9986±0.0008
1.0142 ± 0.0004 0.9981±0.0015
1.0118±0.0020 1.0003±0.0003
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for the

15

(V/K) isotope effect contrasts with the absence of a measureable KIE in this

position in the other two phosphatases. Both observations are consistent with incomplete
neutralization of the leaving group by the general acid in the transition state.
Steady-state kinetics analysis.
Table 3-3 shows the kinetic parameters, kcat, KM, and kcat/KM for VHZ, VHR,
YopH, PTP1B, SsoPTP, and several VHZ mutants, measured at pH 5.5 at 23 °C. This
corresponds to the pH optimum of many PTPs, including VHZ. The kinetic parameters
for VHR, YopH, and PTP1B measured by continuous assay at 400 nm are in good
agreement with the literature values. We obtain values of kcat = 3.9 s-1 and KM = 8.3 mM
for pNPP hydrolysis by VHZ at the pH optimum of 5.5, compared with previously
reported kcat = 0.009 s-1 and KM = 1.5 mM (15, 16). The revised kcat is comparable to
those of native VHR and SsoPTP.

The KM is significantly higher than previously

reported, resulting in lower overall enzymatic efficiency (kcat/KM).
pH dependency for the hydrolysis of pNPP by VHZ:
The pH-rate profiles for native VHZ and the mutants D65A and E134Q are shown
in Figure 3-3. The pKa values of ionizable residues were determined by non-linear least
squares fitting of experimental data to the appropriate equations (see SI), for kcat and
kcat/KM, and shown in Table S-1. The second ionization constant for pNPP was set to the
literature value of 4.96 (17). The pKa values obtained are in good agreement with those
previously obtained for other PTPs, and the bell-shaped profiles are typical of the PTP
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Table 3-3. Kinetic data for native VHZ, YopH, VHR, PTP1B, and SsoPTP and selected
mutants. Values are the results from at least six independent experiments.
Kinetic parameters with pNPP at pH 5.5 (optimum), 25°C
kcat,(s-1)
KM, mM (18)
Native PTPs
VHZ
3.92
± 0.03
8.31 ± 0.71
VHR
3.1
± 0.1
1.96 ± 0.11
SsoPTP
3.15
± 0.05
4.31 ± 0.19
YopH
720
± 25
0.98 ± 0.11
PTP1B
51.7
± 0.9
0.12 ± 0.01
IPD- loop mutations
Sso PTP/V72P
2.61
± 0.1
4.62 ± 0.43
VHZ/D65A
0.84
± 0.12
0.22 ± 0.01
VHZ/D65N
3.42
± 0.12
8.73 ± 0.68
VHZ/D65N/E134Q
0.027 ± 0.002 2.57 ± 1.15
VHZ/P64A
0.07
± 0.04
32.92 ± 2.98
VHZ/P69A
0.09
± 0.05
31.00 ± 3.80
VHZ/P68V
3.34
± 0.06
5.88 ± 0.27
Q-loop
VHZ/E134Q
0.42
± 0.07
7.66 ± 0.25
VHZ/E134A
0.29
± 0.02
10.15 ± 1.32
VHZ/Q138A
0.13
± 0.01
13.1 ± 1.7

kcat/KM, mM-1s-1
0.47
1.59
0.73
735
430
0.56
4.19
0.39
0.001
0.002
0.003
0.57
0.07
0.03
0.01

family. The acid limb is ascribed to the deprotonated C95 nucleophile, which has an
unusually low pKa due to stabilizing influences of the neighboring H94 in VHZ. The
basic limb is ascribed to general acid catalysis in the first step consistent with the PTP
mechanism (Scheme 3-1). The IPD-loop in VHZ bears the putative D65 general acid.
This loop and the position of the acid correspond to the conserved WPD-loop in classical
PTPs (Figure 3-4). D65 was proposed to be the general acid catalyst by structural
analogy, and based on the observation of lost hydrolysis of pNPP by the D65A mutant
(16, 19). In our hands, the D65A mutation resulted in a 5-fold reduction of kcat and a 40fold reduction of KM. The pH-rate profile remains bell-shaped (Figure 3-3). In contrast,
the analogous mutation of the general acid in other PTPs to alanine or to asparagine
results in a 100 to 1000-fold reduction in kcat, and the loss of the basic limb in the kinetic
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Figure 3-3. pH rate profiles. A) kcat for the native VHZ (black), D65A (red), and E143Q
(blue) , D65N/E134Q (green) mutants. B) kcat/KM for native VHZ, D65A ,E134Q,
D65N/E134Q mutants. The D65A mutant is more efficient than the native VHZ due to
simultaneous reduction of kcat and KM. Both D65A and E134Q mutants retain the basic
limb diagnostic of general acid catalysis. The basic limb completely disappears in
VHZ/D65N/E134Q double mutant.

Figure 3-4. Structural comparison of the active sites of: A) the PTP YopH; B) the DSP
VHR; and C) VHZ. The structural arrangement of the VHR active site differs from YopH
and VHZ in the replacement of the highly conserved Q-loop with the N-loop, and a
different position of the general acid.
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Figure 3-5. Pre-steady state kinetics of: A) 48 μM native VHZ, with 50 mM pNPP; B)
26μM native VHR, with 50 mM pNPP; C) 58 μM VHZ/E134Q with 50 mM pNPP; D)
28 μM VHZ/D65A and 10 mM pNPP. All experiments were performed at 25 oC. 2000
data points were collected after 1ms mixing delay and are omitted for the clarity of the
fit.
pH-rate profile, indicating loss of general acid catalysis (20, 21). In contrast, the kinetic
constants for the D65N mutant are similar to those of native VHZ (Table 3-3).
pH-rate profile, indicating loss of general acid catalysis (20, 21). In contrast, the
kinetic constants for the D65N mutant are similar to those of native VHZ (Table 3-3).
The active site of VHZ possesses another acid (E134 from the Q-loop) in position to
potentially protonate the leaving group (Figure 3-4). The E134Q and E134A mutations
both reduce kcat by about an order of magnitude (Table 3-3) with no significant effect on
KM. The pH profile of the E134Q mutant remains bell-shaped. Only the simultaneous
removal of both general acids (D65N/E134Q) leads to a significant reduction of kcat and
loss of the basic limb of the pH-rate profile (Figure 3-3). The double mutants
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Table 3-4. Elementary rate constants for pNPP hydrolysis and substrate dissociation
constant for native VHR, VHZ/D65A, and native VHZ. The values for k3, k5 and KS
were obtained from burst kinetics as described in the SI. The kinetic constants for native
VHZ were calculated based on the assumption that k3 is not affected by the VHZ/D65A
substitution, as described in the text. Under such circumstances, the system consisting of
k k
k5
the two equations kcat  5 3 and K M  K S 
can be solved to obtain values of
k3  k5
k3  k5
k5 and Ks.

VHZ/D65A
VHR
VHZ/WT

k3,(s-1)
17.44
48.30
17.44

± 0.13
± 0.34
± 0.13

k5,(s-1)
KS, mM
1.71 ± 0.37 2.5
9.70 ± 0.21 11.8
5.19
35

precipitated below pH 5.25 precluding measurement of kinetic data at more acidic
conditions.
Pre-steady-state kinetics.
Many PTPs, including YopH, PTP1, and VHR, exhibit burst kinetics, indicating
that the second step is rate-limiting (6, 10). When native VHR was rapidly mixed with
pNPP a pre-steady state burst of p-nitrophenol release was observed (Figure 3-5).
The values of k3 and k5 obtained for VHR are close to those previously reported
(6). Under the same conditions native VHZ and its E134Q mutant revealed no pre-steady
state burst. In contrast, the VHZ/D65A mutant displayed a pre-steady state burst
stoichiometric with the amount of enzyme. Values of k3, k5 and KS (the true substrate
binding constant) were calculated for native VHR and VHZ/D65A and are presented in
Table 3-4. Although the decrease in the ratio (k5/k3) in VHZ/D65A reduces KM (see SI),
it does not fully explain the magnitude of the reduction, indicating that KS is reduced as
well. Despite the absence of a burst, the value of KS for native VHZ may be calculated if
we assume that the D65 residue is primarily important for orienting the nucleophilic
water in the second catalytic step. This assumption is supported by the negligible effect
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on kcat of the VHZ/D65N substitution. By setting k3 for native VHZ equal to that of
VHZ/D65A, the other elementary rate constants for the reaction of the native enzyme
were calculated as shown in Table 3-4. The VHZ/D65A substitution decreases the
magnitude of KS 14-fold. Because substitution of D65 with A (but not N) increases
enzyme substrate affinity, we conclude the existence of an unfavorable steric, rather than
electrostatic, interaction between D65 and the aromatic ring of the substrate. The Ki for
inorganic phosphate is lower than KS for pNPP in both native VHZ and the VHZ/D65A.
However, whereas KS for pNPP is reduced 14-fold by the removal of D65 side chain
(Table 3-4), the Ki for inorganic phosphate is reduced only ~ 1.5-fold (Table 3-1).
Table 3-5. Second order rate constants for alcoholysis and hydrolysis of pNPP by
several members of PTP family. The kcat values obtained in the absence of alcohol
(intercept with Y axis) were divided by the molarity of water (55.5 M) to yield the second
order hydrolysis rate constant kcat’. Nucleophilic specificity is defined by the relative
preference for alcoholysis over hydrolysis. kt corresponds to k7 only when k5>>k3,
k k
otherwise kt  3 7 (see SI for more detailed description). The values of kt depend on
k5  k3
the rate limiting step and on the overall activity, and should not be used to judge the
preference for alcoholysis.
Name
Ltp1/WT(3)
YopH/WT(2)
SsoPTP/WT
VHR/WT(2)
VHZ/WT
VHZ/E134Q
VHZ/E134A
YopH/Q446A(2)
VHZ/D65A
VHZ/P68V
SsoPTP/V72P

kt , M-1*sec-1
5.5
0.0
0.0
0.48
1.3
0.06
0.13
21.6
1.55
0.0
0.49

kcat'=(kcat/55.5), M-1*sec-1
0.026
11.3
0.07
0.07
0.09
0.005
0.0036
1.11
0.015
0.060
0.041

S=kt/kcat'
211.5
0.0
0.0
6.85
14.4
12.1
36.1
19.4
103.3
0.0
11.95
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Reaction in the presence of ethylene glycol.
The dependence of kcat on ethylene glycol concentration was measured for native
VHZ and several mutants. It should be noted (discussed in the SI) that the slope of such
a plot where kcat  k5  k7  [ROH] yields the second order rate constant for ethylene
glycol phosphorylation (k7, Scheme 3-2) only when k3>>k5. In the more general case,
when
no distinct rate-limiting step exists and no pre-steady state burst is present, the expression

kcat 

k3  k5 k3  k7

 [ROH] holds and interpretation of the calculated slope is more
k5  k3 k5  k3

k3  k 7
k k
k
Slope
complex. However, the nucleophilic selectivity S 
 5 3  7 (Table 3-5,
Intercept k3  k5 k5
k5  k3

column 3) is independent of k3 and reflects the relative preference for alcoholysis over
hydrolysis.
The E134Q mutation results in no significant change in phosphotransferase
ability. The E134A mutation significantly increases the alcoholysis to hydrolysis ratio,
indicating that E134 participates in the second step of the reaction, like Q446 in YopH.
Although Q-loop residues in PTPs are generally thought to control access to the
phosphoenzyme intermediate, the D65A mutation on the IPD-loop has a more
pronounced effect than E134A.

Because the closely related SsoPTP lacks

phosphotransferase activity, we compared the effects of mutations on the IPD-loops in
VHZ and SsoPTP. The SsoPTP contains only two proline residues on its IPD-loop, P68
and P73, corresponding to P64 and P69 in VHZ. These residues are highly conserved in
classical PTPs (see the sequence alignment in Figure 3-8) and mutations result in similar,
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adverse catalytic effects in VHZ (Table 3-3). VHZ possesses another proline, P68, which
is occupied by V72 in SsoPTP. The VHZ/P68V mutation abolished phosphotransferase
activity (Figure 3-6). This effect was further supported by 31P NMR spectroscopy shown
in Figure 3-7. The orthogonal SsoPTP/V72P mutation conferred phosphotransferase
ability comparable to that of native VHZ.
Discussion.
Although VHZ is related to classical PTPs and utilizes the same mechanism (1) it
differs in several important ways from most PTP family members.

VHZ is inhibited by commonly used buffers, and by inorganic phosphate more
strongly, than typical PTPs.
Previous kinetic investigations of VHZ utilized single time point assays after 20
or 30 minutes, and buffers containing Tris (16) or Bis-Tris, which are weak competitive
inhibitors (Table 3-1). Although the inhibition constants are in the high millimolar range,
buffers are typically used at such concentrations. While buffers containing the sulfonate
functional group, such as HEPES, are recognized as inhibitors of PTPs, and have been
observed in some PTP crystal structures, the inhibition of VHZ by buffers such as Tris
and triethanolamine was unexpected. This behavior may result from the combined effect
of several anionic residues near the VHZ active site (D65, E44, E134 and E137) but the
molecular origin of buffer inhibition was not tested. The inhibition constant for inorganic
phosphate is lower than in classical PTPs, and is significantly lower than the KS for pNPP
(Table 3-4). Probable structural origins for this difference are discussed below. The net
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effect of these properties led to a significant underestimation of VHZ activity in previous
reports.
In addition to avoiding inhibitory buffers, we validated a method for the
continuous collection of rate data using the substrate pNPP monitoring reaction progress
at 400 nm using extinction coefficients measured at the experimental conditions (see SI).
Continuous monitoring of the reaction showed that VHZ becomes inhibited by product
after several minutes.

Finally, commercial pNPP, which often contains small but

experimentally significant amounts of inorganic phosphate, was used in previous studies.
We developed a purification strategy to minimize contamination by inorganic phosphate,
that also offers a simple means to convert the di-cyclohexylammonium salt to the more
soluble disodium salt. Using non-inhibitory buffers, a continuous assay, and phosphatefree substrate, VHZ proved to be significantly more active than previously thought (kcat =
3.9 s-1 versus 0.009 s-1). We also developed a process for the expression and purification
of the native enzyme with no tags. Although previous reports used tagged versions of
VHZ, the difference in activity is too significant to be explained by the absence of tags.
Furthermore, discontinuous assays with the tagless enzyme using fixed time point
methods like those previously reported yielded results similar to the previous reports
(16).
The leaving group is not fully neutralized in the first step of the VHZ reaction.
The KIEs for the hydrolysis of pNPP have been reported for a number of PTPs
including YopH (22), PTP1B (23), VHR (24), and the LMW PTP Stp1 (4). Because
these are measured by the competitive method, the KIEs reflect the portion of the kinetic
mechanism up to the first irreversible step, cleavage of pNPP. The mechanistic origins of
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the KIEs for pNPP hydrolysis have been described elsewhere (5). In brief, a normal
15

(V/K) up to a maximum of 1.003 arises from negative charge development on the

leaving group. Efficient general acid catalysis by PTPs abolishes this effect, resulting in
a

15

(V/K) of unity. Fission of the P-O bond produces a normal

18

(V/K)bridge effect.

Simultaneous leaving group protonation produces an inverse effect that partially reduces
the normal effect from P-O cleavage. Thus, in general acid mutants,

18

(V/K)bridge is

typically ~ 1.03, compared to ~1.015 in native PTPs. The 18(V/K)nonbridge KIE responds to
change of hybridization state of the phosphoryl group. This KIE is slightly inverse to
near unity in PTPs, reflecting the loose metaphosphate-like transition state; associative
transition states result in normal values. Both of the oxygen isotope effects for the VHZ

Figure 3-6 - Dependence of pNPP turnover on ethylene glycol concentration. A: VHZ
/WT and VHZ/P68V mutant. B: SsoPTP/WT and Sso/V72P. The kcat for pNPP release
was plotted versus ethylene glycol concentration. All experiments were performed at
25oC.
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Figure 3-7 – Reaction of pNPP catalyzed by VHZ/P68V and VHZ monitored by 31P
NMR spectroscopy. Panel A shows the reaction of the VHZ/P68V mutant after 30
minutes in the presence of 1M Ethylene Glycol. Panel B shows the reaction catalyzed by
VHZ after 30 minutes. All reactions were performed at pH 5.5 in 100 mM sodium
acetate buffer in the presence of 20 mM pNPP. The chemical shift of pNPP was -1.6
ppm, inorganic phosphate was set to 0 ppm, and the shift of phosphorylated ethylene
glycol is 1.7 ppm.
reaction are within experimental error of previous data with PTP1B and VHR (Table 34). In contrast, the 15(V/K) differs from the other PTPs and is slightly normal, indicating
that the leaving group is not completely neutralized in the transition state. The magnitude
suggests approximately 1/3 of a negative charge, from protonation that is not fully
synchronous with P-O bond fission. This has been observed in one previous PTP family
member, the LMW PTP Stp1 (25). Incomplete protonation of the leaving group in the
first step may contribute to a reduction of k3 and explain the absence of a burst in the
VHZ catalyzed reaction of pNPP.

82

Figure 3-8 – Sequence alignment of residues 65-138 of VHZ with several classical PTPs
(top) and atypical DSPs (bottom). The alignment is confined to the three catalytically
important PTP regions, as they contain the highest sequence similarity in the PTP family.
VHZ is more similar to classical PTPs than to the DSP family, with two important
distinctions in the aligned regions: substitution of highly conserved W by I in the WPDloop region; and; substitution of Q by E the Q-loop region.
Two potential and functional general acids in the active site of VHZ.
The D65 residue resides on the IPD-loop, a structure analogous to the WPD-loop
in classical PTPs that bears the conserved general acid (Figure 3-8). The E134 residue in
VHZ is superimposable with a conserved Q residue located on the Q-loop in classical
PTPs that orients the nucleophilic water in the second step (26). The pH rate profiles of
the D65 and E134 mutants both retain their basic limbs. The D65N mutation has no
significant effect on catalysis, and the D65A and E134Q mutations have kcat values that
are reduced by only an order of magnitude. Only in the double mutant is catalysis
reduced to the extent seen in general acid mutants of other PTPs, consistent with
complete elimination of general acid catalysis. We conclude the D65 and E134 single
mutants both retain general acid function. We conclude that native VHZ utilizes E134 as
the primary general acid, with a minor contribution from D65, which becomes the major
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general acid when E134 is mutated. The data suggest that, unlike any other known PTP
or DSP, VHZ contains two acidic residues in the active site and either one can protonate
the leaving group in the absence of the other.
D65 has a role primarily in the second step, and affects substrate binding.
The fact that the D65N mutation does not significantly affect activity, while the
D65A mutation does, suggests that the reduced catalysis in the D65A mutant arises due
to inability of the alanine side chain to participate in phosphoenzyme hydrolysis by
orientation of the nucleophilic water. In this sense, the roles of D65 and E134 are
reversed from classical PTPs, in which the conserved glutamine corresponding to E134
positions the nucleophilic water, and the acid corresponding to D65 is the general acid in
the first step and a general base in the second step.
The D65A mutation significantly reduces KM and KS.

This effect is less

pronounced for mutations of the corresponding residue in other PTPs. This may be
explained by fact that in classical PTPs this residue resides on the mobile WPD-loop,
which is primarily in an open conformation in the free enzyme. Because the IPD-loop in
VHZ is permanently closed (1), the D65 side chain is fixed in a position that restricts
access to the deep and narrow VHZ active site. DSPs, such as VHR, also have a nonmovable general acid loop; however, in these enzymes the general acid is positioned on
another side of the active site (Figure 3-4), and presents less steric hindrance to incoming
ligands. This explains the higher KM for pNPP in VHZ compared to other PTPs. The
structurally analogous SsoPTP, which also contains a rigid IPD-loop, has a KM value
approximately 3-fold lower than VHZ and comparable to that of VHR. However, unlike
VHZ, which has a narrow and deep active site pocket (1) the active site of SsoPTP is
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broad and shallow due to the presence of multiple surrounding glycine residues in the Ploop and IPD-loop.
Neither D65A nor D65N substitution significantly affects the Ki for inorganic
phosphate (Table 3-1). It also confirms that the mutation of D65 side chain side chain
does not disrupt the P-loop, which serves as the dominant binding element to the anionic
phosphoryl group. In contrast, the D65A mutation lowers the Ks for pNPP 14-fold. This
suggests the effect of D65 substitutions on binding is primarily steric rather than
electrostatic, involving the ester group of the substrate more than the phosphoryl group.
This would permit the biological activity of VHZ to be more regulated by levels of
intracellular phosphate than most PTPs. The intracellular regulation of phosphatases by
phosphate has been recently discussed (13). Unlike classical PTPs with much higher Ki
values, VHZ, SsoPTP, and VHR have inhibition constants similar to the average
physiological concentration of inorganic phosphate (1-1.3 mM) (27).
VHZ has a low catalytic efficiency and different rate-limiting step compared to most
PTPs.
Despite the fact that VHZ is more active than previously thought, it remains one
of the least active PTPs. A significant part of its reduced catalytic efficiency arises from
its high KS. Indeed, for the PTP catalyzed reaction (Scheme 3-1)

kcat
k
 3 (see SI for
K M KS

derivation), which means that VHZ requires a 5-8 fold higher substrate concentration to
achieve its limiting velocity. In addition to high Ks values, the kcat for VHZ is lower than
classical PTPs. Our data suggest that both steps of the VHZ catalyzed reaction are slower
than in classical PTPs, and both contribute to the overall rate ( kcat 

k5  k3
) under
k3  k5
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steady state conditions. According to the KIE results the neutralization of the leaving
group in the first step is incomplete, which reduces k3, but cannot explain the reduction of
k5. It was previously shown that mutations of Q-loop residues in classical PTPs reduces
k5 by 2 orders of magnitude, an effect that was used to trap the phosphoenzyme
intermediate of PTP1B (26, 28). The E134Q mutation makes VHZ structurally more
similar to classical PTPs and affects only the first step, resulting in the 8-fold reduction of
activity. The kcat value of the E134A mutant is 70% that of the E134Q mutant. Such an
insignificant reduction from complete removal of the functional group indicates that the
residue does not function in the second step like the Q in this position in classical PTPs,
explaining the lower k5 in VHZ compared to other PTPs. The k5 value of native VHZ is
more similar that of VHR (Table 3-4) which, in place of the Q-loop, (Figure 3-4) has an
N-loop region (Figure 3-8) that is highly conserved among atypical DSPs.
VHZ has two substrate binding modes for pNPP.
The expressions for kcat and KM for the PTP-catalyzed reaction (Scheme 3-1),

kcat 

k5  k3
k5
and K M  K S 
contain the same elementary constants, and thus,
k3  k5
k3  k5

any change in kcat is reflected in KM and vice versa. A reduction in k3 results in increased
KM as is seen in the VHZ/E134Q/D65N double mutant, in which both general acids
important in k3 are mutated, but k5 remains unaffected. As k3 becomes smaller with
respect to k5, KM approaches KS. Because of this, the KM for the VHZ/D65N/E134Q
double mutant (Table 3-3) is close to the KS for native VHZ determined from pre-steady
state kinetics (Table 3-4). The same effect has been previously observed in the general
acid D92N mutant of VHR (15). In contrast, mutations of Q loop residues that do not
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affect k3 but decrease k5, have the opposite effect on KM. The same trend was previously
observed in the Q556M Q446A mutants of YopH (2). The reduction of k5 reduces the
rate of formation of the free enzyme form E from the enzyme-phosphate intermediate E-P
(Scheme 3-1), which lowers observed values of KM parameter in the steady-state
experiment. This mutual dependence of kcat and KM becomes less obvious when k3 >>k5
but, because in native VHZ the two constants are relatively similar, (consistent with the
absence of a burst) even small changes should be easily detected. The E134Q mutation
in VHZ eliminates the major general acid but results in only a 10-fold reduction of kcat
and has no effect on KM. The D65N substitution results in a modest rate reduction,
consistent with its role as the minor general acid, but also has no significant effect on KM.
The pH rate profiles of both mutants remain bell-shaped, indicating that when one
general acid is eliminated, the other one takes over, maintaining general acid catalysis.
The kinetic behavior of the mutants suggests the presence of two catalytically equivalent,
but differently populated, forms of the Michaelis complex. Similar to the mode of action
one would expect from a pure noncompetitive inhibitor on the native enzyme, the E134Q
or D65N mutation renders one of the two conformations catalytically unproductive,
which reduces the rate but has no effect on KM.
In order to obtain insights into substrate binding modes in VHZ that might explain
how either D65 or E134 can act as a general acid, the programs AutoDock (12, 29-31)
and FlexX (32, 33) were used to predict the orientation of pNPP in the active site. Both
programs predicted two possible conformations, presented in Figure 3-9. In each, the
phosphate moiety of the substrate is coordinated by the P- loop and the side chain of
R101, and is properly positioned for nucleophilic attack by the negatively charged
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A
B
WT
WT
WT
WT
WT
Vmax
+Vmax
=Vmax
×αA +Vmax
×αB =Vmax
×(αA +αB )=Vmax
×1=Vmax

Figure 3-9 – Two pNPP docking modes in the active site of VHZ predicted by docking
studies. In mode A the scissile ester oxygen of the pNPP substrate is oriented towards
the E134 side chain. Acid catalysis by D65 is unavailable, as its side chain is displaced
to relieve a steric clash with the substrate. The D65A mutation removes this clash,
explaining its lower KM. When E134 is mutated, general acid catalysis by D65 can occur
from the binding mode shown in B. Conformation B is analogous to that observed in the
crystal structure of substrate bound to an inactive mutant of SsoPTP, and is consistent
with the pH rate profile of E134Q.
cysteine at the bottom of the active site. In conformation A the scissile oxygen is
oriented towards E134, consistent with its assignment as the primary general acid. The
D65 side chain turns away to avoid a steric clash with the p-nitrophenyl ring. We
conclude that this substrate conformation is the predominant one, consistent with the
kinetic effects of the E134Q mutation and steric relief observed in the D65A mutant. The
substrate conformation in panel 9B is the one commonly observed in classical PTPs,
except for the position of the glutamine residue analogous to E134, which occupies a
different conformation to avoid a steric clash with the substrate phenyl ring (26).
However, it resembles the position of the corresponding Q135 residue in several
structures of SsoPTP in complex with peptide substrates (7).

In this conformation the
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phenolate ring is in close proximity to the L97 side chain, and D65 is oriented in position
to donate its proton to the scissile oxygen of the leaving group. This substrate orientation
is consistent with the kinetic behavior of the E134Q mutant, which utilizes D65 as its
general acid.
The presence of two binding conformations explains why the E134Q and D65N
mutants have a reduced kcat with no significant effect on KM. If conformation B, in which
the E134Q mutant can utilize the D65 general acid, presents a minor fraction of the
overall enzyme-substrate complex, then it would kinetically appear as a reduction of kcat
because the predominant conformation A would be catalytically unproductive in this
mutant.

The different effects of the D65N and E134Q mutations on kcat with no

significant effect on KM suggest that both conformations A and B coexist, and
conformation A dominates.

The E134Q or D65N substitution, which results in

conformation A or B becoming non-productive, respectively, is similar to the effect from
noncompetitive inhibition. Noncompetitive inhibition results from the formation of a
non-productive enzyme-substrate-inhibitor complex that reduces Vmax but has no effect
on KM.

The reaction catalyzed by the E134Q mutant where conformation A is

unproductive and conformation B leads to product formation according to the equation
A
Vmax


WT
Vmax


1 
1 

 K AB 

WT
, where Vmax
is the maximal rate of the reaction by the native VHZ

A
containing both acids, and Vmax
is the maximal velocity for the E134Q mutant. The

calculated value of K AB =

[B]
=0.12 indicates that about 89% of the VHZ [ES] complex
[A]

exists in conformation A, and 11% in form B. This ratio is consistent with the modest
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reduction of kcat in the D65N mutant. The equilibrium constant of 0.12 implies a modest
energetic difference of slightly more than 1 kcal/mol, consistent with the nearly equal
scoring function obtained from the docking programs for the two conformations.
The predominance of conformation A in which the phenolate ring interacts with
the D65 side chain explains the steric relief produced by the D65A mutation. The
presence of the E134 general acid and its use in conformation A appears to be a
reasonable evolutionary solution which to permit a bulky substrate from entering the
narrow and sterically demanding active site pocket. Conformation B is the one the most
commonly observed in classical PTPs, which possess a movable WPD-loop.

This

conformation allows VHZ to utilize its D65 general acid. However, under the condition
of a non-movable general acid-bearing IPD-loop, conformation B is sterically disfavored,
making it significantly less populated than conformation A. The presence of the two
coexisting but unequally populated A and B conformations explains why both
VHZ/E134Q and VHZ/D65N mutants retained their basic limbs but produced
proportionally different effect on kcat without affecting KM.
A similar phenomenon may explain anomalous behavior reported in the TkPTP, a protein tyrosine phosphatase isolated from the Thermococcus kodakaraensis
KOD1. On the basis of structural comparisons with known PTPs, D63 was assigned as
the putative general acid. Unexpectedly, the D63A mutant was found to be more active,
not less, than the native enzyme (34). No explanation was suggested, and no structure of
Tk-PTP has been published; however, the protein sequence (Figure S-2) suggests the
presence of a glutamic acid residue in a position corresponding to that of E134 in VHZ.
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Like VHZ, Tk-PTP may utilize a different general acid than the one implicated by
structural comparisons with the PTP family.
The possibility that the results arise from the presence of a good leaving group in
pNPP that does not need an enzymatic general acid to protonate it at pH 5.5 is unlikely.
Across the PTP family, KIE results at this pH show that the leaving group leaves as the
nitrophenolate anion when the enzymatic general acid is mutated, rates are significantly
reduced, and pH-rate profiles lose their basic limbs (5). Recently the existence of two
alternate binding modes depending on peptide sequence has been reported for VHR (35).
The results here do not address the question of whether the finding of two alternate
binding modes and two general acids pertains to peptide substrates of VHZ. Specific
substrates for VHZ have not been identified. Tests with pY-containing peptide substrates
(11-mers) of varying sequence yielded kcat values that were the same within experimental
error (0.5 s-1) and KM values from 2 to 4 mM (1).
VHZ exhibits phosphotransferase activity controlled by a single residue in an
unexpected location.
In classical PTPs, Q-loop residues such as Q446 and Q450 in YopH (Figure 3-4),
in locations analogous to E134 and Q138 in VHZ, position the nucleophilic water for the
second step and shield the phosphoenzyme from larger nucleophiles (2). In classical
PTPs catalysis is unaffected by added ethylene glycol. In contrast, YopH mutants in
which these glutamines are mutated show significant phosphoryl transfer to ethylene
glycol (2). This has provided a rationalization for why the native VHR and LMW-Ltp1,
which lack an analogous Q-loop, display phosphotransferase activity (3). Thus, the
observation of phosphotransferase activity by VHZ was unexpected, since its E134 and
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Q138 residues are superimposable with Q446 and Q450 in YopH. The ratio S of the
second-order rate constant for alcoholysis by ethylene glycol (kt) to the hydrolysis of the
phosphoenzyme intermediate (kcat’) is 14.4 (Table 3-5). This ratio was not significantly
affected by the E134Q mutation, indicating that the E and Q residues, as was previously
shown with YopH, are interchangeable (2). The higher transphosphorylation by the
E134A mutant indicates that that E134 provides some shielding of the phosphoenzyme.
However, the analogous YopH/Q446A mutation results in a greater increase, from which
we conclude that E134 in VHZ does not function as effectively in the second step as
Q446 in YopH. The VHZ/D65A substitution results in the most pronounced increase in
the S ratio, which, together with the reduced kcat indicates that D65 is important in the
second catalytic step.
Interestingly, unlike VHZ, there is no effect of ethylene glycol concentration on
catalysis by SsoPTP. A sequence alignment of the IPD-loops of VHZ and SsoPTP
revealed that while SsoPTP contains two proline residues in this region, a pattern that is
highly conserved in the PTP family, VHZ has an extra proline, P68. Other PTPs do not
have a proline in this position. In SsoPTP, V72 is found in the corresponding position.
The VHZ/P68V mutation results in no significant change in kcat; however,
phosphotransferase activity is lost and there is no dependence of rate on ethylene glycol
concentration.

The orthogonal SsoPTP/V72P mutation confers phosphotransferase

ability similar to that of native VHZ. We thus conclude that the single point mutation of
proline at the P68 position in VHZ, and the analogous V72 position in SsoPTP, controls
the ability of these enzymes to phosphorylate alcohols. Because the IPD-loop in VHZ
and SsoPTP is a rigid structural element, this mutation has no effect on kcat. Further
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studies, including structural comparisons, are underway to seek an explanation of how
this residue controls phosphotransferase activity.
Conclusions:
Although VHZ is most closely related to classical PTPs, it is unique and has a
number of unusual and interesting properties. VHZ has two functional general acids,
and, for the small molecule substrate pNPP, two substrate binding modes. Both binding
modes are catalytically equivalent but not equally populated. Each binding mode utilizes
a different general acid.
Despite the fact that VHZ shares a common active site with classical PTPs, it is a
significantly less efficient catalyst. Both catalytic steps k3 and k5 are slower compared to
other PTPs. The reduced k3 is consistent with incomplete neutralization of the leaving
group, as revealed by KIEs. Reduction of k5 is due to the incomplete involvement of the
E134 residue in the second step, as revealed by the E134Q and E134A mutations.
The results also provide a rationale for the advantage of mobility of the general
acid-bearing WPD-loop in classical PTPs.

The availability of an uncatalytic, open

conformation allows the general acid to avoid sterically unfavorable interactions with
substrate binding, and to alleviate product release and avoid product inhibition.
The discovery of phosphotransferase activity by VHZ also leads to several
conclusions:
1. The fact that the reaction rate increases linearly with ethylene glycol
concentration indicates the second step is at least partially rate limiting. Together with the
absence of a burst in the pre-steady state analysis of VHZ, we conclude that both steps
contribute to the overall rate.
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2. The Q-loop does not fully participate in protecting the active site from
incoming alcohol nucleophiles. In VHZ mutations on the IPD-loop have more control
over phosphotransferase ability. It is logical to conclude that the phosphotransferase
activity observed in VH1-related DSPs and Low molecular weight PTPs can no longer be
explained solely by the absence of the Q-loop. Significant difference in position of the
general acid loop between classical PTPs, LMW-PTPs and VH1-related DSPs
undoubtedly contributes as well.
3. The presence of phosphotransferase activity in some phosphatases, but not
others, may have significant biological consequences. It may not be coincidental that
some proteins known to be associated with cancer, such as VH1-related DSPs and LMWPTPs, and, recently, VHZ, reveal a high level of phosphotransferase ability (20, 21).
Whether this process is random and nonspecific, or transphosphorylation is selective for
some protein target, remains to be discovered. However, because VHZ has a stringent
phosphotyrosine specificity because of its deep and narrow active site, we can conclude
that its transphosphorylation target would likely be limited to tyrosine protein sites, or to
small molecule nucleophile acceptors capable of entering the active site.
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CHAPTER 4
METAVANADATE AT THE ACTIVE SITE
OF THE PHOSPHATASE VHZ3

Abstract
Vanadate is a potent modulator of a number of biological processes and has been
shown by crystal structures and NMR to interact with numerous enzymes. Although
these effects often occur under conditions where oligomeric forms dominate, crystal
structures and NMR data suggest the inhibitory form is usually monomeric
orthovanadate, a particularly good inhibitor of phosphatases due to its ability to form
stable trigonal-bipyramidal complexes. We performed a computational analysis of a 1.14
Å structure of the phosphatase VHZ in complex with an unusual metavanadate species,
and compared it with two classical trigonal-bipyramidal vanadate-phosphatase
complexes. The results support extensive delocalized bonding to the apical ligands in the
classical structures. In contrast, in the VHZ metavanadate complex the central, planar
VO3 moiety has only one apical ligand, the nucleophilic cysteine-95, and a gap in
electron density between vanadium and sulfur. A computational analysis shows the V-S
interaction is primarily ionic.

A mechanism is proposed to explain the formation of

metavanadate in the active site from a dimeric vanadate species that previous
crystallographic evidence shows can bind to the active sites of phosphatases related to
VHZ. Together, the results show that the interaction of vanadate with biological systems
is not solely reliant upon the prior formation of a particular inhibitory form in solution.
The catalytic properties of an enzyme may act upon the oligomeric forms primarily
3
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present in solution to generate species such as the metavanadate ion observed in the VHZ
structure.
Introduction
Because of vanadate’s ability to modulate a number of biological processes there
is considerable interest in the origin of the interactions of this simple inorganic species
with proteins(1-8). Over 173 structures in the Protein Data Bank (PDB) display the
interactions of different vanadate forms with a broad number of enzymes from multiple
organisms(9-13). Vanadate is a potent inhibitor of many phosphatases, enzymes with key
roles in biological signaling throughout the living world. In particular, the insulin
mimetic effect of vanadate is associated with its inhibition of protein tyrosine
phosphatases (PTPs) (14, 15). Compared to orthophosphate ion (PO43), orthovanadate ion
(VO43-) is a more potent inhibitor of phosphatases with a Ki that is often several orders of
magnitude lower. This difference is attributed to the ability of vanadate to form a
trigonal bi-pyramidal complex at the active site, resembling the transition state for
phosphoryl transfer (13, 16-20). Experimental data with PTPs indicate that both
formation and hydrolysis of the phosphoenzyme intermediate proceed via a loose
transition state with low bond orders to the nucleophile and the departing leaving group,
(21-24) whereas crystal structures of trigonal bi-pyramidal vanadate complexes in
enzymes are commonly modeled with full bonds to the apical ligands. Previous
experimental and computational results suggest that such complexes resemble the
transition state only in overall geometry and charge, whereas the bond orders between
vanadium and the apical ligands are higher than those of the corresponding bonds in the
transition state (25, 26).
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An understanding of the inhibitory effect of vanadate on phosphatases, and of its
biological effects, is complicated by the tendency of vanadate to oligomerize in solution
(27). These effects are frequently observed under conditions where vanadate is primarily
oligomerized and the monomer is a minor form (3, 27). Interestingly, even though
crystallization conditions often require vanadate concentrations that would primarily
result in oligomeric species, crystal structures almost exclusively show monomeric
vanadate at the active site. This has been attributed to the facile interconvertability of
different vanadate species in solution and the ability of the active site of phosphatases to
selectively stabilize the monomeric form (28). Here, we report results indicating that the
classical trigonal bi-pyramidal vanadate species is not the only form capable of binding to
PTPs, and that other forms contribute to the inhibition of PTPs and potentially to other
biological effects of vanadate.

Results and discussion
VHZ is a recently described member of the PTP family of phosphatases (29). A
recently obtained high-resolution structure of VHZ in complex with vanadate revealed
what appeared to be an unusual “metavanadate” in the active site (Figure 4-1; PDB ID
4ERC). The VO3 moiety is coordinated to the sulfur atom of cysteine 95 as one apical
ligand, with a 2.4 Å V-S distance. The opposite apical position is occupied by a nitrogen
atom of the arginine 60 (RS60) side chain trapped in the active site from a symmetryrelated VHZ molecule in the crystal (Figure 4-2, A). The V-N distance of 3.2Å argues
against a significant bonding interaction, nor would a significant interaction be expected
with the positively charged guanidinium group. Although the V-S distance is typical of
those commonly observed in trigonal bi-pyramidal vanadate-PTP complexes, (17) a
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distinct electron density gap between the atoms is evident in the high resolution unbiased
composite omit map (Figure 4-1). Furthermore, the VO3 moiety is nearly planar, while a
tetrahedral geometry would be expected from a covalent V-S bond and the absence of an
apical V-N bond (20, 30). These observations suggest that the VO3 moiety is better
described as an electrostatically stabilized metavanadate (VO3-) rather than a covalent
thiovanadate adduct. A computational analysis of this structure was carried out to analyze
the unusual bonding in this complex, compared with more typical, previously reported
vanadate-PTP structures (Figure 4-2). The two more conventional structures chosen for
comparison were the complex of PTP1B with a vanadate ester of the peptide DADEYL
(Figure 4-2 B, PDB ID 3I7Z), and PTP1B with orthovanadate (Figure 4-2 C, PDB ID
3I80). Both of the latter structures are typical of the trigonal bi-pyramidal vanadate-PTP
complexes well represented in the literature. The nature of the chemical bonding between
the VO3 ion and the protein was assessed using quantum mechanical calculations. For
this purpose portions of the proteins shown in Figure 4-2 were extracted directly from the
crystal structures.

Figure 4-1. The electron density at the VHZ active site. It suggests a non-covalently
bound VO3- ion. Shown is an unbiased composite omit map contoured at 1.5 σ in the
refined model.
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Truncation was done to include all residues interacting with vanadate; all residues
with hydrogen bonds or pi-stacking to residues that interact with vanadate; and all groups
that are polar or charged, and located in proximity to the vanadate ion even if they do not
directly interact. Hydrogen atoms were added to satisfy all dangling valencies using the
Chimera program(31). The standard protonation states of amino acids were assumed
(deprotonated Asp, Glu, protonated Lys and Arg), except for the Tyr coordinating
vanadium in Figure 4-2 B, which was deprotonated. The nucleophilic cysteine was
assumed to be deprotonated; this residue has a pKa in the range of 5.5 to 6 in this enzyme
family(32). The truncated complexes effectively contained the first and the second
coordination spheres of the vanadate ion, and consisted of 140-170 atoms (including
hydrogens), depending on the complex. The spin states of the complexes were zero,
assuming the empty d-shell in vanadium. The Natural Bond Orbital (NBO) analysis(3336), at the B3LYP (37-39)/6-31G* (40, 41) level of theory, was used to elucidate the
chemical bonds present in the complexes. This level of approximation, including the
fairly modest size of the basis set, were considered adequate for the problem at hand,
because NBO results in general are quite insensitive to the basis set used, and because
only the qualitative assessment was required to differentiate the state of V in the
complexes. Calculations were performed using the Gaussian 09 suite of programs (42).
Table 4-1 contains the key electronic structure parameters characterizing the
vanadium atom and its bonding environment in the three complexes. There is an apparent
difference between the bonding exhibited by VHZ complex containing VO3 (Figure 4-2
A) and the other two complexes. As expected from its distance of 3.2 Å, there is no
significant interaction between the V and the apical N of Rs60. The partially populated
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lone pair (LP) on N of the distant apical Arg (1.66 |e|) donates electron density to the
guanidinium group, participating in π-resonance, and is only weakly coordinated to V
through van der Waals interactions. One of the O atoms of the VO3 ion exhibits a pi
bond with V, representing one of the resonance structures (the lowest energy one)
possible in this π-delocalized VO3 ion. There is a clear 2 center – 2 electron (2c-2|e|)
bond between V and SCys95. This bond is primarily ionic, with 79% of electron density
residing on S and 21% on V. This is consistent with the electron density gap observed in
the unbiased composite omit map between the C95 sulfur and V, which is indicative of
ionic rather than covalent ligand stabilization. The bonding within the vanadate moiety
and its interaction with VHZ differ in several ways from the more conventional PTP1B
complexes. In contrast to the VHZ-VO3 complex 2A, in the PTP1B complexes 2B and
2C there is no π-bonding within the central VO3 part of the ion. This is reflected in
different averaged V-O bond lengths in the x-ray structures, which are 1.70 Å for 2A,
1.89 Å for 2B, and 1.91 Å for 2C. One lone pair on SCys215 (LP3) and one on OTyr (LP3)
are populated only by ca. 1.7 |e|, within the NBO localized picture. The low-populated
lone pair on S (LP3) partially donates electron density to the d-atomic orbitals (AOs) of
vanadium. The low-populated lone pair on O of Tyr (LP3) primarily donates electrons
into π-resonance within the Tyr phenyl ring. However, both LP2 and LP3 on OTyr also
donate to the d-AOs on vanadium.
To summarize, in complexes 2B and 2C neither the V-SCys, nor the V-OTyr apical
interactions are classic 2c-2|e| bonds.

Bonding between vanadium and these apical

ligands is significant and highly delocalized between SCys, V, and OTyr. The equatorial V-
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Figure 4-2. The regions of the three vanadate complexes used in quantum mechanical
calculations. (A) VHZ-VO3 (PDB 4ERC) (B) PTP1B-Tyr-VO4 (PDB 3I7Z), (C) PTP1BVO4 (PDB 3I80). Hydrogens have been omitted from the picture for the sake of clarity.
In the VHZ complex, the Rs60 residue in the active site comes from a symmetry-related
VHZ molecule. DADEYL peptide was omitted with exception of Y side chain.
Coordinates are available in Appendix C.
O interactions are single bonds. In contrast, the complex 2A can be described as a
π-delocalized VO3 ion with only one apical interaction, an ionic bond between V and
SCys.
The complex solution chemistry of vanadate must be considered together with the
chemical properties of the enzymes it can associate with.

Monomeric vanadate

dominates at low concentrations, with dimeric forms becoming significant at
concentrations above 0.2 mM, followed by higher oligomers(28). Interconversion is
rapid, and it is logical that the various forms of vanadate should be similarly labile in an
enzymatic active site. There is no reason, a priori, that an inhibiting form of vanadate
must pre-form in solution before binding to the enzyme. While numerous oligomeric
forms of vanadate have been documented, metavanadate has not been reported in
solution, and presumably was generated by the enzyme from some other vanadate species
present in solution, and subsequently stabilized by the active site environment. We
propose a simple mechanism that can explain the formation of this species from
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Table 4-1. Electronic structure parameters characterizing the vanadium atom and its
bonding in complexes 2A-C. The parameters calculated with NBO at B3LYP/6-31G*:
Charges on atoms (Q) , electronic populations of 2 center-2 electron (2c-2|e|) σ and π
bonds, and electronic populations of lone pairs (LP). Atoms are labeled according to
Figure 4-2.
VO3 (2A)
Q(V)
Q(SCys)

1.09
-0.31

VO4 (2B) VO4
(2C)
1.34
1.33
-0.42
-0.42

Q(N/Oapical)

-0.79a

-0.68

-0.9

1.99 |e| - σ
1.96 |e| - π
1.98 |e|
1.98 |e|
1.95 |e|

1.99 |e|
none
1.99 |e|
1.99 |e|
none

1.98 |e|
none
1.99 |e|
1.98 |e|
none

LP1(S)
LP2(S)
LP3(S)

1.94 |e|
1.87 |e|
noneb

1.94 |e|
1.88 |e|
1.73 |e|

1.94 |e|
1.88 |e|
1.73 |e|

V-N or Oapical

none

none

none

LP1(N or Oapical)

n/ac

1.91 |e|

1.94 |e|

LP2(Oapical)

n/a

1.86 |e|

1.83 |e|

LP3(N or Oapical)

1.66 |e|

1.61 |e|

1.65 |e|

2c-2|e| bonds:
V-O1
V-O2
V-O3
V-S
Lone pairs:

a

-0.79 is the atomic charge on the Rs60 nitrogen atom in an apical position to vanadium;
the total charge on the guanidinium group of this arginine is +0.6. b “none” indicates that
suitable orbitals are available, but not occupied. c “n/a” indicates that the lone pair
orbitals are not present.
divanadate, and possibly polyvanadate, forms that are well known to exist, and usually
dominate, in solution. In light of the highly conserved nature of the active sites of PTPs,
this mechanism would apply to this family as whole, and potentially to any similar
enzyme with a general acid.This proposal (Figure 4-3) incorporates the general acid
conserved in PTPs, and also explains why the first report of a divanadate

.

FIGURE 4-3. A proposed mechanism that explains the formation of a metavanadate species in the active site of VHZ. The vanadium
species D, F and G have been observed in crystal structures. Protonation states of the vanadium species are not known from the crystal
structures, but are depicted in states consistent with the pH at which crystals were grown. D) PDB ID 3F9B - divanadate bound in the
active site of the YopH mutant W354F with catalytic WPD (acid)-loop locked in a half-open conformation; E) transient complex (not
observed in the crystal form) showing the acid-loop closure which triggers the catalytic transformation of divanadate into metavanadate;
VHZ has no mobile loop but its general acid occupies an analogous position. F) PDB ID 4ERC– metavanadate trapped in the active site of
VHZ; G) PDB ID 3I80 – orthovanadadate in the active site of PTP1B
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species at the active site of a PTP was found in a YopH W354F mutant in which the
flexible loop that bears the general acid is locked in a catalytically unproductive
position(43). The crystal structure of this divanadate complex showed that dimeric, and
possibly higher oligomeric species, are capable of binding to PTPs (Figure 4-3 D). We
believe it is no coincidence that this complex was identified in a mutant in which general
acid catalysis is disabled. Presumably, this or other dimeric forms bind to the native
enzyme,

but

are

rapidly

hydrolyzed

to

the

monomer

and

not

observed

crystallographically.
According to the proposed mechanism, divanadate (Figure 4-3 D) binds in the
active site and the general acid protonates one of its bridge oxygens, triggering
decomposition and formation of “metavanadate,” stabilized by the P-loop and
electrostatic interaction with the nucleophilic thiolate. The resulting complex (Figure 4-3
E) is the species trapped in the VHZ-VO3 crystal structure. The classically observed
trigonal bi-pyramidal orthovanadate species can result from a process analogous to the
second step of the PTP-catalyzed reaction, in which a nucleophilic water attacks with
positioning assistance of Q-loop residues, assuming the other apical position. Such a
process would explain the high affinity and selectivity in crystal structures of PTPs for
monomeric orthovanadate under conditions where oligomeric polyvanadates dominate in
solution. Recent work (44) shows that vanadate speciation is sensitive to surfaces such as
micelles, consistent with the idea that an enzyme active site could preferentially stabilize
a species such as the dimer in 3D, or metavanadate.
We note that the reversible interconversion between F and G in Figure 4-3
provides an alternative pathway for enzyme-catalyzed metavanadate formation without
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invoking binding of a dimeric form. However, the VHZ crystals were grown in the
presence of 10 mM vanadate, far above the 0.2 mM level at which dimeric and higher
forms begin to dominate. Potent vanadate inhibition of many phosphatases is reported
across wide ranges of pH and vanadate concentrations, supporting the notion that
multiple forms are capable of binding, and that the interconvertability in the active site is
similar to that in solution. If anything, the active site of an enzyme optimized to catalyze
hydrolysis should facilitate such processes.
The metavanadate species observed here is not an anomalous structure only
relevant to VHZ, or potentially other PTPs. A geometrically similar VO3 species has
been previously observed in a crystal structure of phosphoglucomutase, (45) an enzyme
that has no similarity to PTPs. That structure also reveals a planar VO3 moiety with a
single apical ligand (an aspartate carboxyl group) and a similar gap in the 2Fo-Fc electron
density obtained from the Electron Density Server (EDS) observed at 1.0 σ.

Conclusion
In summary, this work shows that the interaction of vanadate with the active sites
of PTPs in solution is more versatile than the simple trigonal bi-pyramidal model that
dominates the RCSB.

The inhibitory effect of vanadate can involve dimeric, and

potentially higher oligomers, an important factor since such species often dominate in
solution. The ability of the active site environment to electrostatically stabilize a
metavanadate ion adds another facet to the interaction of vanadate with such enzymes. In
the VHZ-VO3 complex there is only a single significant apical interaction, which is
primarily ionic.
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This complex is a good analogue of the loose metaphosphate-like transition state
concluded from experimental studies. The average V-Oeq bond distance in the VHZ-VO3
structure is shorter compared to the commonly observed trigonal bi-pyramidal vanadate
complexes, but in a good agreement with experimental values determined with Raman
difference spectroscopy of vanadate at the active site of the related enzyme YopH.
Hence, it is conceivable that such VO3 species may form more commonly than suspected
in PTP-vanadate solutions, and the dominance among crystal structures of the trigonal bipyramidal structures (like 3E and 3F) arise from species that subsequently form and are
more amenable to trapping. The rich speciation of vanadate in solution clearly extends to
its ability to also adopt multiple species at enzymatic active sites.
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CHAPTER 5
CONCLUSIONS AND PROSPECTIVE DIRECTIONS

Summary of the research
Our work with VHZ has revealed new aspects of this unique enzyme and
corrected in many ways the original misinterpretation primarily affecting its
classification, kinetic behavior, substrate specificity and structural properties. We have
shown that VHZ is the simplest classical PTP with strict phosphotyrosine substrate
specificity. Its sequence and structural analysis revealed that it bears several important
distinctions from the atypical DSP subfamily where it was originally believed to belong
to. Its general acid IPD-loop is highly superimposable with the analogous WPD-loop
region in classical PTPs. However, unlike the WPD-loop in classical PTPs, which is
highly flexible and has been repeatedly observed in open and closed conformational
states, the IPD-loop in VHZ is a rigid and permanently closed element. Our kinetic
analysis of VHZ has shown it has an unusual ability to utilize two alternative general acid
residues which is made possible by two different, unequally populated substrate binding
modes.
Although we showed that VHZ is significantly more active than was previously
believed, its catalytic efficiency remains significantly lower compared to the classical
PTPs. Using kinetic isotope effects we revealed that the leaving group remains only
partially protonated in the first step of the reaction, despite the fact VHZ contains two
general acids. The pre-steady state kinetic analysis revealed that the first step of the
reaction contributes to the rate limiting step of the overall process, whereas in classical
PTPs the second step is predominantly rate limiting. Additionally, we revealed that VHZ
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displays a high level of phosphotransferase ability despite the fact it contains a conserved
Q-loop which is highly superimposable with the analogous region in classical PTPs. This
protein element is believed to protect the phosphoenzyme intermediate from alcohol
nucleophiles. Although, similar to classical PTPs, the Q-loop in VHZ plays an important
role in controlling phosphotransferase ability, the general acid IPD-loop appears to be
more important and critical as shown by the fact that the VHZ/P68A mutation in this
region completely abolishes transphosphorylation. Finally, we identified SsoPTP as the
closest relative to VHZ in terms of structure and kinetic properties. Both VHZ and
SsoPTP are similar in size, and reveal the highest sequence and structural similarity as
well as similar kinetic parameters. Both enzymes, unlike classical PTPs, contain a rigid
IPD-loop and lack a substrate binding loop. SsoPTP, however, like many other PTPs and
unlike VHZ, utilizes a single general acid but appears to have a shallow and broad active
site crevice like many DSPs. Thus, SsoPTP represents a hybrid containing features of
VHZ, classical PTPs, and DSPs in one enzyme.
Prospective research direction
Although VHZ was the major focus of this study, it raised several important
questions pertinent to the PTP family in general. The answers to these questions will lead
to better understanding of the PTP-catalyzed reaction and contribute to the field of
enzymology.
Despite the fact that VHZ is structurally identical to classical PTPs, utilizes the
same mechanism, and all the catalytic residues are highly superimposable, it remains
significantly less active when compared to classical PTPs. Incomplete protonation of the
leaving group in the first step cannot explain the difference in activity, because the

117

second step, which involves water attack on the phosphoenzyme intermediate, is
significantly slower as well. The answer to the question of why VHZ and SsoPTP are less
active will allow a deeper understanding of catalytic mechanism of PTP catalyzed
phosphate monoester hydrolysis. Explanations remain to be discovered to several
questions:


In what way does the mobility of the WPD-loop affect catalytic

activity? Can we make the IPD-loop movable, and what effect will it have on
catalytic activity?


Does the substrate binding loop in classical PTPs contribute to

their catalytic activity, and if so, then in what way? Can we increase the catalytic
activity of VHZ and SsoPTP by introducing a substrate binding loop to these
enzymes?
Importance of the substrate binding loop
This N-terminal region in PTPs is called the substrate binding loop because it
makes a π-π stacking interaction with PTP substrates (1). It is absent in SsoPTP and VHZ
which are shorter versions of classical PTPs. This region has not been considered as
catalytically significant and is primarily responsible for substrate recognition and
interaction. However, a single mutation of highly conserved Y residue in PTP1B
substrate binding loop to yield the PTP1B/Y46E mutation resulted in a 100-fold
reduction of kcat and a 40-fold increase in KM. Although such effect remains primarily
unexplained, more work has to be done to study this phenomenon. In particular, the entire
substrate binding loop can be removed by a simple one-step PCR experiment and the
truncated version of PTP1B should be tested and evaluated crystallographically.
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Alternatively, the substrate binding loop can be genetically introduced to VHZ and/or
SsoPTP and such chimeric proteins can be studied to see if the presence of such loop
changes the activity of these enzymes.
Factors affecting general acid IPD-loop stability in VHZ
In order to selectively target the mobility of IPD-loop region in either VHZ or
SsoPTP we need to understand the underlying factors that stipulate its permanently stable
conformation. We have tested several VHZ and SsoPTP mutants to identify the factors
that stipulate IPD-loop rigidity. The kinetic parameters of the mutants are presented in the
Table 5-1 whereas VHZ/WT substituted positions are presented in Figure 5-1.
IPD-loop vs WPD-loop - the substitution effect
There is very little information available in the literature that describes the factors
affecting WPD-loop mobility. Several studies clearly revealed that the highly conserved
W residue in the structure of WPD-loop is crucial for its proper oscillation and
substitution of this residue to aliphatic alanine results in the reduction of kinetic
parameters as a result of loop being locked in a semi-open conformational state (2, 3).
Another study suggested that the residues surrounding the conserved WPD-loop region
also play important role in its flexibility (4). The sequences of VHZ and classical PTPs
bear one significant difference in this region, and whereas classical enzymes contain a
WPD-loop, VHZ and SsoPTP have an IPD-loop instead. Structurally these regions are
highly superimposable, but the I63 residue in VHZ and I67 in SsoPTP correspond to the
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Figure 5-1. Active site of VHZ and residues analyzed by site directed mutagenesis.
Dashed line connects atoms within hydrogen bond distance (≤ 3Å). We have tested
several positions in VHZ which, based on the structural evidence, or previously
knowledge about analogous WPD-loop motion in classical PTPs, could affect its
mobility. For example, Q73 stabilizes the IPD-loop by making two hydrogen bonds to the
backbone. Analogous stabilization to the IPD-loop is provided by Q77 in SsoPTP.
W residue highly conserved in all classical PTPs. The VHZ/I63W mutant was made to
study the importance of this position on catalytic parameters of VHZ.Substitution of I63
for a bulky W makes it closer to the classical PTPs, yet resulted in the 50-fold reduction
of kcat which makes it very similar to the effect produced by P64A and P69A
substitutions (Table 5-1). VHZ/I63W mutation resulted in no change of KM and Ki for
the inorganic phosphate (Table 5-1 and Table 5-2) indicating it affects the general acid
loop region but not active site geometry. These results suggest that the substitution of W
for I in VHZ is catalytically important and cannot be a mere consequence of IPD-loop
staying in the permanently closed conformation.
Residues surrounding the IPD-loop region
Considering that residues surrounding this loop may affect its flexibility as well,
we observed that unlike any other PTP, VHZ/WT contains three proline residues in its
IPD-loop structure (Figure 5-1). Proline residues are known to affect flexibility of loop
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regions and in classical PTPs the WPD-loop most commonly contains two or even one
proline residue in its structure. VHZ, however, in addition to the P64 and P69 proline
residues (VHZ numbering) common for classical PTPs, also contains P68.
Table 5-1. Kinetic parameters of native and mutated PTPs. The mutants were made to
probe the factors affecting the IPD-loop rigidity.
Native enzymes kinetic parameters
kcat, s-1
KM, mM
kcat/KM, (=mM/s)=
VHZ/WT
3.900 ± 0.028 8.30 ± 0.67
0.47
VHR/WT
3.116 ± 0.102 1.96 ± 0.11
1.59
S.soPTP/WT
3.152 ± 0.048 4.31 ± 0.19
0.73
YopH/WT
720.000 ± 24.600 0.98 ± 0.11
734.69
PTP1B/WT
51.667 ± 0.860 0.12 ± 0.01
430.56
Mutational analysis of WPD/IPD-loop rigidity
kcat,(s-1)
KM, mM
kcat/KM, (mM/s)
Sso PTP/V72P
PTP1B/V184P
VHZ/P68A
VHZ/Q73L
YopH/S287A
VHZ/E44R
VHZ/E44Q
VHZ/E44S

VHZ/I63W
VHZ/P64A
VHZ/P69A

2.61
0.610
3.34
0.93
210.5
4.26
4.75
3.78

± 0.1
4.62 ± 0.43
± 0.130 1.20 ± 0.23
± 0.06 5.88 ± 0.27
± 0.03 13.00 ± 0.99
± 8.5
1.1 ± 0.1
± 0.06 6.53 ± 0.26
± 0.02 8.20 ± 0.67
± 0.03 8.80 ± 1.21
Additional Mutations
kcat,(s-1)
KM, mM
0.065 ± 0.001 8.50 ± 0.42
0.068 ± 0.034 32.92 ± 2.98
0.096 ± 0.005 31.00 ± 2.80

0.56
0.51
0.57
0.07
196.7
0.65
0.58
0.43
kcat/KM, (mM/s)
0.007
0.002
0.003

Mutations of VHZ/P64A and VHZ/P69A, as can be seen from Table 5-1,
significantly alter its kinetic parameters, indicating that similarly to classical PTPs these
proline residues are highly important for catalysis (Table 5-1). The VHZ/P68V mutation
resulted in no kinetic effect. Additionally, the inverse SsoPTP/V72P mutation in SsoPTP
did not yield any significant kinetic effect. Unlike any other amino acids, proline imposes
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significant constraints on the protein backbone which is believed to be one of the
important factors affecting its proper folding. The transformation of the WPD-loop is
accompanied by significant changes of the φ and ψ angles in the movable segment of the
loop. For WPD-FGVP sequence in PTP1B the Δφ and Δψ changes for the closed-to-open
transition were found to be: Δφ=195,Δψ=120; Δφ= 200, Δψ=20; Δφ=6 Δψ=0; Δφ=4
Δψ=30; for F,G,V,P respectively (Figure 5-2). In VHZ the analogous IPD-FCPP segment
contains two proline residues (di-proline segment, P68-P69). The presence of proline and
especially di-proline segments in protein structures presents structural constraints
resulting in a protein element with significantly reduced conformational choices. As was
shown by Schimmel and Flory and later by MacArthur and Thornton (5, 6) the residues
that precede proline are sterically constrained as well, and have a marked preference to be
in the β-region of the Ramachandran plot. For a pre-proline amino acid the preference for
the β-region over the α-region was estimated to be 9:1 respectively, whereas for residues
in general (followed by any other amino acid) the distribution is almost equal. This effect
is due to the steric clashes of the proline five-membered ring with the Cβ carbon and
amide nitrogen of the preceding residue (7). Even glycine which has no Cβ carbon
appeared to be sterically constrained at this position and out of 62 Gly-Pro segments in
the protein databank only 5 were found in an unfavorable α region in the range of ψ -30o 70o whereas the major clustering occurs in a narrow ψ region of 180 (±30o) (5). In the
native PTP1B the G183 residue is located in the β-region (φ=-118, ψ= 180) when WPDloop is closed and in the open conformation it occupies αL (φ=82, ψ=-160) region which
according to MacArthur and Thornton is not observed in the crystal structures if followed
by proline. It becomes the case in PTP1B/V184P mutation (Table 5-1) which introduces
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analogous to VHZ

The P184-P185 diproline segment in its WPD-loop significantly

reduces kcat and at the same time raises KM. However, in contrast to the case of PTP1B/
W179A mutant when the loop was locked in a semi-open state thus abolishing general
acid catalysis, the pH rate profile of PTP1B/V184P mutant remained bell-shaped (Figure
5-2,C) indicating no loss of general acid catalysis which in turn indicates that the loop
has to be locked in the closed conformation. These data indicates that because IPD-loop
is non-movable in VHZ and SsoPTP, introduction of additional proline residues in these
proteins results in no significant kinetic alteration. On the other site, in PTP1B containing
a movable WPD-loop introduction of an additional proline residue imposes
conformational constraints on the loop increasing its rigidity. Hereby we can conclude
that additional proline residue in VHZ and SsoPTP contributes to its rigidity but it is not
the major factor which stipulates it. In search for additional positions which can explain
the rigidity of IPD-loop we found that Q73 residue in VHZ and corresponding Q77 in
SsoPTP provide stabilization to the IPD-loop not previously observed in other PTPs. This
residue makes two hydrogen bonds to the backbone of IPD-loop which stabilizes the
IPD-loop in the closed conformation (Figure 5-1). Despite being distal from the active
site, the VHZ/Q73V substitution decreases kcat four-fold and results in a 50 % increase in
KM indicating it plays important role in stabilization of the IPD-loop (Table 5-1).
Effect of the distal residues on WPD-loop mobility
VHZ and SsoPTP contain E44 and E37, respectively, in close proximity to the active site
pocket. Analysis of WPD-loop motion in classical PTPs (Figure 5-3) indicates that the
residues from the corresponding region (S287 in YopH and R112 in PTP1B) stabilize the
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Table 5-2. Enzyme inhibition by inorganic phosphate. Classical PTPs with movable
WPD-loop have lower Pi inhibition constants due to the 90 o rotation of phosphate
binding catalytic arginine associated with the loop motion which helps to release product.
Rigid IPD-loop permanently holds the R101 in VHZ in the favorable for binding
conformation reflected by significant reduction of Ki. The same holds true for SsoPTP
with a rigid IPD-loop. Inhibition for inorganic phosphate hereby can serve as a useful
reporter to probe the dynamical state of the WPD-loop.
Name
Ki, μM
YopH/WT
4385 ± 126
YopH/S287A 3500 ± 119
PTP1B/WT 3642 ± 110
VHZ/WT
678.5 ± 54
VHZ/E44N
714 ± 98
VHZ/I63W
663 ± 72
Sso/WT
494 ± 45

Figure 5-2. The effect of the PTP1B/V172P substitution. A) Dihedral angle changes for
the G183 residue in the WPD-loop of PTP1B. Green planes correspond to the φ and ψ of
G183 residue in PTP1B when WPD-loop is closed, whereas red planes correspond to the
φ and ψ angles when the loop is in the open conformation. B) The change of
Ramachandran angles for G183 which accompany WPD-loop transition between open
and closed conformations in PTP. When G183 is followed by proline in PTP1B/V184P
mutant this transition becomes disfavored, forcing the loop to occupy predominantly
closed position. C) kcat vs pH profile for PTP1B/V184P mutant. As expected the plot
indicates the closed conformation of the loop is not affected by mutation and general acid
catalysis is fully operational.
loop in its open conformation. We made the YopH/S287A substitution which results in
the 3 fold reduction of kcat with no significant effect on KM (Table 5-1) and accompanied
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by a moderate reduction in Ki for inorganic phosphate (Table 5-2). It is suggested this
stabilization indeed plays a catalytic role in WPD-loop motion, possibly changing the
open-closed loop dynamic equilibrium. The VHZ/E44Q, VHZ/E44S and VHZ/E44R
substitutions resulted in no significant effect on kinetic parameters, indicating the IPDloop does not interact with this residue regardless of the charge or bulkiness of its side
chain. The data suggests that because mutated position did not bring any significant effect
on VHZ activity but affected YopH the presence of bulkier negatively charged residues at
this position is only a secondary factor which may or may not contribute to the IPD-loop
mobility.
Conclusions and further directions
Preliminary data suggested that the rigidity of the IPD-loops in VHZ and SsoPTP
is stipulated by several factors rather than a single one. It may not be plausible, however,
to change the rigidity of the stable IPD-loop to infer about the effect of the WPD-loop
mobility, for as it was revealed by the VHZ/Q73L substitution, some structural factors
can be affected as well. However, information obtained about IPD-loop rigidity can be
used to impose certain restriction on the movable WPD-loop and use catalytic
consequences of such substitution to infer about the importance of this motion.
PTP1B/V172P mutant was designed based on the information obtained from VHZ
studies and revealed significant deterioration of kinetic properties with general acid
catalysis which remained intact. A crystal structure of this mutant will reveal the
structural effect brought about by this substitution. If, consistent with the kinetic pH rate
profile which remained bell shaped in the PTP1B/V184P mutant, the loop will be found
in the predominantly closed conformation, then it can serve as solid evidence to show
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Figure 5-3. General acid loop interactions in the open state. A) Open and closed WPDloop conformations in YopH WT. Stabilization of the WPD-loop in the open
conformation is provided by S287. The YopH/S287A mutation result in the three fold
reduction of kcat (Table 5-1). Analogous stabilization in PTP1B and hematopoetic PTP
(HePTP) is provided by the arginine side chain in the similar position (data not shown).
B) Superimposition of VHZ (PDBID 4ERC) with apo YopH (open loop) reveals a steric
clash which is thought to be one of the factors preventing IPD-loop from occupying an
open conformation. Mutation of E44 to different residues (Table 5-1) shows no
significant effect on catalytic parameters.
that the WPD-loop closure is a catalytically relevant event. Kinetic isotope effects and
pre-steady state kinetics of the PTP1B/V72P mutant will provide additional information
and help to reveal what step of the reaction is mostly affected by this mutation, and if the
structure of the transition state is affected in relation to the wild type.
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APPENDIX A
SUPPORTING INFORMATION FOR NEW ASPECTS OF THE PHOSPHATASE
VHZ REVEALED BY A HIGH-RESOLUTION STRUCTURE WITH VANADATE
AND SUBSTRATE SCREENING
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Table A-1. The substrate screen table from the manufacturer. Column 1 refers to the well
# in the 384 well-format plate. Column 2 shows the phosphorylated peptide sequence.
Column 3 summarizes the proteins in vivo where each phosphopeptide occurs. The
UniProt code is given for the easy identification of the protein target.
A1
A2
A3

(pS)DIEEVVEEYE
(pS)DEEVEQVEEQ
RRGGV(pS)AEVYT

A4

KPFKL(pS)GLSFK

A5

RRGAI(pS)AEVYT

A6

PTRKI(pS)ASEFD

A7

ARVLE(pS)YRSCY

A8

NSVSP(pS)PLMLL

A9
A10

P(pS)DKERLTSDA
KHVPD(pS)GATAT

A11

NVDKHVPD(pS)GA

A12

TKRNS(pS)PPPSP

A13
A14

PPPQL(pS)PFLQP
RHLDI(pS)RELND

TRT2_HUMAN (P45379)
TRT3_HUMAN (P45378)
KAP1_HUMAN (P31321)
KAP1_MOUSE (P12849)
KAP1_RAT (P81377)
MRP_HUMAN (P49006)
MRP_MOUSE (P28667)
MRP_RABIT (P35566)
KAP0_BOVIN (P00514)
KAP0_HUMAN (P10644)
KAP0_PIG (P07802)
KAP0_RAT (P09456)
CN5A_BOVIN (Q28156)
CN5A_CANFA (O77746)
CN5A_HUMAN (O76074)
MINK_HUMAN (P15382)
MINK_HUMAN (P15382)
ESR1_HUMAN (P03372)
ESR1_MESAU (Q9QZJ5)
ESR1_MOUSE (P19785)
ESR1_RAT (P06211)
ITA6_CHICK (P26007)
PPB1_HUMAN (P05187)
PPB2_HUMAN (P06861)
PPB3_HUMAN (P05188)
PPBN_HUMAN (P10696)
PPB1_HUMAN (P05187)
PPB2_HUMAN (P06861)
PPB3_HUMAN (P05188)
ATB1_HUMAN (P20020)
ATB1_RABIT (Q00804)
ATB1_RAT (P11505)
ESR1_HUMAN (P03372)
LGN_HUMAN (P81274)
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A15
A16

VFTSR(pS)AAFSG
VPLDR(pS)SHCQR

A17

APKKG(pS)KKAVT

A18
A19

AKKED(pS)DEEED
L(pS)DQEKRKQIS

A20

SEGEE(pS)TVRFA

A21

AKSFG(pS)PNRAY

A22

LSRMP(pS)PGGRI

K2C7_HUMAN (P08729)
INSR_HUMAN (P06213)
INSR_HUMAN (P06213)
INSR_MOUSE (P15208)
INSR_RAT (P15127)
INSR_RAT (P15127)
H2BA_HUMAN (P02278)
H2BC_HUMAN (Q99880)
H2BD_HUMAN (Q99877)
H2BH_HUMAN (Q93078)
H2BJ_HUMAN (Q93079)
H2BL_HUMAN (Q93080)
H2BN_HUMAN (P23527)
H2BQ_HUMAN (Q16778)
H2BR_HUMAN (P06899)
H2BS_HUMAN (P57053)
H2B1_MOUSE (P10853)
H2B2_MOUSE (P10854)
H2B_RAT (Q00715)
H2B_CAIMO (P14001)
H2B_CHICK (P02279)
H2B_CRONI (P02280)
H2B_SALTR (P02282)
H2B1_XENLA (P02281)
H2B2_XENLA (P06900)
NUCL_HUMAN (P19338)
PHS2_HUMAN (P11217)
PHS2_RABIT (P00489)
KPC1_HUMAN (P05771)
KPC1_RABIT (P05772)
KPC1_RAT (P04410)
KPC2_BOVIN (P05126)
KPC2_HUMAN (P05127)
KPC2_RABIT (P05773)
KPC2_MOUSE (P04411)
CDK7_HUMAN (P50613)
CDK7_MOUSE (Q03147)
MPP9_HUMAN (Q99550)
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A23

GSRRG(pS)FDATG

A24

LTRDS(pS)ILGPH

B1

PQRAT(pS)NVFAM

B2
B3

VTVAY(pS)PKRSP
RDLSS(pS)PPGPY

B4
B5

AAAPA(pS)EDEDD
YYEILN(pS)PEKA

MPP9_HUMAN (Q99550)
PLE1_CRIGR (Q9JI55)
PLE1_CRIGR (Q9JI55)
PLE1_HUMAN (Q15149)
PLE1_RAT (P30427)
DESP_HUMAN (P15924)
CCAA_HUMAN (O00555)
CCAA_MOUSE (P97445)
CCAA_RABIT (P27884)
CCAA_RAT (P54282)
CCAB_HUMAN (Q00975)
CCAB_MOUSE (O55017)
CCAB_RABIT (Q05152)
CCAB_RAT (Q02294)
CCAB_DISOM (P56698)
CCAE_HUMAN (Q15878)
CCAE_MOUSE (Q61290)
CCAE_RABIT (Q02343)
CCAE_RAT (Q07652)
CCAE_DISOM (P56699)
MLRM_CHICK (P02612)
MLRN_CHICK (P24032)
MLRM_HUMAN (P19105)
MLRN_HUMAN (P24844)
MLRN_PIG (P29269)
MLRA_RAT (P13832)
MLRB_RAT (P18666)
MLRH_CAEEL (Q09510)
MPP9_HUMAN (Q99550)
AAKC_HUMAN (O43741)
AAKC_RAT (Q9QZH4)
NUCL_HUMAN (P19338)
143B_BOVIN (P29358)
143B_HUMAN (P31946)
143B_RAT (P35213)
143Z_HUMAN (P29312)
143Z_MOUSE (P35215)
143Z_SHEEP (P29361)
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B6
B7

PMVDQ(pS)PSVST
KKRPQRAT(pS)NV

B8

FFPFH(pS)PSRLF

B9
B10
B11

AAARL(pS)LTDPL
GAGDG(pS)DEEVD
SWGTA(pS)PYSAM

B12
B13

GLSAM(pS)PTKAA
SLGRRA(pS)FHLE

B14

RSGYS(pS)PGSPG

B15

LRQLR(pS)PRRTQ

1433_XENLA (P29309)
Z145_HUMAN (Q05516)
MLRM_CHICK (P02612)
MLRN_CHICK (P24032)
MLRM_HUMAN (P19105)
MLRN_HUMAN (P24844)
MLRN_PIG (P29269)
MLRA_RAT (P13832)
MLRB_RAT (P18666)
CRAB_BOVIN (P02510)
CRAB_HUMAN (P02511)
CRAB_MESAU (P05811)
CRAB_MOUSE (P23927)
CRAB_RABIT (P41316)
CRAB_RAT (P23928)
HSBY_HUMAN (O43416)
GPBB_HUMAN (P13224)
MYH9_HUMAN (P35579)
PMX1_HUMAN (P54821)
PMX1_HUMAN (P54821)
PMX1_MOUSE (P43271)
PMX1_MOUSE (P43271)
PMX1_CHICK (Q05437)
PMX1_CHICK (Q05437)
Z145_HUMAN (Q05516)
CCAC_HUMAN (Q13936)
CCAC_MOUSE (Q01815)
CCAC_RABIT (P15381)
CCAC_RAT (P22002)
TAU_BOVIN (P29172)
TAU_CAPHI (O02828)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_MOUSE (P10637)
TAU_PAPHA (Q9MYX8)
TAU_RAT (P19332)
RB4A_HUMAN (P20338)
RB4A_MOUSE (P56371)
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B16
B17

VDYVN(pS)TEAET
TKSG(pS)TTKNRF

B18

MIGAD(pS)SEEKF

B19

RSRTP(pS)LPTPP

B20

SRGLK(pS)GLKTD

B21

RRKYR(pS)NKGES

B22
B23
B24
C1
C2

AETRVPTMRP(pS)
PTMRP(pS)MSGLH
PTTPL(pS)PTRLS
AWTAD(pS)GEGDF
SSTPL(pS)PTRIT

C3
C4

YSPKR(pS)PKENL
SGQLID(pS)MANS

RB4A_RAT (P05714)
FA9_HUMAN (P00740)
IF4E_HUMAN (P06730)
IF4E_MOUSE (P20415)
IF4E_RABIT (P29338)
IF4E_XENLA (P48597)
STAT_HUMAN (P02808)
STAT_HUMAN (P02808)
TAU_BOVIN (P29172)
TAU_CAPHI (O02828)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_MOUSE (P10637)
TAU_PAPHA (Q9MYX8)
TAU_RAT (P19332)
A1AA_BOVIN (P18130)
A1AA_CANFA (O77621)
A1AA_HUMAN (P35348)
A1AA_MOUSE (P97718)
A1AA_RABIT (O02824)
A1AA_RAT (P43140)
CD27_HUMAN (P26842)
CD27_HUMAN (P26842)
COA2_HUMAN (O00763)
COA2_HUMAN (O00763)
LAM1_HUMAN (P20700)
FIBA_HUMAN (P02671)
LAMA_HUMAN (P02545)
LAMA_MOUSE (P48678)
LAMC_MOUSE (P11516)
LAMA_RAT (P48679)
MPP9_HUMAN (Q99550)
MPK1_CRIGR (Q63980)
MPK1_HUMAN (Q02750)
MPK1_MOUSE (P31938)
MPK1_RABIT (P29678)
MPK1_RAT (Q01986)
MPK1_SERCA (Q91447)
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C5

MRPSM(pS)GLHLV

C6

DSMAN(pS)FVGTR

C7
C8

SGPYE(pS)DEDKS
RDKEV(pS)DDEAE

C9

RTPPK(pS)PSSAK

C10
C11

SSHYD(pS)DGDKS
FELIL(pS)PRSKE

C12

KVRKS(pS)TQEEI

MPK1_XENLA (Q05116)
MPK2_HUMAN (P36507)
MPK2_MOUSE (Q63932)
MPK2_RAT (P36506)
MPK2_CHICK (Q90891)
MPK2_CYPCA (Q90321)
DSOR_DROME (Q24324)
COA2_HUMAN (O00763)
COAC_CHICK (P11029)
MPK1_CRIGR (Q63980)
MPK1_HUMAN (Q02750)
MPK1_MOUSE (P31938)
MPK1_RABIT (P29678)
MPK1_RAT (Q01986)
MPK1_SERCA (Q91447)
MPK1_XENLA (Q05116)
MPK2_HUMAN (P36507)
MPK2_MOUSE (Q63932)
MPK2_RAT (P36506)
MPK2_CHICK (Q90891)
MPK2_CYPCA (Q90321)
DSOR_DROME (Q24324)
TLE2_HUMAN (Q04725)
HS9A_CRIGR (P46633)
HS9A_HUMAN (P07900)
HS9A_MOUSE (P07901)
HS9A_PIG (O02705)
HS9A_CHICK (P11501)
HS90_BRUPA (O61998)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_PAPHA (Q9MYX8)
TLE1_HUMAN (Q04724)
STHM_HUMAN (P16949)
STHM_MOUSE (P54227)
STHM_RAT (P13668)
COF2_HUMAN (Q9Y281)
COF2_MOUSE (P45591)
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C13

SSLRA(pS)TSKS

C14

ASTSK(pS)ESSQK

C15
C16

NKRRG(pS)VPILR
PIDME(pS)QERIK

C17
C18

PSEPP(pS)PATTP
PSAYG(pS)VKAYT

C19

TKRSG(pS)VYEPL

C20

KSKIG(pS)TENLK

C21
C22

SSPRA(pS)PAHSP
ATPRV(pS)PAHSP

C23

QLRRP(pS)DQEVS

C24

VSPAH(pS)PPENG
D1
D2

QTVKS(pS)KGGPG
QLRRP(pS)DRELS

D3

PAKRI(pS)GKMAL

RS6_CHICK (P47838)
RS6_HUMAN (P10660)
RS6_XENLA (P39017)
RS6_CHICK (P47838)
RS6_HUMAN (P10660)
RS6_XENLA (P39017)
42_HUMAN (P16452)
AP1_HUMAN (P05412)
AP1_MOUSE (P05627)
AP1_PIG (P56432)
AP1_RAT (P17325)
AP1_CHICK (P18870)
AP1_COTJA (P12981)
AP1_SERCA (P54864)
TJUN_AVIS1 (P05411)
TLE2_HUMAN (Q04725)
ANX2_BOVIN (P04272)
ANX2_HUMAN (P07355)
KPBB_HUMAN (Q93100)
KPBB_RABIT (P12798)
TAU_BOVIN (P29172)
TAU_CAPHI (O02828)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_PAPHA (Q9MYX8)
TLE1_HUMAN (Q04724)
TLE3_HUMAN (Q04726)
TLE3_MOUSE (Q08122)
REL_CHICK (P16236)
REL_MELGA (P01125)
REL_HUMAN (Q04864)
REL_MOUSE (P15307)
TLE3_HUMAN (Q04726)
TLE3_MOUSE (Q08122)
ANX1_HUMAN (P04083)
TF65_HUMAN (Q04206)
TF65_MOUSE (Q04207)
CC2_BOVIN (P48734)
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D4
D5

HESME(pS)YELNP
SSND(pS)TSVSAV

D6

SSNDSTSV(pS)AV

D7

ESSND(pS)TSVSA

D8
D9

AKKRL(pS)VERIY
APPRR(pS)SIRNA

D10

DENTV(pS)TSLGH

D11

SIHQR(pS)RKRLS

D12
D13
D14

SRKRL(pS)QDAYR
AYRRN(pS)VRFLQ
PWIMQ(pS)TKVPQ

D15
D16

LAQRAR(pS)PSDV
RIGHH(pS)TSDDS

CC2_HUMAN (P06493)
CC2_MOUSE (P11440)
CC2_RAT (P39951)
CC2_CHICK (P13863)
MGP_HUMAN (P08493)
ACM2_BOVIN (P41985)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
ACM2_BOVIN (P41985)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
ACM2_BOVIN (P41985)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
TP2A_HUMAN (P11388)
NCF1_BOVIN (O77774)
NCF1_HUMAN (P14598)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
NCF1_BOVIN (O77774)
NCF1_HUMAN (P14598)
NCF1_MOUSE (Q09014)
NCF1_HUMAN (P14598)
NCF1_HUMAN (P14598)
MKK2_CRILO (P49136)
MKK2_HUMAN (P49137)
MKK2_MOUSE (P49138)
MKK2_RABIT (P49139)
GPRC_HUMAN (P47775)
ODBA_BOVIN (P11178)
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D17

RGQRD(pS)SYYWE

D18
D19

QTQST(pS)GRRRR
RPGPQ(pS)PGSPL

D20
D21

KHLEI(pS)REVGD
PQSPG(pS)PLEEE

D22

MEFSR(pS)KSDNS

D23
D24

GNGYS(pS)NGNTG
SKVPFR(pS)RSPS

E1

SKVPFRSR(pS)PS

E2

RSRKE(pS)YSVYV

E3

VPFRSR(pS)PSEV

E4

VPFRSRSP(pS)EV

ODBA_HUMAN (P12694)
ODBA_MOUSE (P50136)
ODBA_RAT (P11960)
KMIL_AVIMH (P00531)
KMIL_CHICK (P05625)
KRAF_HUMAN (P04049)
KRAF_RAT (P11345)
KRAF_XENLA (P09560)
ATF2_HUMAN (P15336)
NCF1_HUMAN (P14598)
NCF1_HUMAN (P14598)
LGN_HUMAN (P81274)
NCF1_HUMAN (P14598)
NCF1_HUMAN (P14598)
EDG1_HUMAN (P21453)
EDG1_HUMAN (P21453)
EDG1_MOUSE (O08530)
EDG1_RAT (P48303)
B2AR_HUMAN (P07550)
GPR6_HUMAN (P46095)
GPR6_HUMAN (P46095)
GPR6_RAT (P51651)
GPR6_HUMAN (P46095)
GPR6_RAT (P51651)
H2BA_HUMAN (P02278)
H2BC_HUMAN (Q99880)
H2BD_HUMAN (Q99877)
H2BE_HUMAN (Q99879)
H2BH_HUMAN (Q93078)
H2BJ_HUMAN (Q93079)
H2BS_HUMAN (P57053)
H2B1_MOUSE (P10853)
H2B2_MOUSE (P10854)
H2B_RAT (Q00715)
GPR6_HUMAN (P46095)
GPR6_RAT (P51651)
GPR6_HUMAN (P46095)
GPR6_RAT (P51651)
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E5

SNRKP(pS)KDKDK

E6

PKSKQ(pS)PISTP

E7

PEFPL(pS)PPKKK

E8

ISTPT(pS)PGSLR

E9

STRTY(pS)LGSAL

E10

AER(pS)LKDMEES

E11

KDMEE(pS)IRNLE

E12

ARKAV(pS)MHEVN

E13

LKLSP(pS)PSSRV

E14

LMFKTEGPD(pS)D

E15

SPSPS(pS)RVTVS

GAC2_BOVIN (P22300)
GAC2_CHICK (P21548)
GAC2_HUMAN (P18507)
GAC2_MOUSE (P22723)
GAC2_RAT (P18508)
DCX_HUMAN (O43602)
DCX_MOUSE (O88809)
DCX_MOUSE (O88809)
STHM_HUMAN (P16949)
STHM_RAT (P13668)
STHM_CHICK (P31395)
DCX_HUMAN (O43602)
DCX_MOUSE (O88809)
DCX_MOUSE (O88809)
VIME_BOVIN (P48616)
VIME_HUMAN (P08670)
VIME_MOUSE (P20152)
VIME_PIG (P02543)
VIME_RAT (P31000)
G19P_BOVIN (Q28034)
G19P_HUMAN (P14314)
G19P_BOVIN (Q28034)
G19P_HUMAN (P14314)
NAC1_BOVIN (P48765)
NAC1_CANFA (P23685)
NAC1_CAVPO (P48766)
NAC1_FELCA (P48767)
NAC1_HUMAN (P32418)
NAC1_MOUSE (P70414)
NAC1_RAT (Q01728)
LAM2_CHICK (P14732)
LAM1_HUMAN (P20700)
LAM1_MOUSE (P14733)
LAM2_HUMAN (Q03252)
P53_HUMAN (P04637)
P53_TUPGB (Q9TTA1)
LAM2_CHICK (P14732)
LAM1_HUMAN (P20700)
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E16
E17
E18

NSRRP(pS)RATWL
LGRRH(pS)MENME
SRGRA(pS)SHSSQ

E19

VSGDT(pS)PRHLS

E20
E21

RGRAS(pS)HSSQT
SRASS(pS)RSVRT

E22
E23

SKNES(pS)PIRFD
DRPRA(pS)GCLAR

E24
F1
F2

VSNTN(pS)PTKIL
ATPQV(pS)DSMRK
TSTSL(pS)PFYLR

F3

LMRRN(pS)VTPLA

F4

MYRRS(pY)VFQTR

F5
F6
F7

RERRP(pS)YLPTP
SYPIGEDEE(pS)E
SQ(pS)PQYSFESL

LAM1_MOUSE (P14733)
LAM2_HUMAN (Q03252)
VTNC_HUMAN (P04004)
LGN_HUMAN (P81274)
LAMA_HUMAN (P02545)
LAMA_MOUSE (P48678)
LAMC_MOUSE (P11516)
LAMA_RAT (P48679)
TAU_BOVIN (P29172)
TAU_BOVIN (P29172)
TAU_CAPHI (O02828)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_MOUSE (P10637)
TAU_PAPHA (Q9MYX8)
TAU_RAT (P19332)
LAMA_HUMAN (P02545)
LAM1_CHICK (P14731)
LAM1_HUMAN (P20700)
LAM1_MOUSE (P14733)
MPP9_HUMAN (Q99550)
B1AR_HUMAN (P08588)
B1AR_MACMU (P47899)
B1AR_MOUSE (P34971)
B1AR_RAT (P18090)
TDP2_HUMAN (Q14188)
GLYG_HUMAN (P46976)
CRAB_HUMAN (P02511)
CRAB_RABIT (P41316)
HSBY_HUMAN (O43416)
F263_HUMAN (Q16875)
F263_RAT (O35552)
FILS_BOVIN (Q06002)
FILS_HUMAN (Q12934)
CIK6_HUMAN (P17658)
VMT2_HUMAN (Q05940)
PRGR_HUMAN (P06401)
PRGR_RABIT (P06186)
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F8
F9
F10
F11

VQRKV(pS)GSRGS
PSRGK(pS)SSYSK
SRGKS(pS)SYSKQ
PGLRR(pS)PIKKV

F12
F13

SYSKQFTS(pS)TS
SKRRN(pS)EFEIF

F14

FLRAP(pS)WFDTG

F15
F16

GRIHG(pS)PLQKL
PARND(pS)VIVAD

F17

ILKPP(pS)PISEA

F18

EERRK(pS)HEAEV

F19
F20

GYGSR(pS)LYNLG
YPRPA(pS)VPPSP

F21

ASVPP(pS)PSLSR

F22

PASVPP(pS)PSLS

F23

SRHS(pS)PHQSED

PRGR_SHEEP (Q28590)
CIK5_HUMAN (P22460)
FIBA_HUMAN (P02671)
FIBA_HUMAN (P02671)
MYBB_HUMAN (P10244)
MYBB_MOUSE (P48972)
FIBA_HUMAN (P02671)
TR5H_HUMAN (P17752)
TR5H_RABIT (P17290)
TR5H_RAT (P09810)
TR5H_CHICK (P70080)
TR5H_XENLA (Q92142)
CRAB_HUMAN (P02511)
HSBY_HUMAN (O43416)
MP10_HUMAN (O00566)
ATF2_HUMAN (P15336)
ATF2_MOUSE (P16951)
ATF2_RAT (Q00969)
ATF2_CHICK (O93602)
SCG1_HUMAN (Q93045)
SCG1_MOUSE (P55821)
STHM_HUMAN (P16949)
STHM_MOUSE (P54227)
STHM_RAT (P13668)
STHM_CHICK (P31395)
K2C5_HUMAN (P13647)
GYS1_HUMAN (P13807)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
GYS1_HUMAN (P13807)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
GYS1_HUMAN (P13807)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
GYS1_HUMAN (P13807)
GYS1_MOUSE (Q9Z1E4)
GYS1_RABIT (P13834)
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F24

SRH(pS)SPHQSED

G1

SRHSSPHQ(pS)ED

G2
G3

LSYAP(pS)PLQKP
LSRHS(pS)PHQSE

G4

GSQAS(pS)PQSSD

G5

IGRRQ(pS)LIEDA

G6

GSKRN(pS)VDTAT

G7
G8

DLLPM(pS)PSVYA
NLLPM(pS)PEEFD

G9

PDGNK(pS)PAPKP

G10
G11
G12

AGALY(pS)GSEGD
RKTTA(pS)TRKVS
QRMKE(pS)SFYSL

G13

RGRSL(pS)VTSLG

G14
G15

IRSSW(pS)GLHLV
LSRQL(pS)SGVSE

GYS3_MOUSE (P54859)
GYS1_HUMAN (P13807)
GYS1_MOUSE (Q9Z1E4)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
GYS1_HUMAN (P13807)
GYS1_MOUSE (Q9Z1E4)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
MPP5_HUMAN (Q99546)
GYS1_HUMAN (P13807)
GYS1_MOUSE (Q9Z1E4)
GYS1_RABIT (P13834)
GYS3_MOUSE (P54859)
GYS2_HUMAN (P54840)
GYS2_HUMAN (P54840)
TY3H_HUMAN (P07101)
TY3H_MOUSE (P24529)
TY3H_PHASP (P11982)
TY3H_RAT (P04177)
GYS1_HUMAN (P13807)
GYS1_HUMAN (P13807)
STA4_HUMAN (Q14765)
STA1_HUMAN (P42224)
STA1_MOUSE (P42225)
CALD_HUMAN (Q05682)
CALD_HUMAN (Q05682)
CALD_RAT (Q62736)
SRF_HUMAN (P11831)
CFTR_HUMAN (P13569)
PRGR_HUMAN (P06401)
PRGR_RABIT (P06186)
PRGR_SHEEP (Q28590)
PRGR_CHICK (P07812)
GYS2_HUMAN (P54840)
GYS2_RAT (P17625)
COA1_HUMAN (Q13085)
HS27_CANFA (P42929)
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G16
G17

GSEGD(pS)ESGEE
GTFRS(pS)IRRL

G18
G19
G20
G21

EGDSE(pS)GEEEE
EPEKMES(pS)ISS
KEKIKQS(pS)SSE
VEGAG(pS)IAAAT

G22
G23

MESSI(pS)SSSEE
TSTLA(pS)SFKRR

G24
H1

ESSIS(pS)SSEEM
SFKRRRS(pS)KDT

H2

KRRRS(pS)KDTST

H3

GRPRTT(pS)FAES

H4

FGVER(pS)VRPTD

H5
H6

ETPAI(pS)PSKRA
AIAAD(pS)EAEQD

H7
H8

RRKKK(pT)PRKAE
TYVG(pT)PYYVPP

H9

PRRKD(pT)PALHM
KPVSV(pT)PQGND

H10

HS27_HUMAN (P04792)
SRF_HUMAN (P11831)
PLM_CANFA (P56513)
PLM_HUMAN (O00168)
PLM_RAT (O08589)
SRF_HUMAN (P11831)
CAS1_HUMAN (P47710)
CIN6_HUMAN (Q01118)
SYUA_HUMAN (P37840)
SYUA_HUMAN (P37840)
CAS1_HUMAN (P47710)
NMZ1_HUMAN (Q05586)
NMZ1_HUMAN (Q05586)
NMZ1_MOUSE (P35438)
NMZ1_RAT (P35439)
CAS1_HUMAN (P47710)
NMZ1_HUMAN (Q05586)
NMZ1_MOUSE (P35438)
NMZ1_RAT (P35439)
NMZ1_HUMAN (Q05586)
NMZ1_MOUSE (P35438)
NMZ1_RAT (P35439)
KG3B_HUMAN (P49841)
KG3B_MOUSE (Q9WV60)
KG3B_RAT (P18266)
KPB1_HUMAN (P46020)
KPB1_MOUSE (P18826)
KPB1_RAT (Q64649)
KPB1_RABIT (P18688)
DUT_HUMAN (P33316)
IRS1_HUMAN (P35568)
IRS1_MOUSE (P35569)
IRS1_RAT (P35570)
MPP8_HUMAN (Q99549)
NEK3_HUMAN (P51956)
NEK3_MOUSE (Q9R0A5)
GSUB_HUMAN (O96001)
MPP9_HUMAN (Q99550)
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H11

KIGEG(pT)YGTVF

H12

RTRES(pT)AKKIK

H13

ITSQV(pT)GQIGW

H14
H15

PVSAQ(pT)PKGRR
PVRTY(pT)HEVVT

H16

PIRVY(pT)HEVVT

H17

EGEES(pT)VRFAR

H18

ADAEM(pT)GYVVT

H19

TDDEM(pT)GYVAT

H20

TPYVV(pT)RYYRA

CDK5_BOVIN (Q02399)
CDK5_HUMAN (Q00535)
CDK5_MOUSE (P49615)
CDK5_RAT (Q03114)
CDK5_XENLA (P51166)
CDK5_DROME (P48609)
RGS1_HUMAN (Q08116)
RGS1_HUMAN (Q08116)
A2M1_HUMAN (P20172)
AP50_CAEEL (P35603)
MPP8_HUMAN (Q99549)
CDK2_CRIGR (O55076)
CDK2_HUMAN (P24941)
CDK2_MESAU (P48963)
CDK2_MOUSE (P97377)
CDK2_RAT (Q63699)
CDK2_CARAU (P43450)
CC2_CAEEL (P34556)
CC2_BOVIN (P48734)
CC2_HUMAN (P06493)
CC2_MOUSE (P11440)
CC2_RAT (P39951)
KPC1_HUMAN (P05771)
KPC1_RABIT (P05772)
KPC1_RAT (P04410)
KPC2_BOVIN (P05126)
KPC2_HUMAN (P05127)
KPC2_RABIT (P05773)
KPC2_MOUSE (P04411)
MK13_HUMAN (O15264)
MK13_PANTR (Q9N272)
MK14_CANFA (O02812)
MK14_HUMAN (Q16539)
MK14_MOUSE (P47811)
MK14_RAT (P70618)
MK14_CYPCA (Q90336)
MK08_HUMAN (P45983)
MK08_RAT (P49185)
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H21

ADEEM(pT)GYVAT

H22

AQASS(pT)PLSPT

H23
H24
I1

DLFKL(pT)PEEKN
QEYVQ(pT)VKSSK
EMPGE(pT)PPLSP

I2

NGSPR(pT)PRRGQ

I3

NEDPA(pT)PRVSP

I4
I5
I6
I7
I8

QRRQRKSRR(pT)I
PRDPV(pT)ENCVQ
LPDHKK(pT)LEHL
KEGPG(pT)PTRSS
KKIYEEKKKK(pT)

I9

KISQG(pT)KVPEE

I10

EKTTN(pT)VSKFD

I11

TKVPQ(pT)PLHTS

MK09_HUMAN (P45984)
MK09_MOUSE (Q9WTU6)
MK09_RAT (P49186)
MK10_HUMAN (P53779)
MK10_MOUSE (Q61831)
MK10_RAT (P49187)
MK11_HUMAN (Q15759)
MK11_MOUSE (Q9WUI1)
LAMA_HUMAN (P02545)
LAMA_MOUSE (P48678)
LAMC_MOUSE (P11516)
LAMA_RAT (P48679)
MPP8_HUMAN (Q99549)
ANX1_HUMAN (P04083)
AP1_HUMAN (P05412)
AP1_MOUSE (P05627)
AP1_PIG (P56432)
AP1_RAT (P17325)
AP1_CHICK (P18870)
AP1_COTJA (P12981)
AP1_SERCA (P54864)
RB_HUMAN (P06400)
RB_MOUSE (P13405)
RB_RAT (P33568)
TLE3_HUMAN (Q04726)
TLE3_MOUSE (Q08122)
TLE1_BRARE (O13168)
IL2A_HUMAN (P01589)
ACM2_HUMAN (P08172)
IL7R_HUMAN (P16871)
Z145_HUMAN (Q05516)
VGLN_HUMAN (Q00341)
VGLN_CHICK (P81021)
KPC1_HUMAN (P05771)
KPC2_HUMAN (P05127)
KPC1_HUMAN (P05771)
KPC2_HUMAN (P05127)
MKK2_CRILO (P49136)
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I12

PRHRD(pT)GILDS

I13

RRRRP(pT)PATLV

I14
I15

VIPPH(pT)PVRTV
QSPIS(pT)PTSPG

I16

DQEGD(pT)DAGLK

I17

NGGIM(pT)PPKST

I18
I19

PSGLL(pT)PPQSG
VAAVN(pT)HRDRP

I20

LTPKS(pT)PVKTL

I21

NATFKK(pT)FKHL

I22

NA(pT)FKKTFKHL

MKK2_HUMAN (P49137)
MKK2_MOUSE (P49138)
MKK2_RABIT (P49139)
MBP_BOVIN (P02687)
MBP_CAVPO (P25188)
MBP_HUMAN (P02686)
MBP_MOUSE (P04370)
MBP_PANTR (P06906)
MBP_RAT (P02688)
IPP1_HUMAN (Q13522)
IPP1_RABIT (P01099)
IPP1_RAT (P19103)
RB_HUMAN (P06400)
DCX_HUMAN (O43602)
DCX_MOUSE (O88809)
DCX_MOUSE (O88809)
TAU_HUMAN (P10636)
TAU_MACMU (P57786)
TAU_PAPHA (Q9MYX8)
CGE2_HUMAN (O96020)
CGE2_MOUSE (Q9Z238)
CGE1_HUMAN (P24864)
F264_HUMAN (Q16877)
F264_RAT (P25114)
MYBB_HUMAN (P10244)
MYBB_MOUSE (P48972)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
ACM2_CHICK (P30372)
ACM4_CHICK (P17200)
ACM4_XENLA (P30544)
ACM2_HUMAN (P08172)
ACM2_MOUSE (Q9ERZ4)
ACM2_PIG (P06199)
ACM2_RAT (P10980)
ACM2_CHICK (P30372)
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I23

ATFKK(pT)FRHLL

I24

RTFRK(pT)FKMLL
J1

ALGKR(pT)AKYRW

J2

AGGPL(pT)PRRVS

J3

ADQTP(pT)PTRFL

J4

ARAGE(pT)RFTDT

J5

QKKRV(pT)MILQS

J6

GETRF(pT)DTRKD

J7

FDKEF(pT)RQPVE

ACM4_CHICK (P17200)
ACM4_XENLA (P30544)
ACM4_HUMAN (P08173)
ACM4_MOUSE (P32211)
ACM4_RAT (P08485)
ACM5_HUMAN (P08912)
ACM5_MACMU (P56490)
NPT2_HUMAN (Q06495)
NPT2_MOUSE (Q60825)
NPT2_RABIT (Q28620)
NPT2_RAT (Q06496)
NPT2_SHEEP (O97704)
ERF_HUMAN (P50548)
ERF_HUMAN (P50548)
ATF2_HUMAN (P15336)
ATF2_MOUSE (P16951)
ATF2_RAT (Q00969)
ATF2_CHICK (O93602)
ATF7_HUMAN (P17544)
EF2_CHICK (Q90705)
EF2_CRIGR (P09445)
EF2_HUMAN (P13639)
EF2_MESAU (P05086)
EF2_RAT (P05197)
ADDB_HUMAN (P35612)
ADDB_MOUSE (Q9QYB8)
ADDB_RAT (Q05764)
EF2_CAEEL (P29691)
EF2_CHICK (Q90705)
EF2_CRIGR (P09445)
EF2_DROME (P13060)
EF2_HUMAN (P13639)
EF2_MESAU (P05086)
EF2_RAT (P05197)
KPC1_HUMAN (P05771)
KPC1_HUMAN (P05771)
KPC1_RABIT (P05772)
KPC1_RAT (P04410)
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J8

HPPVL(pT)PPDQE

J9

AAPAL(pT)PPDRL

J10

KIRKY(pT)MRRLL

J11

LVEPL(pT)PSGEA

J12

EEPVL(pT)LVDE

J13

IDEPS(pT)PYHSM

J14
J15
J16

PTAAG(pT)PNKET
HVTRR(pT)LSMDK
PQDKE(pY)YKVKE

J17

RGEEV(pY)VKKTM

J18
J19

VKRRD(pY)LDLAA
VDADE(pY)LIPQQ

J20
J21

EGDND(pY)IIPLP
ETDKE(pY)YTVKD

J22
J23

SPQPE(pY)VNQPD
KPKQE(pY)LNPVE

KPC2_BOVIN (P05126)
KPC2_BOVIN (P05126)
KPC2_HUMAN (P05127)
KPC2_HUMAN (P05127)
KPC2_RABIT (P05773)
KPC2_MOUSE (P04411)
KPCG_BOVIN (P05128)
KPCG_BOVIN (P05128)
KPCG_HUMAN (P05129)
KPCG_MOUSE (P05697)
ERB2_HUMAN (P04626)
ERB2_MESAU (Q60553)
ERB2_RAT (P06494)
KERB_ALV (P00534)
KERB_AVIER (P00535)
KERB_AVIEU (P11273)
EGFR_HUMAN (P00533)
EGFR_MOUSE (Q01279)
KPCE_HUMAN (Q02156)
KPCE_RABIT (P10830)
IPP2_HUMAN (P41236)
IPP2_RABIT (P11845)
CALD_HUMAN (Q05682)
K6PL_HUMAN (P17858)
JAK2_HUMAN (O60674)
JAK2_MOUSE (Q62120)
JAK2_RAT (Q62689)
TIE1_BOVIN (Q06805)
TIE1_HUMAN (P35590)
TIE1_MOUSE (Q06806)
RET_HUMAN (P07949)
EGFR_HUMAN (P00533)
EGFR_MOUSE (Q01279)
PGDR_HUMAN (P09619)
JAK1_HUMAN (P23458)
JAK1_MOUSE (P52332)
ERB2_HUMAN (P04626)
ERB4_HUMAN (Q15303)
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J24
K1

ENGLN(pY)IDLDL
EEEHV(pY)SFPNK

K2

MTRDI(pY)ETDYY

K3
K4

LDNPE(pY)HNASN
AENAE(pY)LRVAP

K5

FDNLY(pY)WDQDP

K6

MYDKE(pY)YSVHN

K7

AENPE(pY)LGLDV

K8

FESR(pY)QQPFED

K9
K10
K11

LQHPD(pY)LQEYS
AENPE(pY)LSEFS
EDKAK(pY)DAIFD

K12

GFKRS(pY)EEHIP

K13

LLGDH(pY)VQLPA

K14

SSGAD(pY)PDELQ

ERB4_RAT (Q62956)
IRS1_HUMAN (P35568)
PAXI_CHICK (P49024)
PAXI_HUMAN (P49023)
IG1R_BOVIN (Q05688)
IG1R_HUMAN (P08069)
IG1R_MOUSE (Q60751)
IG1R_RAT (P24062)
INSR_HUMAN (P06213)
INSR_MOUSE (P15208)
INSR_RAT (P15127)
MIPR_LYMST (Q25410)
ILPR_BRALA (O02466)
INSR_DROME (P09208)
INSR_AEDAE (Q93105)
ERB4_HUMAN (Q15303)
EGFR_HUMAN (P00533)
EGFR_MOUSE (Q01279)
ERB2_HUMAN (P04626)
ERB2_MESAU (Q60553)
MET_HUMAN (P08581)
MET_MOUSE (P16056)
MET_RAT (P97523)
ERB2_HUMAN (P04626)
ERB2_MESAU (Q60553)
ERB2_RAT (P06494)
PIG1_HUMAN (P19174)
PIG1_HUMAN (P19174)
ERB4_HUMAN (Q15303)
ERB4_HUMAN (Q15303)
EP15_HUMAN (P42566)
EP15_MOUSE (P42567)
INSR_HUMAN (P06213)
INSR_HUMAN (P06213)
RON_HUMAN (Q04912)
RON_HUMAN (Q04912)
TRY1_HUMAN (P07477)
TRY2_HUMAN (P07478)
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K15

CTNFMMTP(pY)VV

K16
K17
K18
K19

ELVNN(pY)GKGWS
NEEQE(pY)VQTVK
LEQEE(pY)EDPDI
IYKND(pY)YRKRG

K20

PEPGP(pY)AQPSV

K21
K22

TDEGI(pY)DVPLL
HVTRRTPD(pY)FL

K23
K24

SEETP(pY)SYPTG
EEEEE(pY)MPMED

L1

GGKGGS(pY)SQAA

MK09_HUMAN (P45984)
MK09_MOUSE (Q9WTU6)
MK09_RAT (P49186)
RAPS_HUMAN (Q13702)
ANX1_HUMAN (P04083)
B3AT_HUMAN (P02730)
KROS_AVISU (P00529)
KROS_HUMAN (P08922)
KROS_CHICK (P08941)
CRK_HUMAN (P46108)
CRK_MOUSE (Q64010)
CRK_RAT (Q63768)
CRK_XENLA (P87378)
EFS_HUMAN (O43281)
P2AA_HUMAN (P05323)
P2AA_MOUSE (P13353)
P2AA_CHICK (P48463)
P2AB_HUMAN (P11082)
P2AB_PIG (P11493)
P2AB_RABIT (P11611)
P2A_DROME (P23696)
P2A1_SCHPO (P23635)
PAXI_HUMAN (P49023)
TAMI_POVM3 (P03076)
TAMI_POVMA (P03077)
TAMI_POVMC (P12906)
1B02_HUMAN (P01889)
1B02_HUMAN (P01889)
1B04_HUMAN (P30460)
1B04_HUMAN (P30460)
1B05_HUMAN (P30461)
1B05_HUMAN (P30461)
1B07_HUMAN (P30462)
1B07_HUMAN (P30462)
1B08_HUMAN (P30463)
1B08_HUMAN (P30463)
1B10_HUMAN (P30464)
1B10_HUMAN (P30464)
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1B11_HUMAN
1B11_HUMAN
1B12_HUMAN
1B12_HUMAN
1B13_HUMAN
1B13_HUMAN
1B14_HUMAN
1B14_HUMAN
1B15_HUMAN
1B15_HUMAN
1B16_HUMAN
1B16_HUMAN
1B18_HUMAN
1B18_HUMAN
1B19_HUMAN
1B19_HUMAN
1B20_HUMAN
1B21_HUMAN
1B21_HUMAN
1B22_HUMAN
1B22_HUMAN
1B23_HUMAN
1B23_HUMAN
1B24_HUMAN
1B25_HUMAN
1B25_HUMAN
1B26_HUMAN
1B26_HUMAN
1B27_HUMAN
1B28_HUMAN
1B29_HUMAN
1B31_HUMAN
1B32_HUMAN
1B34_HUMAN
1B35_HUMAN
1B36_HUMAN
1B38_HUMAN
1B39_HUMAN

(P30465)
(P30465)
(P30513)
(P30513)
(P30466)
(P30466)
(P03989)
(P03989)
(P10317)
(P10317)
(P19373)
(P19373)
(P10318)
(P10318)
(Q08136)
(Q08136)
(P30467)
(P30685)
(P30685)
(P30468)
(P30468)
(P30469)
(P30469)
(P30470)
(P30471)
(P30471)
(P30472)
(P30472)
(P30473)
(P30474)
(P18463)
(P30475)
(P30476)
(Q04826)
(P30477)
(P30478)
(P30479)
(P30480)
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L2

RKGGS(pY)SQAAS

1B40_HUMAN
1B41_HUMAN
1B42_HUMAN
1B43_HUMAN
1B44_HUMAN
1B45_HUMAN
1B46_HUMAN
1B47_HUMAN
1B48_HUMAN
1B49_HUMAN
1B52_HUMAN
1B54_HUMAN
1B54_HUMAN
1B55_HUMAN
1B56_HUMAN
1B57_HUMAN
1B58_HUMAN
1B59_HUMAN
1B60_HUMAN
1B61_HUMAN
1B62_HUMAN
1B63_HUMAN
1B01_GORGO
1B02_GORGO
1B02_GORGO
1B04_GORGO
1A02_PANTR
1B01_PANTR
1B02_PANTR
1A02_HUMAN
1A23_HUMAN
1A24_HUMAN
1A25_HUMAN
1A26_HUMAN
1A29_HUMAN
1A31_HUMAN
1A32_HUMAN
1A33_HUMAN

(P10320)
(P30481)
(P30482)
(P30483)
(P30484)
(P30485)
(P30486)
(P30487)
(P30488)
(P18464)
(P30489)
(P30491)
(P30491)
(P30492)
(P30493)
(P30494)
(P30495)
(P30496)
(P18465)
(P30497)
(P10319)
(P30498)
(P30379)
(P30380)
(P30380)
(P30382)
(P16210)
(P13750)
(P13751)
(P01892)
(P30447)
(P05534)
(P18462)
(P30450)
(P30512)
(P16189)
(P10314)
(P16190)
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0

L3
L4

EEEPV(pY)EAEPE
HAQDT(pY)LVLDK

L5

IIDSE(pY)TAQEG

L6

RGTDE(pY)FIRKP

L7
L8

SKAEE(pY)FLLKS
RVIEDNE(pY)TAR

L9
L1

IKDDE(pY)NPCQG

1A34_HUMAN (P30453)
1A43_HUMAN (P30456)
1A66_HUMAN (P30457)
1A68_HUMAN (P01891)
1A74_HUMAN (P30459)
1A80_HUMAN (Q09160)
1AXX_HUMAN (P10313)
HLAH_HUMAN (P01893)
1A01_GORGO (P30375)
1A02_GORGO (P30376)
1A03_GORGO (P30377)
1A04_GORGO (P30378)
1OKO_GORGO (P30388)
1A04_PANTR (P13749)
1A01_PONPY (P16211)
HS1_HUMAN (P14317)
EPOR_HUMAN (P19235)
EPOR_MOUSE (P14753)
BLK_HUMAN (P51451)
BLK_MOUSE (P16277)
ACHB_BOVIN (P04758)
ACHB_HUMAN (P11230)
ACHB_MOUSE (P09690)
ACHB_RAT (P25109)
ACHD_HUMAN (Q07001)
HCK_HUMAN (P08631)
LYN_HUMAN (P07948)
LYN_MOUSE (P25911)
LYN_RAT (Q07014)
FGR_HUMAN (P09769)

IEDNE(pY)TARQG

FYN_CHICK (Q05876)
FYN_HUMAN (P06241)
FYN_MOUSE (P39688)
FYN_XENLA (P13406)
FYN_XIPHE (P27446)
SRC1_XENLA (P13115)
SRC2_XENLA (P13116)
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L11

MKDEE(pY)EQMVK

L12
L13

AASFE(pY)TILDP
ASTGI(pY)EALEL

SRC_AVISR (P00525)
SRC_AVIS2 (P15054)
SRC_AVIST (P14085)
SRC_AVISS (P14084)
SRC_CHICK (P00523)
SRC_HUMAN (P12931)
SRC_MOUSE (P05480)
SRC_RAT (Q9WUD9)
SRC_RSVP (P00526)
SRC_RSVSR (P00524)
SRC_RSVH1 (P25020)
YES_AVISY (P00527)
YES_CANFA (Q28923)
YES_CHICK (P09324)
YES_HUMAN (P07947)
YES_MOUSE (Q04736)
YES_XENLA (P10936)
YES_XIPHE (P27447)
YRK_CHICK (Q02977)
IKBA_HUMAN (P25963)
IKBA_PIG (Q08353)
EPOR_HUMAN (P19235)
ENO_ARATH (P25696)
ENO1_HEVBR (Q9LEJ0)
ENO2_HEVBR (Q9LEI9)
ENO_LYCES (P26300)
ENO1_MAIZE (P26301)
ENO_RICCO (P42896)
ENO_PLAFA (Q27727)
ENO_ALLMI (P42897)
ENO_XENLA (P08734)
ENOA_BOVIN (Q9XSJ4)
ENOA_HUMAN (P06733)
ENOA_MOUSE (P17182)
ENOA_RAT (P04764)
ENOA_ANAPL (P19140)
ENOA_CHICK (P51913)
ENOB_HUMAN (P13929)
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L14

MTGDT(pY)TAHAG

L15
L16
L17
L18

QREAE(pY)EPETV
SSIDE(pY)FSEQP
EPETV(pY)EVAGA
NVVPV(pY)DLLLE

L19
L20
L21

IIENPQ(pY)FSDA
AEENT(pY)DEYEN
TATEGQ(pY)QPQP

L22

TATEGQ(pY)QQQP

L23

VLDDQ(pY)TSSTG

L24

LSNPA(pY)RLLLA

ENOB_MOUSE (P21550)
ENOB_RABIT (P25704)
ENOB_RAT (P15429)
ENOG_HUMAN (P09104)
ENOG_MOUSE (P17183)
ENOG_RAT (P07323)
ENOG_CHICK (O57391)
ABL1_HUMAN (P00519)
ABL1_MOUSE (P00520)
ABL2_HUMAN (P42684)
ABL_FSVHY (P10447)
ABL_MLVAB (P00521)
SRC8_CHICK (Q01406)
INR1_HUMAN (P17181)
SRC8_CHICK (Q01406)
ESR2_BOVIN (Q9XSB5)
ESR2_CALJA (Q95171)
ESR2_HUMAN (Q92731)
ESR2_MACMU (Q9TTE5)
ESR2_MOUSE (O08537)
ESR2_RAT (Q62986)
ESR2_SHEEP (Q9TU15)
ESR2_CHICK (Q9PTU5)
ESR2_COTJA (O93511)
ESR2_STUVU (Q9PVE2)
TRKA_HUMAN (P04629)
SRC8_CHICK (Q01406)
LCK_HUMAN (P06239)
LCK_MOUSE (P06240)
LCK_CHICK (P42683)
LYN_HUMAN (P07948)
LYN_MOUSE (P25911)
LYN_RAT (Q07014)
ITK_HUMAN (Q08881)
ITK_MOUSE (Q03526)
DDR1_HUMAN (Q08345)
DDR1_MOUSE (Q03146)
DDR1_RAT (Q63474)
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M1

IENPQ(pY)FGITN

M2
M3

FLDDQ(pY)TSSSG
RADEN(pY)YKAQT

M4

ED(pY)FTSTEPQY

M5

STEPQ(pY)QPGEN

M6

ATEPQ(pY)QPGEN

M7

ED(pY)FTATEPQY

M8

VMMGP(pY)RQDLL

M9

RKGHE(pY)TNIKY

TRKB_HUMAN (Q16620)
TRKB_MOUSE (P15209)
TRKB_RAT (Q63604)
TRKB_CHICK (Q91987)
TEC_HUMAN (P42680)
KSYK_HUMAN (P43405)
KSYK_MOUSE (P48025)
KSYK_PIG (Q00655)
KSYK_RAT (Q64725)
FGR_MOUSE (P14234)
SRC_CHICK (P00523)
SRC_HUMAN (P12931)
SRC_MOUSE (P05480)
SRC_CHICK (P00523)
SRC_HUMAN (P12931)
SRC_MOUSE (P05480)
FYN_HUMAN (P06241)
FYN_MOUSE (P39688)
YES_HUMAN (P07947)
YES_MOUSE (Q04736)
FYN_CHICK (Q05876)
FYN_HUMAN (P06241)
FYN_MOUSE (P39688)
FYN_XENLA (P13406)
SRC2_XENLA (P13116)
YES_CHICK (P09324)
YES_HUMAN (P07947)
YES_MOUSE (Q04736)
YES_XENLA (P10936)
YES_XIPHE (P27447)
YES_XIPHE (P27447)
YRK_CHICK (Q02977)
VINC_HUMAN (P18206)
VINC_MOUSE (Q64727)
VINC_CHICK (P12003)
PTNB_HUMAN (Q06124)
PTNB_MOUSE (P35235)
PTNB_RAT (P41499)
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M1
0

VLDDE(pY)TSSVG

M11

INGNN(pY)VYIDP

M12

MEDST(pY)YKASK

M13

IEDED(pY)YKASV

M14

DSARV(pY)ENVGL

M15

VDPFT(pY)EDPNQ

M16

NTEDQ(pY)SLVED

M17

HTDDG(pY)MPMSP

M18

IDPET(pY)EDPNR

M19

DGENI(pY)IRHSN

M20
M21

KGSGD(pY)MPMSP
KDGRG(pY)VPATI

BTK_HUMAN (Q06187)
BTK_MOUSE (P35991)
KKIT_BOVIN (P43481)
KKIT_CANFA (O97799)
KKIT_CAPHI (Q28317)
KKIT_FELCA (Q28889)
KKIT_HUMAN (P10721)
KKIT_MOUSE (P05532)
KKIT_CHICK (Q08156)
FAK1_CHICK (Q00944)
FAK1_HUMAN (Q05397)
FAK1_MOUSE (P34152)
FAK1_RAT (O35346)
FAK1_XENLA (Q91738)
FAK2_HUMAN (Q14289)
FAK2_RAT (P70600)
PTNB_HUMAN (Q06124)
PTNB_RAT (P41499)
EPA4_HUMAN (P54764)
EPA4_MOUSE (Q03137)
EPA4_CHICK (Q07496)
EP4A_XENLA (Q91845)
EP4B_XENLA (Q91694)
P85A_BOVIN (P23727)
P85A_HUMAN (P27986)
P85A_MOUSE (P26450)
IRS1_HUMAN (P35568)
IRS1_MOUSE (P35569)
IRS1_RAT (P35570)
EPA7_HUMAN (Q15375)
EPA7_MOUSE (Q61772)
EPA7_RAT (P54759)
EPA7_CHICK (O42422)
41_HUMAN (P11171)
41_MOUSE (P48193)
IRS1_HUMAN (P35568)
STA6_HUMAN (P42226)

157
M22

GADDG(pY)MPMTP

M23

NNIDY(pY)KKTTN

M24
N1
N2

RSDD(pY)MPMSPA
IYRAS(pY)YRRGD
MSRDI(pY)STDYY

N3

RGDKG(pY)VPSVF

N4

KAVDG(pY)VKPQI

N5

YNGDY(pY)RQGRI

N6

GSAAP(pY)LKTKF

N7
N8

YSTDY(pY)RLFNP
VYSTD(pY)YRVGG

N9

MSRDV(pY)STDYY

IRS2_HUMAN (Q9Y4H2)
IRS2_MOUSE (P81122)
FGR2_HUMAN (P21802)
FGR2_MOUSE (P21803)
BFR2_HUMAN (Q01742)
CEK3_CHICK (P18461)
IRS2_HUMAN (Q9Y4H2)
KLTK_HUMAN (P29376)
TRKA_HUMAN (P04629)
TRKA_RAT (P35739)
TRKA_CHICK (Q91009)
STA4_HUMAN (Q14765)
STA4_MOUSE (P42228)
ST5A_BOVIN (Q95115)
ST5A_HUMAN (P42229)
ST5A_MOUSE (P42230)
ST5A_PIG (Q9TUZ1)
ST5A_RAT (Q62771)
ST5A_SHEEP (P42231)
ST5B_BOVIN (Q9TUM3)
ST5B_HUMAN (P51692)
ST5B_PIG (Q9TUZ0)
UFO_HUMAN (P30530)
UFO_MOUSE (Q00993)
STA3_HUMAN (P40763)
STA3_MOUSE (P42227)
STA3_RAT (P52631)
TRKC_HUMAN (Q16288)
TRKB_HUMAN (Q16620)
TRKB_MOUSE (P15209)
TRKB_RAT (Q63604)
TRKB_CHICK (Q91987)
TRKC_PIG (P24786)
TRKC_CHICK (Q91044)
TRKB_HUMAN (Q16620)
TRKB_MOUSE (P15209)
TRKB_RAT (Q63604)
TRKB_CHICK (Q91987)
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N10

YSTDY(pY)RVGGH

N11

HLEKK(pY)VRRDS

N12

PSAEL(pY)SNALP

N13

DSTNE(pY)MDMKP

N14

LYSGD(pY)YRIQG

N15

TSTDE(pY)LDLSA

N16

TSNQE(pY)LDLSM

N17

TTNEE(pY)LDLSQ

N18
N19

IESSN(pY)MAPYD
TAEPD(pY)GALYE

N20

ANNPL(pY)KEATS

N21

NEDDG(pY)DVPKP

TRKC_HUMAN (Q16288)
TRKC_PIG (P24786)
TRKC_RAT (Q03351)
TRKC_CHICK (Q91044)
TRKB_HUMAN (Q16620)
TRKB_MOUSE (P15209)
TRKB_RAT (Q63604)
TRKB_CHICK (Q91987)
TRKC_PIG (P24786)
TRKC_CHICK (Q91044)
KFMS_FELCA (P13369)
KFMS_HUMAN (P07333)
KFMS_MOUSE (P09581)
KFMS_RAT (Q00495)
KFMS_FSVMD (P00545)
PGDR_HUMAN (P09619)
PGDR_MOUSE (P05622)
KKIT_BOVIN (P43481)
KKIT_CANFA (O97799)
KKIT_CAPHI (Q28317)
KKIT_FELCA (Q28889)
KKIT_HUMAN (P10721)
KKIT_FSVHZ (P04048)
DDR2_HUMAN (Q16832)
DDR2_MOUSE (Q62371)
FGR3_HUMAN (P22607)
FGR3_HUMAN (P22607)
FGR1_HUMAN (P11362)
FGR1_RAT (Q04589)
FGR2_HUMAN (P21802)
FGR2_HUMAN (P21802)
PGDR_HUMAN (P09619)
PIG1_BOVIN (P08487)
PIG1_HUMAN (P19174)
PIG1_RAT (P10686)
ITB3_HUMAN (P05106)
ITB3_MOUSE (O54890)
CBL_HUMAN (P22681)
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N22

APYDN(pY)VPSAP

N23
N24

DSNPL(pY)KSAIT
DFDGT(pY)ETQGG
O1

RNPGF(pY)VEANP

O2

DPEAV(pY)TTTGG

O3
O4

QAPPV(pY)LDVLG
YAGDY(pY)RVQGR

O5
O6

ELQDD(pY)EDMME
KASPV(pY)LDILG

O7

FLDSG(pY)RILGA

O8
O9

KVGPG(pY)LGSGG
MHDSN(pY)VSKGS

O10

MRDSN(pY)ISKGS

O11

EEEEA(pY)GWMDF

O12

KSPGE(pY)VNIEF

CBL_MOUSE (P22682)
PGDR_HUMAN (P09619)
PGDR_MOUSE (P05622)
ITB7_HUMAN (P26010)
EPA1_HUMAN (P21709)
EPA1_MOUSE (Q60750)
PIG1_BOVIN (P08487)
PIG1_HUMAN (P19174)
PIG1_RAT (P10686)
EPA7_HUMAN (Q15375)
EPA7_MOUSE (Q61772)
EPA7_RAT (P54759)
EPA7_CHICK (O42422)
TRKA_HUMAN (P04629)
DDR1_HUMAN (Q08345)
DDR1_MOUSE (Q03146)
DDR1_RAT (Q63474)
B3AT_HUMAN (P02730)
TRKB_HUMAN (Q16620)
TRKB_MOUSE (P15209)
TRKB_RAT (Q63604)
TRKB_CHICK (Q91987)
VINC_HUMAN (P18206)
VINC_MOUSE (Q64727)
VINC_CHICK (P12003)
RET_HUMAN (P07949)
PGDS_HUMAN (P16234)
PGDS_MOUSE (P26618)
PGDS_RAT (P20786)
PGDS_XENLA (P26619)
PGDR_HUMAN (P09619)
PGDR_MOUSE (P05622)
GAST_DIDMA (P33713)
GAST_HUMAN (P01350)
GAST_MOUSE (P48757)
GAST_PIG (P01351)
GAST_RAT (P04563)
IRS1_HUMAN (P35568)
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O13
O14

IKMGR(pY)EARFA
IKMDR(pY)KDNFT

O15

STNHI(pY)SNLAN

O16

IKMER(pY)KDNFT

O17
O18

TGTEE(pY)MKMDL
IKMGR(pY)KESFV

O19

KDGNG(pY)ISAAE

O20

RGQEV(pY)VKKTM

O21

DRV(pY)IHPFHL

O22

EDTLT(pY)ADLD

IRS1_MOUSE (P35569)
IRS1_RAT (P35570)
EPB4_HUMAN (P54760)
EPA4_HUMAN (P54764)
EPA4_MOUSE (Q03137)
KKIT_BOVIN (P43481)
KKIT_CANFA (O97799)
KKIT_CAPHI (Q28317)
KKIT_FELCA (Q28889)
KKIT_HUMAN (P10721)
KKIT_HUMAN (P10721)
EPA4_CHICK (Q07496)
EP4A_XENLA (Q91845)
EPA7_HUMAN (Q15375)
EPA7_MOUSE (Q61772)
EPA7_RAT (P54759)
EPA7_CHICK (O42422)
IRS1_HUMAN (P35568)
EPB3_HUMAN (P54753)
EPB3_MOUSE (P54754)
CALM_DICDI (P02599)
CALM_ELEEL (P02594)
CALM_HUMAN (P02593)
CALM_PLECO (P11120)
CALM_STIJA (P21251)
CALS_CHICK (P02597)
TIE2_BOVIN (Q06807)
TIE2_HUMAN (Q02763)
TIE2_MOUSE (Q02858)
ANGT_HORSE (P01016)
ANGT_HUMAN (P01019)
ANGT_MOUSE (P11859)
ANGT_RAT (P01015)
ANGT_SHEEP (P20757)
SHS1_BOVIN (O46631)
SHS1_HUMAN (P78324 )
SHS1_MOUSE (P97797)
SHS1_RAT (P97710)
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Table A-2. Phosphopeptides that showed the highest % of phosphate release. Each of
the phosphotyrosine (pY)-containing peptides from the library (Table S1) showed some
degree of hydrolysis by VHZ, yielding on average 50% of hydrolysis, while none of the
phosphoserine (pS) or phosphothreonine (pT) substrates showed measureable phosphate
release.
Substrate source
(UniProt
Databank)
Filensin
(Q06002),(Q12934)
Receptor tyrosineprotein kinase erbB4 (Q15303)

Anion exchange
protein 1 (P02730)

BDNF/NT-3 growth
factors
receptor(Q16620),(P
15209),(Q63604),(Q
91987);

Peptide sequence

%
reaction

MYRRS(pY)VFQTR

80%

LDNPE(pY)HNASN

80%

ELQDD(pY)EDMM
E

80%

KASPV(pY)LDILG

80%

VYSTD(pY)YRVGG

75%

Substrate biological role
Structural constituent of eye
lens
Cell differentiation, cell
growth and cell proliferation.
Belongs to EGF receptor
superfamily.
Anion exchange; cytoplasmic
domain provides binding sites
for cytoskeletal proteins,
glycolytic enzymes, and
hemoglobin.

Nervous system development
and/or maintenance.
Structural element of the
erythrocyte membrane
skeleton; mechanical stability
and deformability of
membranes
Organization of the actin
cytoskeleton and cell structure;
regulation of cell migration,
and transformation.

Protein 4.1
(P11171)(P48193)

DGENI(pY)IRHSN

80%

Src substrate protein
p85 (Q01406)

QREAE(pY)EPETV

100%

PQDKE(pY)YKVKE

70%

Cell growth, development,
differentiation, and histone
modifications.

RGEEV(pY)VKKT
M

70%

Protein tyrosine-kinase
transmembrane receptor.

VKRRD(pY)LDLAA

75%

Tyrosine-protein kinase
activity; important for
development.

Tyrosine-protein
kinase JAK2
(O60674)(Q62120)(
Q62689)
Tyrosine-protein
kinase receptor Tie1 (Q06805),
(P35590), (Q06806);
Proto-oncogene
tyrosine-protein
kinase receptor Ret
(P07949)

Figure A-1. Partial sequence alignment of VHZ (residues 63-138) with classical PTPs (A), atypical DSPs (B);
several PTPs containing the XXDXXXP sequence of the general acid loop and structurally related to VHZ (C).
Boxes enclose catalytically significant PTP regions. The sequences were aligned with T-coffee (49) and amino acids
encountered in at least 70% of aligned sequences are highlighted.
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Figure A-2. Selective alignment of VHZ-VO3 (white) with YopH WT (1YPT, green).
To align the structures the P-loop of YopH was selectively aligned to the analogous
region in VHZ with (RMSD=0.238). The steric environment of the open WPD loop was
analyzed using the MolProbity server. The analysis revealed a steric clash of E44 (VHZ)
residue with the side chain of D65 if the IPD-loop of VHZ were to assume an open
conformation analogous to that of YopH, PTP1B. In YopH the negatively charged E44 is
occupied by the smaller, neutral S287. General acid has always been observed in this
particular rotamer due to the hydrogen bond with the backbone carbonyl of invariant W
when the WPD-loop occupies its open conformation (not shown in the figure). E44 can
occupy several conformations; however the present clash cannot be avoided regardless of
E44 side chain position. This figure illustrates that the general acid loop oscillation in
VHZ cannot follow the classical pathway which is to best of our knowledge the only one
exclusively observed in PTP family.
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APPENDIX B

SUPPORTING INFORMATION FOR “UNUSUSAL AND UNACCOUNTED
PROPERTIES OF LDP3(VHZ) PROTEIN TYROSINE PHOSPHATASE
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Table B-1. Ionization constants of catalytic residues in VHZ/WT and VHZ/D65A
obtained from non-linear least squares fit of equation derived in Section B-4 to the
experimental data presented in the Figure 3-3. pK1E – is assigned to the ionization of
nucleophilic cysteine whereas pK2E – is attributed to the general acid catalysis.
kcat
kcat/KM
pK1E
pK2E
pK1E
pK2E
VHZ/WT
5.16 ± 0.43 5.54 ± 0.21 4.84 ± 0.11 5.02 ± 0.31
VHZ/E134Q 5.18 ± 0.6 5.30 ± 0.52 5.17 ± 0.42 5.61 ± 0.34
VHZ/D65A 4.71 ± 0.63 5.06 ± 0.42 4.21 ± 0.52 5.61 ± 0.28

B-1. Validation of the continuous spectrophotometric assay method for PTP activity
with pNPP
p-Nitrophenyl phosphate (Acros) was recrystallized from 100 % ethanol and dried
under high vacuum. A set of buffered standard solutions of p-nitrophenol was prepared in
the range pH 4.5-9.0 (in steps of 0.12). The buffers used were 50mM acetate (pH 4.55.5), 50 mM succinate (pH 5.75-6.5), 50 mM 3,3-dimethylglutarate (6.75-7.25), 50 mM
glycyl-glycine (pH7.5-8.5 ). Ionic strength was adjusted to 150 mM with NaCl. For each
pH at least eight dilutions of the buffered standard solution were prepared with the same
buffer containing no chromophore and pNP concentration was plotted vs A 400 nm and
10 mM path length (Figure C-1 A). The inverse values of the slopes were plotted vs
corresponding pH values (Figure C-1 B) and fitted to the equation using least squares
linear regression.
A 400 =α×CpNP
tot ×ε=

K pNP
+

K pNP +[H ]

×CpNP
tot ×ε

K pNP
A 400
1


×CpNP
tot ×ε
pNP
+
C tot
Slopes K pNP +[H ]
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Where α is the fraction of deprotonated p-nitrophenol, ε is extinction coefficient
of p-nitrophenolate, CpNP
is the total concentration of p-nitrophenol, KpNP is the ptot
nitrophenol ionization constant.
The acid dissociation constant obtained from the fit was K pNP  7.73 108 and
extinction coefficient of ε=18.59 mM-1×sm-1 .

3.5

0.022
0.020
0.018
0.016

2.5

1/Slope, L

p-nitrophenol,M/L

3.0

2.0

1.5

1.0

0.014
0.012
0.010
0.008
0.006
0.004
0.002

0.5

0.000
-0.002

0.0
0

200

400

600

800

A400nm

4

6

8

pH

Figure B-1. Validation of the partial extinction coefficients method. A) A set of pnitrophenol dilution at each pH has been prepared and total concentration of each
dilution is plotted vs corresponding absorbance at 400 nm yielding a set of slopes.
Steeper slopes correspond to lower pH. B) In order to validate the approach the inverse
of the slopes has been plotted vs pH. The plot was fitted to the p-nitrophenol titration
curve which yields a pKa of p-nitrophenol (7.11) and extinction coefficient of fully
deprotonated p-nitrophenolate (18.5) (equation 3).

B-2. Derivation of Expression for steady-state kinetics of PTP catalyzed hydrolysis
of phosphate monoester substrates
Protein tyrosine phosphatases catalyze hydrolysis of phosphate monoester
substrates via two-step Ping-Pong mechanism represented by the following scheme:
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Scheme B-1 . Kinetic scheme of classical PTP mechanism. All forward rates constant are
given odd subscripts whereas all the reverse rate constants given are even subscripts.

To derive the kinetic rate law for the mechanism presented in scheme B-1 we
write a series of equations describing the rate of change of each enzyme form. Under
steady state assumption concentration of each intermediate remains constant (the rate of
change is set to 0):
E total =E+ES+EP

 dEP =0=k 3×[ES]-k 5 ×[EP]
 dt

 dES
 dt =0=k1×[E]×[S]-(k 2 +k 3 )×[ES]

 dE =0=k ×[ES]-k ×[E]×[S]+k ×[EP]
2
1
5
 dt

We can re-arrange each equation as follows:
[EP]=[E total ]-[E]-[ES]

[ES]= k 5 ×[EP]

k3

k1

[ES]= k +k ×[E]×[S]
2
3

k 2 ×[ES]+k 5 ×[EP]

[E]=
k1×[S]


Substituting [ES] from equation 3 into equation 4 we can find:

k 2 ×k1
×[E]×[S]+k 5 ×[EP]
k 2 +k 3
[E]=
k1×[S]
[E]=

k 5 ×[EP]
k 5 ×[EP]
(k +k )×k 5 ×[EP]
=
= 2 3
k ×k
k ×k
k1×k 3×[S]
k1×[S]- 2 1 ×[S] k1×[S]- 2 1 ×[S]
k 2 +k 3
k 2 +k 3
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Substituting expression for ES and obtained expression for E into equation 1 we
obtain:

[EP]=[E total ][EP]=

=

(k 2 +k 3 )×k 5 ×[EP] k 5
(k +k )×k 5 +k1×k 5 ×[S]
- ×[EP]=[E total ]- 2 3
×[EP]
k1×k 3 ×[S]
k3
k1×k 3 ×[S]

[E total ]
k1×k 3×[S]×[E total ]
=
=
(k 2 +k 3 )×k 5 +k1×k 5 ×[S] k1×k 3 ×[S]+(k 2 +k 3 )×k 5 +k1×k 5 ×[S]
1+
k1×k 3 ×[S]

k1×k 3 ×[S]×[E total ]
(k 2 +k 3 )×k 5 +k1×  k 3 +k 5  ×[S]

Reaction rate corresponds to the rate of product release:
k 5 ×k1×k 3
k5  k3
×[S]×[E total ]
×[S]×[E total ]
k1×  k 3 +k 5 
k 3 +k 5 

k ×[S]×[E total ]
V=k 5 ×[EP]=
=
 cat
(k 2 +k 3 )×k 5
(k 2 +k 3 )×k 5
K M +[S]
+[S]
+[S]
k1×  k 3 +k 5 
k1×  k 3 +k 5 

We can see now that:

k cat 

k 5 ×k 3
k 3 +k 5

KM 

(k 2 +k 3 )×k 5
k5
 KS 
k1×  k 3 +k 5 
k 3 +k 5

k 3×k 5
k cat
k 5 +k 3
k
=
 3
KM K × k5
KS
S
k 5 +k 3
Where Ks is the enzyme substrate complex ([ES]) dissociation constant.
The obtained expressions are equally valid for native VHZ and its mutants. The
following conclusions can be drawn:
1. kcat/KM characterizes the events from substrate trapping by free enzyme E up until the
first irreversible step k3 regardless of what step (k3 or k5) is a rate limiting. The kcat

169

parameter reports on the chemical behavior of enzyme-substrate complex and when
k3>>k5 (dephosphorylation is much slower than phosphorylation) we write:

k cat 

k 5 ×k 3 k 5 ×k 3

 k5
k 3 +k 5
k3

K M  KS 

k5
k
 KS  5
k 3 +k 5
k3

k 3 ×k 5
k cat
k 5 +k 3
k5
k
=

 3
k
K M K × k5
KS  5 KS
S
k 5 +k 3
k3
2. KM values are determined by two major terms: Ks and

k5
.
k 3 +k 5

Residues which affect Ks (substrate binding) as well as the relative kinetic ratio

k5
will have a measurable effect on KM.
k 3 +k 5
In the presence of two substrate binding modes earlier presented in Figure 3-9 of
the main text,

The general law will be affected as it will contain a fractional terms α A and α B
modulating Vmax and the calculated kcat will depend on which of the two conformations
has catalytic viability (which in turn will depend on which general acid, E134 or D65, is
available).
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K AB =

[B]
[A]

A
WT
Vmax
=Vmax
×α A =

B
WT
Vmax
=Vmax
×α B =

A
B
Vmax
 Vmax

Vmax
1+K AB 
Vmax


1 
1+

 K AB 
WT
WT
WT
WT
 Vmax
×α A  Vmax
×α B  Vmax
 (α A  α B )  Vmax

B-3. Derivation of expression for the steady-state kinetics of PTP-catalyzed
hydrolysis in the presence of alternative nucleophilic acceptors.
Although native classical PTPs generally cannot transfer phosphate to acceptors
other than water (hydrolysis of enzyme phosphate intermediate), atypical DSPs, Low
Molecular Weight PTPs, as well as VHZ/WT revealed an ability to phosphorylate
alcohols (alcoholysis of phosphoenzyme intermediate), when such alternative
nucleophiles are added. In this case the breakdown of the phosphoenzyme intermediate
proceeds via two simultaneous (additive, not competing) pathways according to Scheme
B-2:
To derive the kinetic expression for the PTP-catalyzed reaction of phosphoester
hydrolysis in the presence of an alternative nucleophilic agent, the algorithm developed
by King and Altman will be used (JPC 60, 1375). The reaction mechanism (Panel A) is
presented in a closed cyclic form (Panel B).
The appropriate rate constants are multiplied by their corresponding concentration
factors ([S] for k1 and [ROH] for k7). Three open loop patterns (Panel C) are obtained
from the catalytic triangle of Panel B by erasing one side at a time because none of the
pattern should contain open loops.
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Scheme B-2. King-Altman derivation of kinetic law for PTP catalyzed reaction in the
presence of alternative nucleophilic acceptors.

We need to write down distribution equation for each enzyme form (e.g., E, ES
and EP). From each of the three open patterns (Panel C) we write a product of elementary
constants (e.g., k1, k2, k3, k5) that point towards an enzyme form from the breach in the
cycle (clockwise and counterclockwise). If some elementary step on the way from the
breach to an enzyme form is absent due to irreversibility, then the rate constant of the
step in reverse direction is considered to be 0 (for example, the reverse rate of k3 is
k4=0). Now starting from left to right we can write for each enzyme form:
k ×(k +k  [ROH])+0×k 2 +k 2 ×(k 5 +k 7  [ROH]) (k 3 +k 2 )×(k 5 +k 7  [ROH])
[E]
= 3 5 7
=
[E total ]
([E]+[ES]+[EP])

[ES] 0×0+k1  [S]×0+k1  [S]×(k 5 +k 7  [ROH]) k1  [S]×(k 5 +k 7  [ROH])
=
=
[E total ]
([E]+[ES]+[EP])

[EP] k 3 ×0+k1  [S]×k 3 +k 2 ×0 k1  [S]×k 3
=
=
[E total ]
([E]+[ES]+[EP])

  [E]+[ES]+[EP]

172

[Enz.Form] PatternC1+PatternC2+PatternC3
=
[E total ]
[E]+[ES]+[EP]

By adding all three equations together we find:

(k +k )×(k 5 +k 7  [ROH])+k1  [S]×(k 5 +k 7  [ROH])+k1  [S]×k3
[E]
[ES]
[EP]

+
=1= 3 2
[E total ] [E total ] [E total ]

  (k 3 +k 2 )×(k 5 +k 7  [ROH])+k1  [S]×(k 5 +k 7  [ROH])+k1  [S]×k 3
The rate of the process is described by last irreversible step associated with
release of the reaction product and liberation of free enzyme form:

V=(k5 +k 7  [ROH])×[EP]

.

k1  [S]×k 3
[EP] k1  [S]×k 3
=
=
[E total ]
Δ
(k 3 +k 2 )×(k 5 +k 7  [ROH])+k1×(k 5 +k 7  [ROH])+k 3 )  [S]
V=(k 5 +k 7  [ROH])×[EP]=

(k 5 +k 7  [ROH])×k1×k 3×[S]  E total
(k 3 +k 2 )×(k 5 +k 7  [ROH])+k1×(k 5 +k 7  [ROH])+k 3 )  [S]

Finally we divide the numerator and denominator by coefficient before [S] to
obtain:
k 3×(k 5 +k 7  [ROH])
×[S]×[E total ]
(k 5 +k 7  [ROH])+k 3
k ×[S]×[E total ]
V=
= cat
(k 3 +k 2 )×(k 5 +k 7 [ROH])
K M +[S]
+[S]
k1×((k 5 +k 7 [ROH])+k 3 )
k cat =

k 3×  k 5 +k 7  [ROH]) 
k 5 +k 7  [ROH]+k 3

 k +k 
k 5 +k 7  [ROH]
k 5 +k 7  [ROH]
KM =  3 2 ×
=K S ×
k 5 +k 7  [ROH])+k 3
 k1  k 5 +k 7  [ROH])+k 3
k cat k 3×  k 5 +k 7  [ROH]

K M K S ×  k 5 +k 7  [ROH]
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We have two potential interpretations of kcat in the presence of an alternative
nucleophile depending on whether the second step (k5) of the process is rate limiting, or
both steps (k3 and k5) simultaneously contribute to the overall rate of the process.
In the case (k3>>( k 5 +k 7  [ROH] ) – the second step is the rate limiting one, we
can simplify:
k cat =

k 3×k 5 +k 3×k 7  [ROH]
 k 5 +k 7  [ROH]
 k 5 +k 7 [ROH] +k 3

This expression indicates that kcat values should increase linearly with
concentration of [ROH] . Then plotting kcat vs [ROH] will yield a linear plot with the
slope equal to k7.
However, when k3 and ( k 5 +k 7  [ROH] ) are comparable, the plot will be linear at
low nucleophile concentration when [ROH] <<

k 5 +k 3
:
k7

k 3×k 5 +k 3×k 7
 [ROH]
k7
k ×k
k ×k
k cat =
 3 5 + 3 7  [ROH]
k 5 +k 3
k3  k5 k3  k5
+[ROH]
k7

In the broad range of alcohol concentrations and eventually at

k 5 +k 3
<<[ROH]
k7

reaction will become independent of [ROH]:
k 3×k 5 +k 3×k 7
 [ROH]
k7
k ×k +k ×k
k cat =
 3 5 3 7
k 5 +k 3
k7
+[ROH]
k7
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Because concentration of ethylene glycol in our experiment was too low to reach
saturation (as revealed by linear dependence of experimental kcat values on [ROH], we
can simplify as earlier (considering ROH<<

k 5 +k 3
)
k7

k 3×k 5 k 3×k 7
+
 [ROH]
k 3×k 5 +k 3×k 7  [ROH]
k7
k7
k ×k
k ×k
k cat =

 3 5  3 7  [ROH]
k 5 +k 3
k 5 +k 7  [ROH]+k 3
k 5 +k 3 k 5 +k 3
+[ROH]
k7
In this case the slope of the plot of kcat vs [ROH] is no longer the rate of
alcoholysis but the ratio of three rate constants. However, we can still define enzymatic
preference for alcoholysis over hydrolysis rate by looking at the ratio:

k 3×k 7
k +k
k
Slope
S
 5 3= 7
Intercept k 3×k 5 k 5
k 5 +k 3
We can see that in the absence of alcohol ([ROH]=0), the expression for kcat
reduces to the ordinary steady-state expression algebraically derived in B-2:
 k ×k
 k ×k
k ×k
k cat  lim  3 5  3 7  [ROH]  = 3 5
[ ROH ]0 k +k
 5 3 k 5 +k 3
 k 5 +k 3

Likewise for KM:

K M =KS×

k 5 +k 7  [ROH]
k
 KS× 5
k 5 +k 7  [ROH])+k 3
k 5 +k 3
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B-4. Derivation of expression for pH dependence of steady-state kinetics of PTP
catalyzed hydrolysis of phosphate monoester.
PTPs utilize a cysteine residue which attacks the phosphate moiety of the
substrate monoester in the first step and therefore must be deprotonated for catalytic
activity. At the same time a catalytic general acid must be protonated to donate a proton
to the leaving group of the substrate. Additionally, phosphate monoester substrate
protonation state changes from mono-ionic to di-ionic, which is known to affect binding.
Because of this the reaction rate of the PTP-catalyzed reaction is affected by pH which
controls the protonation state of catalytically relevant residues.
The following protonation events can occur:

Scheme B-3. Intermediates in PTP catalyzed reaction affected by pH
Scheme B-3contains the following assumptions:
1. Substrate can bind to each of the three enzyme forms.
2. Binding to EH1 (cysteine deprotonated, general acid protonated) produces a
reactive enzyme-substrate complex. EH1 hereby is considered as an optimal ionization
state of enzyme.
3. Binding to E (general acid deprotonated, cysteine deprotonated) produces
essentially unreactive enzyme-substrate complex, which, however, can gain a proton
from solution producing a reactive EH1S complex. It is possible because unlike catalytic
cysteine in EH2 the general acid remains exposed to the solvent environment.

176

4. Binding to EH2 (protonated cysteine and general acid) produces a completely
unreactive enzyme-substrate complex which cannot lose proton to produce EH1 because
of the shielding of the catalytic cysteine by the substrate.
5. Substrate binding does not affect the pKA (KA1=KA2) of the general acid, and it
follows from the thermodynamic box that affinity of E and ES for the substrate are
identical.
The scheme can be simplified:

Scheme B-4. Simplified from Scheme B-3representation of pH effect on PTP catalyzed
reaction.
The three enzyme forms in the box can be reduced to one (analogous to Cha
approximation). We account for protonation states by multiplying the rate constant k1 by
the fraction of EH1 in the box, and by the fraction of substrate in the correct (dianionic)
form. The mechanism can be further simplified:

Scheme B-5. pH effect on PTP catalyzed reaction.The dashed box as a single
intermediate. It is justified by Cha approximation. X represents the species present in the
box; fx is the fraction of correctly protonated enzyme form (E H1); fs is the fraction of
correctly protonated substrate (di-anionic form of pNPP).

177

To find the expression for the fraction of the correctly protonated form present we
write:
 H +  ×K1E
HE
1
fx =
=

2
+
+
+
H 2 E+HE+E  H  +  H  ×K +K ×K
H 
    1E 1E 2E    1  K 2E
K1E
 H + 

fs =

K1S ×K 2S
S
=
2
+
H 2 S+HS+S  H  +  H +  ×K +K ×K
    1S 1S 2S




 lim 
K1S 







K 2S
1

2
+
+
 H 
 1   H 
+
+  H  +K 2S 
K 2S
K1S


pNPP has two ionizable sites (K1S,K2S). However, because K1S is outside of the
experimental pH range (experimental pH range is higher than K1S ) we can simplify the
expression by assuming that the first stage is 100% deprotonated (setting K1S  ).
The initial rates method developed by W. W. Cleland will be used. The
mechanistic scheme is re-written to contain only the net rate constants:

Scheme B-6. Net rate constant representation of PTP catalyzed reaction according to the
W.W. Cleland.

Net rate constants are used to represent only the forward flux through each step of
the mechanism. In other word it represents the fraction of the overall transformation
through each step that proceeds forward (the net flux) to the next step rather than
returning back via a reverse rate constant. For irreversible steps we can write equalities
like k'5 =k 5 and k'3 =k 3 because 100% of the transformation moves on to the next step
and reverse rate constants for these steps equal 0. However, for the k’1 step we need to
write:
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k'1 =k1×

k'3
k3
×S×f x ×fs  k1×
×S×f x ×f s
k'3 +k 2
k 3 +k 2

According to the net rate constant method, we write:
k1×k 3×k 5 ×S×f x ×f s
V
1
1
=
=
=
=
k 3 +k 2
1 1 k 5 × k 3 +k 2 +k1×f x ×f s × k 5 +k 3 × S
Et 1 + 1 + 1
+ +
k'1 k'3 k'5 k1×k 3×S×f x ×f s k 3 k 5









k 3 ×k 5 × S
k 3×k 5 × S
k cat ×S
k 5 +k 3
k 5 +k 3
=
=
=
+
+
KSk 5
+ S k 5 ×K S   H  K 2E    H   K M + S
× 1+
+
× 1+
f x ×fs × k 5 +k 3
k 5 +k 3 
K1E  H +   
K 2S 

 

k ×k
k cat = 3 5
k 5 +k 3



KM =



KSk 5



f x ×fs × k 5 +k 3



Substituting the previously derived expressions for fx and fs we obtain.
k3
KS

k cat
=
K M  H+  K   H+  
1+   + 2E
 × 1+   
+

K1E  H   
K 2S 

 


Because the expression for kcat does not contain k1 we multiply it only by fx (not fs).

k cat 

k 3 ×k 5
k 5 +k 3
 H+  K 
1+   + 2E


K1E  H +  
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B-5. Derivation of the pre-steady state kinetics expressions for PTP-catalyzed pNPP
hydrolysis:

Scheme B-7. Schematic representation of PTP catalyzed pNPP hydrolysis.
Let’s write the system of first order differential equations for each enzyme form
as follows:
 dE
 dt =k 2 ×[ES]-k1×[E]×[S]+k 5×[EP]

 dES =k ×[E]×[S]-(k +k )×[ES]
1
2
3
 dt

 dEP
=k 3×[ES]-k 5 ×[EP]

 dt
E total =E+ES+EP

K S  [E]  [S]

[ES]


These equations are identical to the ones previously derived for steady-state in
the section B-2, except for the rate for each enzyme form (intermediate) is not 0
(assumption we made for steady state).
First, we need to find the dependence of [E-P] (formation of [E-P] accompanies
chromophore release) on time. To do this we need to integrate the corresponding
differential equation, but before we derive the expression connecting [E-P] and [ES].
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[E]  [S]
[ES]
[E]=[E total ]-[ES]-[EP]
KS 

[ES]=

[S]
[S]
×[E]=
× [E total ]-[ES]-[EP]
KS
KS

[S]
× [E total ]-[EP]
[S]× [E total ]-[EP]
KS
ES=

[S]+K S
 [S] 
1+

 KS 

Substitution into equation for [EP] enzyme form we obtain:
k ×[S]× [E total ]-[EP]
d[EP]
=k 3×[ES]-k 5 ×[EP]= 3
-k 5 ×[EP]=
dt
[S]+K S
=


k 3×[S]×[E total ]  k 3×[S]
-
+k 5  ×[EP]=A-B×[EP]
[S]+KS
 [S]+KS


Integration of both sides yields:

d[EP]

1 dA-B×[EP]
= dt
A-B×[EP] 

 A-B×[EP] =- B 
t=-

1
1
1
  ln  A-B×[EP] +C  =- ×ln  A-B×[EP] - C
B
B
B

The value of integration constant C can be calculated at t=0

Ct=0,[EP]=0 =-ln  A-B×[EP] =-ln  A 
Substitution of C expression into equation yields:
1
1  A-B×[EP] 
t=- ×  ln  A-B×[EP] -ln  A   =- ln 

B
B 
A

A-B×[EP] -B×t
=e
A

Substitution of A and B back into the equation will yields:

[EP]=



A× 1-e-B×t
B



 k 3 ×[S]

 - k3 ×[S] +k5 ×t 
k 3×[S]×[E total ]  - [S]+KS +k5 ×t 
[S]+KS
 
× 1-e
k 3×[E total ]× 1-e 
[S]+KS





=


=
 k 3×[S]

 KS 
k 3 +k 5 × 1+
+k 5 


[S]+K
 [S] 
S



181

Now let’s substitute it to the expression for the rate of pNP release and rearrange
prior to integration in order to separate the time-dependent and time-independent parts:


 - k3 ×[S] +k5 ×t  
[S]+KS
 

k 3×[E total ]× 1-e 



[S] 


k 3 × × E total KS 
 K 

k 3 +k 5 × 1+ S 


[S]
 [S] 
k 3 × × [E total ]-[EP]


KS
d[pNP]


=k 3×[ES]=
=
dt




S
S
1+

1+

 KS 
 KS 



 k ×[S]

- 3
+k 5 ×t


2
2
 [S]+KS

k ×[S]×[E total ]
k 3×[S]×[E total ]
 + k 3×[S]×[E total ]×e
= 3
=

K S +[S]


 KS   
 KS  

 KS +[S] ×  k 3 +k 5× 1+     K S +[S]×  k 3 +k 5× 1+  

 [S]   
 [S]  



=C+D×e

 k ×[S]

- 3
+k 5 ×t
 [S]+KS


As can be seen after re-arrangement the only part dependent on time is the one
included under the exponential term, whereas C and D are t-independent constants.
By integrating the expression we obtain:
 k ×[S]

 k ×[S]


- 3
+k 5 ×t 
- 3
+k 5 ×t
D
[S]+KS
[S]+KS




 ×dt=C×t[pNP]=  C+D×e
×e
+F
k
×[S]


3
+k 5


[S]+KS

Where F is the constant of integration. We obtain its value by setting t=0.
 k 3 ×[S]



-
+k 5 ×t
D
D
[S]+KS

Ft=0,[pNP]=0 =-C×t+
×e 
=
 k 3×[S]

 k 3×[S]

+k 5 
+k 5 


 [S]+KS

 [S]+KS


Substitution of the expression for F , C and D into the equation yields after a series of rearrangements:
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 k ×[S]

 - k3 ×[S] +k5 ×t 
- 3
+k 5 ×t
D
D
[S]+KS
 [S]+KS

 
[pNP]=C×t×e
+F=C×t+
× 1-e 
=

 k 3×[S]

 k 3×[S]
 

+k 5 
+k 5  


[S]+K
[S]+K
S
S





k 23 ×[S]×[E total ]



 K 
 KS +[S] ×  k 3 +k 5× 1+ S    - k3 ×[S] +k5 ×t 


2
k ×[S]×[E total ]
k 3×[S]×[E total ]
 [S]   
[S]+KS

 ×t+
 
= 3
× 1-e 
=


K S +[S]



 k 3×[S]

 KS  



+k 5 
 KS +[S] ×  k 3 +k 5 × 1+   


[S]+K
[S]


S





2

 k 3×k 5

 k 3×k 5

×[S]  ×[E total ]

 - k3 ×[S] +k5 ×t 
 k +k ×[S]×[E total ] 
k 3 +k 5
[S]+KS


3
5
 


=
×t+
× 1-e 
=
2
k


 [S]+

5


k
2
×K
5

S


×K S  
 k 5  ×  [S]+
k 3 +k 5


k 3 +k 5



 k ×[S]×[E total ] 
k cat ×[S]
=  cat
 ×t+ 
[S]+K M


 k 5 × [S]+K M 

2



k cat ×[S]
 ×[E total ]- 

 k × [S]+K 
M

 5

2

 k ×[S]

- 3
+k 5 ×t

 [S]+KS

 ×[E total ]×e
=



=  LinearSlope  ×t + BurstAmplitude - BurstAmplitude×e- BurstRate ×t

The first two terms in the obtained expression correspond to a straight line with the slope
of

k cat ×[S]×[E total ] Vmax ×[S]
=
which corresponds to the steady-state rate of product pNP
[S]+K M
[S]+K M


k cat ×[S]
release and Y intercept 
 k × [S]+K 
M
 5

2


 ×[E total ] which corresponds to the amplitude



of the burst proportional to the total enzyme concentration. We can notice that when
[S]>>KM, and k3>>k5 (such that kcat = k5 – de-acylation of enzyme is the rate limiting
step), the expression can be simplified and the magnitude of the burst is equal to the
[Etotal]:


k cat ×[S]

 k × [S]+K 
M
 5

2

2

 k 5 ×[S] 
 ×[E total ]= 
 ×[E total ]=[E total ]

k 5 ×[S] 
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When one of the conditions (either [S]>>KM or k3>>k5) is not satisfied
k cat ×[S]

k 5 × [S]+K M 

 1 and the magnitude of the burst rapidly reduces because of the square

power of the term. This term can be viewed as a product of two terms:
k cat ×[S]

k 5 × [S]+K M 



k cat
[S]

k 5 [S]+K M 

The first one depends exclusively on the nature of the enzyme at hand and totally
k 3×k 5
k
k +k
k3
determined by the ratio: cat  3 5 
. The ratio shows that if k3>>k5 condition
k5
k5
k 3 +k 5

is not satisfied, the ratio

k cat
[S]
corresponds to the fraction
 1 . The second term
k5
[S]+K M 

of enzyme-substrate complex which forms upon rapid mixing from the total enzyme
present in solution. This term can be experimentally maximized and approached to unity
by using saturated ([S]>>KM ) substrate concentrations. If such concentration is not
achievable it is possible a set of lower substrate concentrations can be used to construct a
saturation curve. Finally, the exponential term or burst rate constant

k ×[S]
3
+k can be
5
[S]+K
S

simplified if we use a saturating amount of substrate (or its values can be obtained from
saturating curve at lower substrate concentrations). In this case the expression of the





k ×[S]
Burst rate constant simplifies to the simple sum 3
+k  k +k .
5
3 5
[S]
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APPENDIX C

SUPPORTING INFORMATION FOR “METAVANADATE AT THE ACTIVE
SITE OF THE PHOSPHATASE VHZ”
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Below are the absolute energies (in Hartrees) and the atomic coordinates of the structures that
were computationally analyzed. The coordinates were obtained from the x-ray structure.
Complex shown in Figure 4-2, A:
E(B3LYP/6-31G*) = -5421.28129098
C
C
C
C
C
C
C
C
C
O
N
C
O
C
N
C
O
C
C
C
C
N
C
O
C
C
N
C
O
C
N
C
S
V
O
O

-2.564078
-2.074282
-2.828828
-4.073112
-4.564762
-3.806093
-2.315088
-3.178162
-2.845657
-3.652161
-3.103828
-4.186200
-5.342292
-3.991763
-2.643245
-2.156038
-2.811871
-0.711852
0.139054
1.604621
1.817242
-0.168211
0.065405
-0.222864
0.702578
2.208904
0.038880
-1.157248
-1.698806
-1.853628
-3.291855
-1.360245
-1.835093
0.198156
0.639040
-0.408457

6.097605
4.809721
3.841212
4.184683
5.465201
6.421611
2.454911
1.397957
0.007788
-0.583823
1.543927
1.758800
1.748475
2.009069
2.312415
3.555649
4.525966
3.757697
4.047198
4.421267
5.327482
2.644116
2.731680
3.729175
1.486602
1.429259
0.261248
-0.032245
0.657185
-1.304514
-1.056816
-1.841526
-0.855900
-0.347226
-1.848475
0.847159

-2.147937
-2.298077
-2.936995
-3.423734
-3.268804
-2.631369
-3.101813
-2.402183
-2.952113
-3.667401
-0.941127
-0.201678
-0.648949
1.284148
1.734752
1.711129
1.325986
2.159414
0.919841
1.126244
2.313061
2.945790
4.255662
4.930432
4.903246
4.622323
4.467666
4.961671
5.826250
4.472887
4.482188
3.108760
1.673917
0.543004
-0.195223
-0.483213
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O
C
N
C
C
O
N
C
C
O
C
C
C
N
C
N
N
C
C
O
N
C
O
C
O
N
C
N
N
C
C
C
O
C
O
C
C
O
C
O
C
C
C
C
C
C

1.124727
2.170170
-1.666263
-1.184227
-1.768774
-2.611233
-1.342354
-1.856383
-3.360347
-4.108995
-1.090184
0.388416
1.215266
1.551456
2.250850
2.518622
-3.798787
-5.209695
-6.025967
-5.655896
2.690387
-5.405523
-4.935639
-6.865303
-7.063408
2.912325
3.663337
3.545988
4.546597
5.422844
6.387897
5.706988
1.942221
1.503987
1.615513
0.834520
1.533546
5.363528
4.959816
3.993422
5.710443
5.098360
6.216263
5.598078
5.633930
6.283716

0.154276
5.052550
-0.511593
-1.724278
-2.997412
-3.650042
-3.346069
-4.536348
-4.421715
-5.362964
-4.757891
-5.150963
-5.066767
-3.683642
-3.333675
-2.051964
-3.260691
-3.008286
-3.105870
-2.518798
-4.265005
-1.614876
-1.659815
-1.197231
-3.773521
0.452939
1.545394
2.482147
1.707043
2.869734
2.756612
3.008483
2.044727
0.880095
-0.025316
0.551134
-0.579303
-0.578767
-1.690444
-1.819585
-2.922476
-4.224968
0.643233
0.022967
-1.358612
-2.134160

1.848070
-0.139512
-2.655395
-3.297674
-2.727347
-3.354617
-1.520591
-0.860530
-0.633147
-0.917708
0.449855
0.229796
1.501703
1.851085
2.930953
3.179963
-0.156681
0.089763
-1.196346
-2.199737
3.773083
0.724107
2.073267
0.749411
-1.242127
-0.974720
-0.919259
-1.856543
0.060695
0.166581
1.330761
2.669403
-4.103413
-4.282680
-3.430465
-5.594611
-6.317362
1.505494
1.095837
0.308681
1.561836
1.051585
-2.934691
-4.005037
-4.119179
-3.165843
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C
C
C
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

6.888214
6.853870
6.302191
4.104848
5.705043
6.652879
7.051832
6.457311
5.186899
5.126250
6.201896
7.289773
7.353614
-3.643441
-1.614621
-0.361489
-1.730929
0.479126
0.577042
2.638512
2.361494
2.611146
0.035401
-0.689231
0.119238
-0.294972
2.097503
3.129897
1.650798
2.101692
2.790171
1.500385
1.301839
-2.064508
-4.294251
-4.574509
-2.213194
-4.146067
-1.391624
-2.283865
-4.625643
-5.471948
-4.159995
-2.011251
-1.168424
-1.091731

-1.500961
-0.113721
-3.623501
-4.115862
-2.939110
-2.864288
-3.978678
-3.861909
-1.802454
0.570192
1.640568
0.333493
-2.046095
-0.240423
-2.044477
-1.884784
-2.761978
-0.347375
1.562436
2.278941
1.314877
0.656060
1.783030
4.534758
3.227482
4.804410
3.573545
5.293020
5.877830
4.401797
5.539210
4.869409
6.174811
1.569458
1.188573
2.780846
1.479784
1.536835
2.412522
2.242885
3.496791
5.698254
7.350616
6.791787
4.578711
-0.060059

-2.090181
-1.971079
-3.287680
1.069705
2.561872
1.233526
-2.729838
-4.245958
-4.896487
-4.696387
-2.858431
-1.190166
-1.393309
4.024463
5.102165
3.136593
2.987507
3.807347
5.892545
4.929531
3.640217
5.113326
2.479621
2.788130
0.348217
0.431812
1.323611
0.007048
-0.361966
-0.895880
2.400579
3.143309
2.182856
2.071884
1.769831
1.538133
-0.490838
-2.610536
-2.721526
-4.078364
-3.894918
-3.619004
-2.521352
-1.686771
-1.942246
-1.973113
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

-1.417379
-0.190397
-0.657733
-1.714022
-1.118162
-1.540473
0.421523
0.785364
0.693399
2.062903
1.236286
3.215010
2.496436
3.043513
2.194125
-3.136784
-5.535402
-4.898375
-6.946564
-7.392686
-7.220029
-5.056209
1.618130
2.445032
0.847665
-0.111991
5.229480
5.048045
7.118584
6.778580
4.860315
5.947913
4.614491
2.883617
4.120282
2.249991
3.008410
6.455486
5.403442
5.442600
5.354065
0.947721
-3.921634
-3.778547

-1.679104
-1.761200
-2.782962
-5.334325
-3.911535
-5.489146
-6.090689
-4.534370
-5.470835
-5.580716
-2.956607
-3.999812
-5.230006
-1.800004
-1.342341
-2.537093
-3.709472
-0.953515
-0.291886
-1.858153
-1.165572
-0.762827
-1.351587
-0.265536
1.364528
0.284000
2.176840
3.753336
3.428507
1.835889
3.686151
2.954557
0.996552
2.367963
3.300496
0.338708
-0.256297
3.281923
-5.046927
-4.414406
-4.028215
-0.870826
-1.728595
-0.946061

-4.269589
-3.194248
-1.057527
-1.445667
0.981588
0.961545
-0.111435
-0.450413
2.253064
1.369386
1.241177
4.582146
3.596297
3.992505
2.554012
0.038861
0.723539
0.172399
1.166792
1.283460
-0.185109
2.498372
-5.687042
-6.585061
-6.177001
-5.416235
2.954108
2.565536
1.210372
1.336898
0.293082
-0.679509
0.761104
-2.596805
-1.820645
-1.715007
-0.276513
3.411631
1.697518
0.035941
-2.936703
-7.187849
4.072121
5.357932
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Complex shown in Figure 4-2, B:

E(B3LYP/6-31G*) = -4901.42875623

C
C
C
C
C
C
O
V
O
S
C
C
C
O
N
N
C
C
O
C
O
N
C
C
O
C
N
C
C
O
N
C
C
O
C
C

1.727809
1.534656
0.789643
0.238858
0.418934
1.150954
1.313912
-0.178825
0.015483
-2.033199
-1.580835
-2.523536
-2.444495
-3.332658
-3.916007
-1.421330
-1.438805
-2.382298
-3.269642
-0.018669
-0.032582
-2.207915
-3.023011
-4.176822
-5.166811
-2.175192
-4.051352
-5.115785
-5.189436
-6.260771
-4.063602
-4.009606
-2.926851
-3.181200
-3.807687
-5.075728

-3.634447
-4.937697
-5.177939
-4.058681
-2.772195
-2.505815
-1.191292
-0.082110
-1.328264
1.040534
1.265999
0.665752
-0.853382
-1.451832
0.860783
-1.509442
-2.971294
-3.551682
-4.376542
-3.537010
-4.954399
-3.096254
-3.542385
-2.591690
-2.987161
-3.706508
-1.339991
-0.363870
0.276766
0.730773
0.316066
0.924449
1.995037
3.058049
-0.170324
-0.993166

0.694462
1.214981
2.374034
2.966769
2.447145
1.300343
0.823651
-0.199831
-1.610982
-1.380700
-3.139307
-4.191768
-4.300928
-4.889324
-3.859496
-3.782888
-3.828894
-2.733723
-3.023285
-3.749231
-3.726518
-1.491983
-0.374403
-0.082012
0.536400
0.870188
-0.513731
-0.316466
1.052562
1.450842
1.772424
3.106474
3.258521
3.800787
4.171845
4.336565
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C
C
N
C
C
O
N
C
C
O
C
C
C
N
C
N
N
C
N
O
O
O
C
O
C
C
C
O
N
N
C
C
C
C
C
C
C
C
H
H
H
H
H
H
H
H

-2.669698
-2.385786
-1.725030
-0.593441
-0.587122
-0.758003
-0.371502
-0.359712
-1.798885
-2.078995
0.266551
1.740247
2.198336
1.849414
2.355226
1.977220
-2.724702
-4.139673
3.236832
-1.454465
0.787256
3.576364
4.157960
3.872275
5.237784
5.362564
6.130834
7.341321
6.036255
5.415129
5.998837
6.736438
5.822616
5.221561
4.383723
4.148191
4.764458
5.592356
5.018500
6.112356
4.432811
5.541278
6.970479
4.433709
5.244703
7.234000

-1.107453
-2.198536
1.718731
2.611285
3.913613
4.989356
3.818488
4.989654
5.451274
6.663586
4.703487
4.338870
3.688475
2.270835
1.411695
0.140861
4.501564
4.869363
1.822744
-0.472374
1.523491
-0.701956
-1.433388
-2.649856
-0.789508
0.714788
0.988061
0.818263
1.386014
1.440272
1.741698
0.524842
-0.498080
-1.484802
-2.419125
-2.380328
-1.420793
-0.480179
-0.929077
-1.226017
1.072626
1.213516
1.037538
1.582367
1.962981
0.076320

3.763119
4.771378
2.757149
2.950550
2.200356
2.786739
0.884910
0.048258
-0.083670
-0.095901
-1.318377
-1.261433
-2.556632
-2.611525
-3.489091
-3.463878
-0.182743
-0.237593
-4.389483
1.160609
-0.015362
-0.384177
-1.207098
-1.357554
-2.049276
-1.785704
-0.491544
-0.438913
-2.880664
0.534521
1.850364
2.429018
3.076973
2.327408
2.910239
4.244300
5.024519
4.434102
-3.014395
-1.838695
-1.701020
-3.732450
-2.961593
0.405585
2.469019
1.686751
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

7.385253
5.394406
3.951665
3.529242
4.613424
6.027344
-4.101129
-4.122666
-2.229159
-0.680034
-1.525781
-0.654331
-1.813222
0.499921
0.420141
0.905050
-1.488633
-3.412870
-2.751233
-1.753884
-1.460050
-3.211877
-4.988591
-5.987766
-3.230657
-4.885642
-3.582558
-2.912463
-1.838998
-1.634547
-3.203766
-2.131140
-4.928209
-5.307427
-5.826356
-1.597189
-0.549340
0.228993
-0.216312
0.203953
-0.229242
0.166730
2.275584
1.888861
1.762803
3.191574

0.848849
-1.526631
-3.122955
-3.045253
-1.405066
0.219745
1.838264
0.392196
1.130634
0.853199
2.249642
-1.019008
-3.259208
-3.228665
-3.202036
-5.296945
-2.422431
-4.425399
-4.013590
-2.829963
-4.384495
-1.063271
0.365725
-0.824879
-0.082586
1.389256
0.280148
-1.536753
-0.562515
-2.770261
-2.760738
-1.785952
-1.698246
-1.426487
-0.397099
0.876399
2.829740
2.109908
2.919681
5.706047
3.942905
5.520203
5.168960
3.700674
4.158193
3.778888

3.117842
1.343459
2.346899
4.663222
6.012781
4.999956
-3.758141
-3.001056
-5.027187
-3.272545
-3.311284
-3.369770
-4.710505
-4.546117
-2.915675
-3.674268
-1.323354
-0.637266
1.627892
1.105029
0.700287
-0.981607
-0.987907
-0.484752
1.388945
3.235763
5.036399
2.893828
3.646415
4.441513
4.893921
5.646347
5.030770
3.465997
4.622366
2.234315
3.925307
2.683817
0.474956
0.458214
-1.737380
-1.886524
-1.106957
-0.505735
-3.325160
-2.629466
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

1.187679
3.616833
3.521633
2.357268
1.311902
-2.455256
-4.709168
-4.423733
-4.262434
0.603659
-0.308115
-0.002806
2.288940
1.945159
6.687273
6.062033
-4.492953

1.925576
1.174727
2.780681
-0.507184
-0.169868
3.539183
4.054027
5.392402
5.458260
-6.068417
-4.171757
-2.003651
-3.515455
-5.714058
2.582278
2.377705
0.484042

-1.945533
-5.049857
-4.408593
-4.124196
-2.784674
-0.219361
-0.342018
0.565986
-1.036423
2.789313
3.796790
2.929052
-0.124973
0.736932
1.776871
-2.701919
-4.595202

Complex shown in Figure 4-2, C:

E(B3LYP/6-31G*) = -5203.76225829

C
C
C
C
C
C
C
C
N
C
O
C
N
C
C
O
O

-4.650931
-5.278665
-5.628832
-5.322039
-4.697310
-4.359132
-6.284062
-5.305790
-5.017139
-5.973152
-7.177812
-5.500137
-6.163584
-5.767077
-4.801517
-3.860552
-4.988004

-3.875018
-4.241590
-3.288152
-1.959816
-1.589556
-2.550930
-3.692621
-3.787446
-2.467767
-1.657321
-1.931931
-0.338456
-0.116872
0.823982
0.836201
0.006070
1.679369

3.942494
2.771297
1.825213
2.070362
3.237779
4.174980
0.544783
-0.629041
-1.186787
-1.629435
-1.565809
-2.237071
-3.514996
-1.273457
-0.084474
-0.059148
0.825546
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N
C
O
V
O
S
C
C
C
O
N
N
C
C
O
C
O
N
C
C
O
C
N
C
C
O
N
C
C
O
C
C
C
C
N
C
C
O
N
C
C
O
C
C
C
N

-5.392620
-6.239458
-1.546300
-0.002954
1.311197
1.883731
1.208610
1.920465
1.432286
1.992607
3.354112
0.404434
0.014065
0.902312
1.519655
-1.465620
-1.861487
0.964358
1.771541
3.186869
4.121871
1.068468
3.337482
4.626439
4.976289
6.152042
3.975371
4.275810
3.534785
4.082805
4.090591
5.089950
2.661827
2.407522
2.294956
1.439084
1.648074
2.220247
1.173176
1.410533
2.909037
3.450556
0.573782
-0.927415
-1.746686
-1.814711

4.285088
5.176589
-0.181465
0.388743
-0.168568
1.195505
2.388941
3.745262
4.689840
5.762388
3.612265
4.319671
5.166578
4.882213
5.791369
4.985311
5.957286
3.611880
3.172265
2.735966
2.765025
2.038414
2.318050
1.864789
0.426998
0.064384
-0.413965
-1.824306
-2.870116
-3.938281
-2.141754
-1.360034
-1.829555
-2.153398
-2.574437
-3.573991
-3.702581
-4.689406
-2.704263
-2.656178
-2.485172
-3.122013
-1.536479
-1.791855
-0.549739
0.358230

0.301963
1.133674
1.461650
0.152605
1.419883
-1.300103
-2.470610
-2.495497
-1.404799
-1.233670
-2.305461
-0.657937
0.458862
1.672577
2.227934
0.808062
1.759792
2.064897
3.200785
2.792450
3.603494
3.921931
1.540878
1.049711
1.386249
1.412984
1.629518
1.899476
1.073520
0.783314
3.407836
4.238041
3.865084
5.337411
0.699756
0.082003
-1.408919
-1.894179
-2.142942
-3.575901
-3.877756
-4.782873
-4.206497
-4.116157
-4.437622
-3.288516
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C
N
N
C
C
O
N
C
O
O
O
O
C
N
C
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

-2.547265
-2.552921
3.573528
5.015125
5.727304
6.614370
-3.277831
5.530193
4.848441
-0.697240
-0.568146
-1.164762
-0.830482
-0.894025
-0.278291
-5.748066
-4.453702
-5.404347
-5.850005
-7.153058
-4.513944
-5.669438
-6.701274
-4.065558
-5.654901
-4.447898
-6.985674
-6.711525
-5.556666
-4.487521
-3.901734
-4.408424
-5.484169
3.727454
3.536822
1.709023
0.249832
1.266173
-0.092955
0.140702
-2.016180
-1.605605
-2.828644
0.435568
1.873334
1.624671

1.465695
2.237516
-1.628623
-1.452502
-2.785290
-3.139465
1.800308
-0.417249
0.817683
2.166232
-0.901112
-2.564030
-3.039655
-2.379140
-4.423922
3.351992
4.299654
4.602445
0.746974
-0.080039
-0.387651
1.683865
0.743544
-2.163636
-4.403767
-4.165462
-3.017049
-4.587106
-1.263727
-0.627303
-2.281806
-4.569225
-5.205704
2.998177
3.236383
4.118632
2.546096
1.991617
3.475655
6.120018
5.089091
4.071582
5.831964
2.929220
3.958060
1.741290

-3.259972
-2.173840
-3.107339
-3.238876
-3.045624
-3.819558
-4.323512
-2.232223
-2.400596
0.117176
-1.140502
2.235684
3.282536
4.389191
3.363198
0.344755
0.646145
-0.646377
-3.908246
-3.375735
-2.393155
-1.774605
-0.926433
-1.236964
-1.334921
-0.280780
0.319389
0.674982
1.391916
3.409995
5.023000
4.619935
2.600969
-3.000647
-1.396381
-3.399094
-2.234880
-3.386077
-0.856736
0.185889
-0.020439
1.190062
1.982016
1.560421
3.810922
4.697841
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

0.938567
0.178194
2.549237
4.628541
5.331769
3.029509
5.229613
4.253308
2.490027
2.026732
1.461918
3.028409
2.566753
4.959415
4.951048
6.018820
1.944732
1.628393
0.485833
0.645612
1.125806
0.780271
0.825847
-1.169719
-1.147580
-1.323171
-2.674087
-1.277116
-3.831372
-3.272268
-3.105821
-2.004845
3.074695
5.210521
5.375555
6.509128
5.193876
5.470502
-0.171569
0.615967
-1.255759
-0.581884
-0.964588
-6.226210
-5.851777
-7.261623

1.272414
2.353723
2.315142
1.958913
2.455236
-0.089428
-1.908390
-3.119656
-0.854892
-2.366568
-1.928047
-1.616306
-3.127920
-1.573274
-0.380460
-1.609694
-1.649048
-4.459370
-3.321684
-1.976296
-3.523679
-0.679528
-1.455244
-2.513980
-2.090247
-0.070568
-0.827270
0.130157
2.633465
1.218533
3.071208
1.983040
-1.095027
-1.114577
-0.755031
-0.275296
1.482250
-3.377594
-4.665364
-4.433411
-1.447015
-2.799489
-5.117275
4.830426
6.193157
5.160183

3.292161
4.251129
0.925327
0.054706
1.442603
1.628632
1.609701
3.540769
3.721499
3.308817
5.570072
5.909138
5.497141
5.205971
4.091747
3.964486
0.845280
0.505942
0.247514
-1.704648
-3.982658
-3.734504
-5.170492
-4.764697
-3.187529
-5.206211
-4.687512
-2.476867
-4.307986
-5.137359
-2.155430
-1.376724
-2.424139
-4.159945
-1.303650
-2.377123
-1.738686
-2.281498
4.328090
2.915992
4.394571
5.241174
2.879277
2.166107
1.086655
0.758400
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H
H
H

-5.941132 -0.872080 -4.144471
-1.402170 -1.074746 1.751090
3.789450 4.517629 -2.388291
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editor considers Web posting to be “prior publication”, the paper will not be accepted for
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publication, check with the appropriate editor prior to posting your manuscript electronically.
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